AGILENT TECHNOLOGIES, INC., 10-K filed on 12/20/2023
Annual Report
v3.23.4
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Dec. 08, 2023
Apr. 30, 2023
Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Oct. 31, 2023    
Document Fiscal Period Focus FY    
Current Fiscal Year End Date --10-31    
Document Fiscal Year Focus 2023    
Document Transition Report false    
Entity File Number 001-15405    
Entity Registrant Name Agilent Technologies, Inc.    
Entity Central Index Key 0001090872    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 77-0518772    
Entity Address, Address Line One 5301 Stevens Creek Blvd.    
Entity Address, City or Town Santa Clara,    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 95051    
City Area Code (800)    
Local Phone Number 227-9770    
Title of 12(b) Security Common Stock, $0.01 par value    
Trading Symbol A    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction false    
Entity Shell Company false    
Entity Public Float     $ 31,200
Entity Common Stock, Shares Outstanding   293,004,102  
Amendment Flag false    
Documents Incorporated by Reference [Text Block]
Portions of the Proxy Statement for the Annual Meeting of Stockholders (the "Proxy Statement") to be held on March 14, 2024, and to be filed pursuant to Regulation 14A within 120 days after registrant's fiscal year ended October 31, 2023 are incorporated by reference into Part III of this Report
    
v3.23.4
Audit Information
 12 Months Ended
Oct. 31, 2023
Audit Information [Abstract]  
Auditor Name PricewaterhouseCoopers LLP
Auditor Location San Jose, California
Auditor Firm ID 238
v3.23.4
CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Net revenue:      
Net revenue $ 6,833 $ 6,848 $ 6,319
Costs and expenses:      
Cost of revenue 3,368 3,126 2,912
Research and development 481 467 441
Selling, general and administrative 1,634 1,637 1,619
Total costs and expenses 5,483 5,230 4,972
Income from operations 1,350 1,618 1,347
Interest income 51 9 2
Interest expense (95) (84) (81)
Other income (expense), net 33 (39) 92
Income before taxes 1,339 1,504 1,360
Provision for income taxes 99 250 150
Net Income $ 1,240 $ 1,254 $ 1,210
Net income per share:      
Net income per share - basic $ 4.22 $ 4.19 $ 3.98
Net income per share - diluted $ 4.19 $ 4.18 $ 3.94
Weighted Averge Shares Used In Computing Net Income Per Share      
Basic (in shares) 294 299 304
Diluted (in shares) 296 300 307
Products      
Net revenue:      
Net revenue $ 5,051 $ 5,187 $ 4,756
Costs and expenses:      
Cost of revenue 2,428 2,242 2,078
Services and Other      
Net revenue:      
Net revenue 1,782 1,661 1,563
Costs and expenses:      
Cost of revenue $ 940 $ 884 $ 834
v3.23.4
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Statement of Comprehensive Income [Abstract]      
Net Income $ 1,240 $ 1,254 $ 1,210
Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of ($1),$13, and $1 (3) 43 1
Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $0, $(8) and $4 0 (26) 13
Other comprehensive income (loss):      
Foreign currency translation, net of tax expense (benefit) of $(1), $(12) and $2 34 (150) 9
Net defined benefit pension cost and post retirement plan costs:      
Change in actuarial net gain (loss), net of tax expense (benefit) of $(5), $9 and $74 (10) 69 218
Change in net prior service benefit, net of tax benefit of $0, $0 and $0 (1) (1) (1)
Other Comprehensive Income (Loss) 20 (65) 240
Total comprehensive income $ 1,260 $ 1,189 $ 1,450
v3.23.4
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]      
Unrealized gain (loss) on derivatives, tax expense (benefit) $ (1) $ 13 $ 1
Amounts reclassified into earnings related to derivative instruments, tax expense (benefit) 0 (8) 4
Foreign currency translation, tax expense (benefit) (1) (12) 2
Change in actuarial net loss, tax expense (benefit) (5) 9 74
Change in net prior service benefit, tax (benefit) $ 0 $ 0 $ 0
v3.23.4
CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Oct. 31, 2023
Oct. 31, 2022
Current assets:    
Cash and cash equivalents $ 1,590 $ 1,053
Short-term Investments 0 0
Accounts receivable, net 1,291 1,405
Inventory 1,031 1,038
Other current assets 274 282
Total current assets 4,186 3,778
Property, plant and equipment, net 1,270 1,100
Goodwill 3,960 3,952
Other intangible assets, net 475 821
Long-term investments 164 195
Other assets 708 686
Total assets 10,763 10,532
Current liabilities:    
Accounts payable 418 580
Employee compensation and benefits 371 455
Deferred revenue 505 461
Short-term debt 0 36
Other accrued liabilities 309 329
Total current liabilities 1,603 1,861
Long-Term Debt 2,735 2,733
Retirement and post-retirement benefits 103 97
Other long-term liabilities 477 536
Total liabilities 4,918 5,227
Commitments and contingencies (Note 12 and 17)
Stockholders' equity:    
Preferred stock; $0.01 par value; 125,000,000 shares authorized; none issued and outstanding 0 0
Common stock; $0.01 par value; 2,000,000,000 shares authorized; 292,123,241 shares at October 31, 2023 and 295,259,092 shares at October 31, 2022 issued and outstanding 3 3
Additional paid-in-capital 5,387 5,325
Retained earnings 782 324
Accumulated other comprehensive loss (327) (347)
Total stockholders' equity 5,845 5,305
Total liabilities and equity $ 10,763 $ 10,532
v3.23.4
CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares
Oct. 31, 2023
Oct. 31, 2022
Stockholders' equity:    
Preferred stock par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock shares authorized (in shares) 125,000,000 125,000,000
Preferred Stock, Shares Issued (in shares) 0 0
Preferred Stock, Shares Outstanding (in shares) 0 0
Common stock par value (in dollars per share) $ 0.01 $ 0.01
Common stock shares authorized (in shares) 2,000,000,000 2,000,000,000
Common stock issued (in shares) 292,123,241 295,259,092
Common stock outstanding 292,123,241 295,259,092
v3.23.4
CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Cash flows from operating activities:      
Net Income $ 1,240 $ 1,254 $ 1,210
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 271 317 321
Share-based compensation 111 125 110
Deferred taxes (56) 8 14
Excess and obsolete inventory related charges 40 24 29
Net gain (loss) on equity securities (41) (67) 98
Asset impairment charges 277 0 2
Change in fair value of contingent consideration 1 (25) (21)
Loss on extinguishment of debt 0 9 17
Net gain on Divestiture of Business 43 0 0
Other non-cash expense, net 6 11 3
Changes in assets and liabilities:      
Accounts receivable, net 132 (321) (128)
Inventory (33) (248) (136)
Accounts payable (171) 121 64
Employee compensation and benefits (91) (22) 112
Other assets and liabilities 47 (8) (14)
Net cash provided by operating activities 1,772 1,312 1,485
Cash flows from investing activities:      
Proceeds from the sale of property, plant and equipment 0 0 1
Payments to acquire property, plant and equipment (298) (291) (188)
Proceeds from the sale of equity securities 5 22 12
Payments to acquire equity securities (8) (13) (22)
Proceeds from convertible note 4 0 0
Payment in exchange for convertible note (12) (4) (5)
Proceeds from Divestiture of Businesses 50 0 0
Acquisitions of businesses and intangible assets, net of cash acquired (51) (52) (547)
Net cash used in investing activities (310) (338) (749)
Cash flows from financing activities:      
Proceeds from the issuance of common stock under employee stock plans 67 58 55
Payment of taxes related to net share settlement of equity awards (54) (67) (76)
Payments for repurchase of common stock (575) (1,139) (788)
Payment of dividends (265) (250) (236)
Proceeds from Issuance of Long-Term Debt 0 600 848
Repayments of Long-Term Debt 0 609 417
Payments of debt issuance costs 0 0 (7)
Net proceeds from (Repayments of ) Short-Term Debt (35) 35 (75)
Payment for Contingent Consideration (68) 0 0
Net cash used in financing activities (930) (1,372) (696)
Effect of exchange rate movements 5 (36) 3
Cash, cash equivalents and restricted cash at beginning of year 1,056 1,490 1,447
Net increase (decrease) in cash, cash equivalents and restricted cash 537 (434) 43
Cash, cash equivalents and restricted cash at end of year 1,593 1,056 1,490
Supplemental Cash Flow Information [Abstract]      
Income Taxes Payments, Net of refunds received 199 279 211
Interest payments, net of capitalized interest 89 85 76
Net change in property, plant and equipment included in accounts payable and accrued liabilities-increase (decrease) 4 $ 26 $ 27
Resolution Bioscience, Inc.      
Adjustments to reconcile net income to net cash provided by operating activities:      
Net gain on Divestiture of Business $ 43    
v3.23.4
CONSOLIDATED STATEMENT OF EQUITY - USD ($)
shares in Thousands, $ in Millions
Total
Common Stock
Additional Paid-in Capital
Retained Earnings (Accumulated Deficit)
Accumulated Other Comprehensive Loss
Total Stockholders Equity
Total stockholders' equity   $ 3 $ 5,311 $ 81 $ (522) $ 4,873
Balance (in shares) at Oct. 31, 2020   306,198        
Net Income $ 1,210     1,210   1,210
Other comprehensive income (loss) 240       240 240
Total comprehensive income 1,450         1,450
Cash dividends declared (236)     (236)   (236)
Shares-based awards issued, Net of tax (Shares)   2,083        
Share-based awards issued, Net of tax (Value)     (20)     (20)
Stock Repurchased and Retired During Period, Shares   (6,073)        
Stock Repurchased and Retired During Period, Value   $ 0 (81) (707)   (788)
Share-based compensation     110     110
Balance (in shares) at Oct. 31, 2021   302,208        
Total stockholders' equity   $ 3 5,320 348 (282) 5,389
Net Income 1,254     1,254   1,254
Other comprehensive income (loss) (65)       (65) (65)
Total comprehensive income 1,189         1,189
Cash dividends declared (250)     (250)   (250)
Shares-based awards issued, Net of tax (Shares)   1,419        
Share-based awards issued, Net of tax (Value)     (9)     (9)
Stock Repurchased and Retired During Period, Shares   (8,368)        
Stock Repurchased and Retired During Period, Value   $ 0 (111) (1,028)   (1,139)
Share-based compensation     125     125
Balance (in shares) at Oct. 31, 2022   295,259        
Total stockholders' equity 5,305 $ 3 5,325 324 (347) 5,305
Net Income 1,240     1,240   1,240
Other comprehensive income (loss) 20       20 20
Total comprehensive income 1,260         1,260
Cash dividends declared (265)     (265)   (265)
Shares-based awards issued, Net of tax (Shares)   1,473        
Share-based awards issued, Net of tax (Value)     13     13
Stock Repurchased and Retired During Period, Shares   (4,609)        
Stock Repurchased and Retired During Period, Value   $ 0 (62) (517)   (579)
Share-based compensation     111     111
Balance (in shares) at Oct. 31, 2023   292,123        
Total stockholders' equity $ 5,845 $ 3 $ 5,387 $ 782 $ (327) $ 5,845
v3.23.4
CONSOLIDATED STATEMENT OF EQUITY (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Statement of Stockholders' Equity [Abstract]      
Payment, Tax Withholding, Share-based Payment Arrangement $ 54 $ 67 $ 76
Cash Dividends Declared (per common share) $ 0.900 $ 0.840 $ 0.776
v3.23.4
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Oct. 31, 2023
Accounting Policies [Abstract]  
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Overview.  Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Announced Exit and Subsequent Divestiture of Resolution Bioscience Business. During the third quarter of fiscal year 2023, we made the decision to exit the Resolution Bioscience business within our diagnostics and genomics segment and recorded a long-lived asset impairment charge of $270 million. In the fourth quarter of fiscal year 2023, we received an unsolicited offer and entered into an agreement to divest the Resolution Bioscience business for $50 million. As a result, we recorded a gain on the divestiture of $43 million in other income (expense), net in the consolidated statement of operations, which included an adjustment to goodwill of $13 million.

Basis of Presentation.  The accompanying consolidated financial statements have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year.

Principles of Consolidation.  The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated.

Use of Estimates.  The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement plan assumptions, restructuring and accounting for income taxes.

Restructuring. The main components of our restructuring plan are related to workforce reductions, consolidation of excess leased facilities and site closures. Workforce reduction charges are accrued when payment of benefits becomes probable that the employees are entitled to the severance and the amounts can be estimated. Consolidation of facilities costs primarily consists of accelerated depreciation of right-of-use assets classified as held and used. In accordance with the accounting guidance, it was determined that certain assets had been abandoned, and an assessment was made of the remaining useful lives and potential alternative uses. If the amounts and timing of cash flows from restructuring activities are significantly different from what we have estimated, the actual amounts of restructuring and other related charges could be materially different, either higher or lower, than those we have recorded.

Risks and Uncertainties. We are subject to risks common to companies in the analytical instrument industry, such as global economic and financial market conditions, fluctuations in foreign currency exchange rates and fluctuations in customer demand, among others.

Revenue Recognition.  We enter into contracts to sell products, services or combinations of products and services. Products may include hardware or software and services may include one-time service events or services performed over time.

We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers, (“ASC 606’’). See also Note 3, "Revenue" for additional information on revenue recognition.

Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled in exchange for
those products or services, the transaction price. For equipment, consumables, and most software licenses, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. For products that transfer control over time, revenue is recognized as the performance obligation is satisfied. Product over time revenue is assessed against the following criteria: the performance creates an asset that the customer controls as the asset is created; the asset has no alternative use; and we have an enforceable right to payment. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded.

Service revenue includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. Revenue for these contracts is recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls not included in a support contract are recognized to revenue at the time a service is performed.

We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis.

Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue.

For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per geographic region for each performance obligation. Standalone selling prices are determined for each distinct good or service in the contract, and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations.

A portion of our revenue relates to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance.

Deferred Revenue.  Contract liabilities (deferred revenue) primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements (performance obligations) to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either in current liabilities in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation.

Sales Taxes.  Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue.

Shipping and Handling Costs.  Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented.
Research and Development.  Costs related to research, design and development of our products are charged to research and development expense as they are incurred.

Advertising.  Advertising costs are generally expensed as incurred and amounted to $54 million in 2023, $66 million in 2022 and $63 million in 2021.

Taxes on Income.  Income tax expense or benefit is based on income or loss before taxes. Deferred tax assets and liabilities are recognized principally for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. See Note 5, "Income Taxes" for more information.

Net Income Per Share.  Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense are assumed proceeds to be used to repurchase hypothetical shares. See Note 6, "Net Income Per Share".

Cash, Cash Equivalents and Short-Term Investments.  We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value.

As of October 31, 2023, approximately $1,287 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries. Our cash and cash equivalents mainly consist of short-term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds.

We classify equity investments as short-term investments based on their nature and our intent and ability to exit within a year or less. As of October 31, 2023, we had no short-term investments.

Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows:
October 31,
202320222021
(in millions)
Cash and cash equivalents$1,590 $1,053 $1,484 
Restricted cash included in other assets3 3 6 
Total cash, cash equivalents and restricted cash$1,593 $1,056 $1,490 


Accounts Receivable, net.  Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable have been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2023 and 2022 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of estimated product returns which are not material.

Concentration of Credit Risk.  Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, equity investments with readily determinable fair value securities, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents or short-term investments. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis.
Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount, and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of accounts receivable as of October 31, 2023, or 2022.

Inventory.  Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates and assumptions about future demand, economic conditions and actual usage, which require management judgment. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of inventory levels, sales trends and forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory and to estimate and record reserves for excess, slow-moving and obsolete inventory.

Property, Plant and Equipment.  Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over 3 years to 10 years. We use the straight-line method to depreciate assets.

Capitalized Software.  We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over 3 years to 5 years once development is complete.

Leases. We determine whether an arrangement is, or contains, a lease at inception. We record the present value of operating lease payments as right-of-use ("ROU") assets and lease liabilities on the consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, we have used a number of factors including the company's credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component.

A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of Accounting Standard Codification ("ASC") Topic 606, Revenue Contracts with Customers, and are therefore accounted for in accordance with ASC Topic 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance. In a lease arrangement that is a multiple-element arrangement that contains equipment leases and the supply of consumables, the revenue associated with the instrument rental is treated under the lease accounting standard ASC 842, whereas the revenue associated with the consumables, the non-lease component, is recognized in accordance with the ASC 606 revenue standard.

   See also Note 9, "Leases" for additional information about our leases.

Acquisitions. Agilent accounts for the acquisition of a business using the acquisition method of accounting, and we allocate the fair value of the purchase price to the tangible assets acquired, liabilities assumed, and intangible assets acquired, including in-process research and development (“IPR&D”), based on their estimated fair values. The excess value of the cost of an acquired business over the fair value of the assets acquired and liabilities assumed is recognized as goodwill. The fair value
of IPR&D is initially capitalized as an intangible asset with an indefinite life. When an IPR&D project is completed, the IPR&D is reclassified as an amortizable purchased intangible asset and amortized to costs of revenues over the asset’s estimated useful life.

Our determination of the fair value of the intangible assets acquired involves the use of significant estimates and assumptions. Specifically, our determination of the fair value of the developed product technology and IPR&D acquired involve significant estimates and assumptions related to revenue growth rates and discount rates. Our determination of the fair value of customer relationships acquired involved significant estimates and assumptions related to revenue growth rates, discount rates, and customer attrition rates. Our determination of the fair value of the tradename acquired involved the use of significant estimates and assumptions related to revenue growth rates, royalty rates and discount rates. The company believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use. Actual results could differ materially from these estimates.

Goodwill and Purchased Intangible Assets. We assess our goodwill and purchased intangible assets for impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Under the authoritative guidance, we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the quantitative test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e., greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required.

The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers.

If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, then we are required to perform a quantitative impairment test on goodwill to identify and measure the amount of a goodwill impairment loss to be recognized. A goodwill impairment loss, if any, is measured as the amount by which a reporting unit's carrying value, including goodwill, exceeds its fair value, not to exceed the carrying amount of goodwill. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units.

In fiscal year 2023, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a quantitative test for goodwill impairment of the three reporting units as of September 30, 2023, our annual impairment test date. Based on the results of our quantitative testing, there was no impairment of goodwill as of September 30, 2023. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2023, 2022 and 2021.

Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. IPR&D is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned.

Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e., greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2023. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair values of these indefinite-lived intangible assets are greater than their respective carrying values. Each quarter we review the events and
circumstances to determine if impairment of indefinite-lived intangible assets is indicated. During the year ended October 31, 2023, 2022 and 2021, there were no impairments of indefinite-lived intangible assets.

Impairment of Long-Lived Assets.  We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. During the year ended October 31, 2023, we recorded an impairment charge of long-lived assets including intangible assets of $277 million primarily related to the exit of our Resolution Bioscience business. During the year ended October 31, 2022, there were no impairments of other long-lived assets or intangible assets. During the year ended October 31, 2021, we recorded an impairment charge of long-lived assets of $2 million.

Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). We evaluate our investments in privately held companies on an ongoing basis. We have determined that as of October 31, 2023 and 2022, there were no VIEs required to be consolidated in our consolidated financial statements because we do not have a controlling financial interest in any of the VIEs in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs and vice-versa, based on changes in facts and circumstances including changes in contractual arrangements and capital structure.

As of October 31, 2023 and 2022, the total carrying value of investments and loans in privately held companies considered as VIEs was $82 million and $87 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are classified as long-term investments and the loans are classified within other current assets and other assets (depending upon tenure of loan) on the consolidated balance sheet.

Investments.  Equity investments without readily determinable fair value consist of non-marketable equity securities (typically investments in privately-held companies). These investments are accounted for using the measurement alternative at cost, and we adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) included in net income as and when it occurs. Equity investments with readily determinable fair value consist of marketable equity securities which were reclassified from non-marketable equity securities following the commencement of public market trading of the issuers and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. There are no equity investments with readily determinable fair value at October 31, 2023 and 2022. Other investments with readily determinable fair value consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Trading securities, which are comprised of mutual funds, bonds and other similar instruments and deferred compensation liabilities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. There are no equity method investments as of October 31, 2023 and 2022. The company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.

Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of short-term and long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. As of October 31, 2023, and October 31, 2022, the fair value of the term loan approximates its carrying value. As of October 31, 2023, the fair value of our senior notes was $1,747 million with a carrying value of $2,135 million. This compares to the fair value of our senior notes of $1,754 million with a carrying value of $2,133 million as of October 31, 2022. The change in the fair value compared to carrying value in the year ended October 31, 2023, is primarily due to increased market interest rates. The fair value was calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign
exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 12, "Fair Value Measurements" for additional information on the fair value of financial instruments and contingent consideration.

Warranty.  Our standard warranty terms typically extend for one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 16, "Guarantees".

Employee Compensation and Benefits.  Amounts owed to employees, such as accrued salary, bonuses and vacation benefits are accounted for within employee compensation and benefits. The total amount of accrued vacation benefit was $120 million and $123 million as of October 31, 2023, and 2022, respectively.

Retirement and Post-Retirement Plans. We have various defined benefit and defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Assumptions used to determine the benefit obligations and the expense for these plans are derived annually. See Note 14, “Retirement plans and post-retirement pension plans” for additional information.

Retirement of Treasury Shares. Upon the formal retirement of treasury shares, we deduct the par value of the retired treasury shares from common stock and allocate the excess of cost over par as a deduction to additional paid-in capital, based on the pro-rata portion of additional paid-in-capital, and the remaining excess as a deduction to retained earnings. All retired treasury shares revert to the status of authorized but unissued shares.

Share-Based Compensation.  For the years ended 2023, 2022 and 2021, we accounted for share-based awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant date fair value method of accounting. Under the fair value method, we recorded compensation expense for all share-based awards of $112 million in 2023, $126 million in 2022 and $111 million in 2021. See Note 4, "Share-based Compensation" for additional information.

Derivative Instruments.  Agilent is exposed to global foreign currency exchange rate and interest rate risks in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts, interest rate swaps and interest rate locks to manage financial exposures resulting from changes in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the company's fixed-rate debt. To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk otherwise inherent in the amount and duration of the hedged exposures and comply with established risk management policies. Foreign exchange hedging contracts generally mature within twelve months, interest rate swaps mature at the same time as the maturity of the debt and interest rate locks mature at the same time as the issuance of debt. In order to manage foreign currency exposures in a few limited jurisdictions, we may enter into foreign exchange contracts that do not qualify for hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the parent company. We do not use derivative financial instruments for trading or speculative purposes.

All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are designated and qualify as a cash flow hedge, changes in the value of the effective portion of the derivative instrument are recognized in accumulated comprehensive income (loss), a component of stockholders' equity. For derivative instruments that are designated and qualify as a net investment hedge, changes in the value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss) - translation adjustment. Amounts associated with cash flow hedges are reclassified and recognized in income when either the forecasted transaction occurs or it becomes probable the forecasted transaction will not occur. Derivatives not designated as hedging instruments are recorded on the balance sheet at their fair value and changes in the fair values are recorded in the income statement in the current period. Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet. Changes in the fair value of the ineffective portion of derivative instruments are recognized in earnings in the current period. The impact of the ineffectiveness measurement in 2023, 2022 and 2021 was not material. Cash flows from derivative instruments are classified in the statement of cash flows in the same category as the cash flows from the hedged or economically hedged item, primarily in operating activities.
Foreign Currency Translation.  We translate and remeasure balance sheet and income statement items into U.S. dollars. For those subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using monthly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity.
For those subsidiaries that operate in a U.S. dollar functional environment, foreign currency assets and liabilities are remeasured into U.S. dollars at current exchange rates except for non-monetary assets and capital accounts which are remeasured at historical exchange rates. Revenue and expenses are generally remeasured at monthly exchange rates which approximate average exchange rates in effect during each period. Gains or losses from foreign currency remeasurement are included in consolidated net income. Net gains or losses resulting from foreign currency transactions, including hedging gains and losses, are reported in other income (expense), net and were $2 million gain for 2023, $6 million loss for 2022 and $4 million loss for 2021.
v3.23.4
NEW ACCOUNTING PRONOUNCEMENTS
 12 Months Ended
Oct. 31, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]  
NEW ACCOUNTING PRONOUNCEMENTS NEW ACCOUNTING PRONOUNCEMENTS
Recently Adopted Accounting Pronouncements
In November 2021, the FASB issued updates to increase the transparency in the annual disclosure requirements relating to government assistance received by business entities in Topic 832, Government Assistance. The guidance requires certain disclosures about transactions with a government that are accounted for by applying a grant or contribution model. On November 1, 2022, we adopted this guidance which did not have a material impact on our consolidated financial statements and disclosures.

New Accounting Pronouncements Not Yet Adopted

In November 2023, the FASB issued guidance to improve segment reporting through enhanced disclosure requirements of significant segment expenses. These amendments are effective for our fiscal year 2025, and interim periods within fiscal year 2026, with early adoption permitted. These amendments apply on a retrospective basis. We are currently evaluating the impact of these amendments on our consolidated financial statements.

On December 14, 2023, the FASB issued guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for our fiscal year 2026, with early adoption permitted. These amendments apply on a prospective basis with a retrospective option. We do not expect that the adoption of this guidance will have a material impact on our consolidated financial statements.

Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.
v3.23.4
REVENUE
 12 Months Ended
Oct. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer REVENUE
The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:

Life Sciences and Applied MarketsAgilent CrossLabDiagnostics and GenomicsTotal
(in millions)
Year Ended October 31, 2023:
Americas$1,284 $634 $814 $2,732 
Europe920 417 417 1,754 
Asia Pacific1,652 517 178 2,347 
Total$3,856 $1,568 $1,409 $6,833 
Year Ended October 31, 2022:
Americas$1,331 $567 $784 $2,682 
Europe907 382 410 1,699 
Asia Pacific1,769 503 195 2,467 
Total$4,007 $1,452 $1,389 $6,848 
Year Ended October 31, 2021:
Americas$1,199 $510 $695 $2,404 
Europe893 378 417 1,688 
Asia Pacific1,571 472 184 2,227 
Total$3,663 $1,360 $1,296 $6,319 

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
Years Ended October 31,
202320222021
(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical$2,433 2,515 $2,224 
Chemicals and Advanced Materials1,543 1,521 1,328 
Diagnostics and Clinical966 963 938 
Food628 617 601 
Academia and Government601 576 576 
Environmental and Forensics662 656 652 
Total$6,833 $6,848 $6,319 
Revenue by Type
Instrumentation$2,742 2,907 $2,657 
Non-instrumentation and other4,091 3,941 3,662 
Total$6,833 $6,848 $6,319 

Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue include sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services.
Contract Balances

Contract Assets

Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheet. The balances of contract assets as of October 31, 2023 and 2022, were $252 million and $275 million, respectively.

Contract Liabilities

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2022 and 2023:

Contract
Liabilities
(in millions)
Ending balance as of October 31, 2021$519 
Net revenue deferred in the period437 
Revenue recognized that was included in the contract liability balance at the beginning of the period(372)
Change in deferrals from customer cash advances, net of revenue recognized11 
Currency translation and other adjustments(38)
Ending balance as of October 31, 2022$557 
Net revenue deferred in the period488 
Revenue recognized that was included in the contract liability balance at the beginning of the period(409)
Change in deferrals from customer cash advances, net of revenue recognized(28)
Currency translation and other adjustments8 
Ending balance as of October 31, 2023$616 

Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation.

Contract Costs

Incremental costs of obtaining a contract with a customer are recognized as an asset if we expect the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The changes in total capitalized costs to obtain a contract were immaterial during the years ended October 31, 2023 and 2022 and are included in other current and long-term assets on the consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities.

Transaction Price Allocated to the Remaining Performance Obligations

We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less.
The estimated revenue expected to be recognized for remaining performance obligations that have an original term of more than one year, as of October 31, 2023, was $331 million, the majority of which is expected to be recognized over the next 12 months. Remaining performance obligations primarily include extended warranty, customer manufacturing contracts, and software maintenance contracts and revenue associated with lease arrangements.
v3.23.4
SHARE-BASED COMPENSATION
 12 Months Ended
Oct. 31, 2023
Share-Based Payment Arrangement, Noncash Expense [Abstract]  
SHARE-BASED COMPENSATION SHARE-BASED COMPENSATION
Agilent accounts for share-based awards in accordance with the provisions of the accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including restricted stock units, employee stock options, employee stock purchases made under our employee stock purchase plan and performance share awards granted to selected members of our senior management under the long-term performance plan ("LTPP") based on estimated fair values.

Description of Share-Based Plans

Employee Stock Purchase Plan.    Effective May 1, 2020, we adopted the 2020 Employee Stock Purchase Plan ("ESPP") which replaced our previous Employee Stock Purchase Plan. The ESPP allows eligible employees to contribute up to 10 percent of their base compensation to purchase shares of our common stock at 85 percent of the closing market price at purchase date. There are 31 million shares authorized for issuance in connection with the ESPP.

Under our ESPP, employees purchased 487,735 shares for $57 million in 2023, 469,701 shares for $54 million in 2022 and 462,237 shares for $46 million in 2021. As of October 31, 2023, the number of shares of common stock authorized and available for issuance under our ESPP was 24,277,203. This includes 324,092 shares for $28 million of common stock to be settled in November 2023 to participants in consideration of the aggregate participant contributions as of October 31, 2023.

Incentive Compensation Plans. On November 15, 2017 and March 21, 2018, the Board of Directors and the stockholders, respectively, approved the Agilent Technologies, Inc. 2018 Stock Plan (the "2018 Plan") which amends, including renaming and extending the term of, the Agilent Technologies, Inc. 2009 Stock Plan (the "2009 Plan"). The 2018 Plan provides for the grant of awards in the form of stock options, stock appreciation rights ("SARs"), restricted stock, restricted stock units ("RSUs"), performance shares and performance units with performance-based conditions on vesting or exercisability, and cash awards. The 2018 Plan has a term of ten years. As of October 31, 2023, 19,519,780 shares were available for future awards under the 2018 Plan.

Stock Options. In fiscal year 2021, we resumed granting stock options. Stock options granted under the 2018 Plan may be either "incentive stock options", as defined in Section 422 of the Internal Revenue Code, or non-statutory. Options generally vest at a rate of 25 percent per year over a period of four years from the date of grant with a maximum contractual term of ten years. The exercise price for stock options is generally not less than 100 percent of the fair market value of our common stock on the date the stock award is granted. We issue new shares of common stock when employee stock options are exercised.

Performance Shares. We have two LTPP performance stock award programs, which are administered under the 2018 Stock Plan, for our executive officers and other key employees. Participants in our LTPP Total Stockholders’ Return (“TSR”) and LTPP Earnings Per Share (“EPS”) programs are entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets for the programs are met. The LTPP-TSR awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the TSR set at the beginning of the performance period. The LTPP-EPS awards are based on the company’s EPS performance over a three-year period. The performance targets for the LTPP-EPS for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. All LTPP awards are subject to a one-year post-vest holding period. The final LTPP award may vary from zero to 200 percent of the target award. The maximum contractual term for awards under the LTPP program is three years. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met.

Restricted Stock Units. We also issue restricted stock units under our share-based plans. The estimated fair value of the restricted stock unit awards granted under the Stock Plans is determined based on the market price of Agilent's common stock on the date of grant adjusted for expected dividend yield. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant. All restricted stock units granted to our executives after November 1, 2015, are subject to a one-year post-vest holding period.
Impact of Share-based Compensation Awards

We have recognized compensation expense based on the estimated grant date fair value method under the authoritative guidance. For all share-based awards we have recognized compensation expense using a straight-line amortization method. As the guidance requires that share-based compensation expense should be based on awards that are ultimately expected to vest, estimated share-based compensation has been reduced for estimated forfeitures.

The impact on our results for share-based compensation was as follows:

Years Ended October 31,
202320222021
(in millions)
Cost of products and services$34 $30 $26 
Research and development13 14 12 
Selling, general and administrative65 82 73 
Total share-based compensation expense$112 $126 $111 

At October 31, 2023 and 2022, no share-based compensation was capitalized within inventory.

Valuation Assumptions

The fair value of share-based awards for our employee stock option awards was estimated using the Black-Scholes option pricing model. Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock. For the volatility of our LTPP (TSR) grants, we used our own historical stock price volatility.

The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the price at purchase and uses the purchase date to establish the fair market value.

We use historical volatility to estimate the expected stock price volatility assumption for employee stock option awards. In reaching the conclusion, we have considered many factors including the extent to which our options are currently traded and our ability to find traded options in the current market with similar terms and prices to the options we are valuing. In estimating the expected life of our options granted, we considered the historical option exercise behavior of our executives, which we believe is representative of future behavior.

The estimated fair value of restricted stock units and LTPP (EPS) awards is determined based on the market price of our common stock on the date of grant adjusted for expected dividend yield. The compensation cost for LTPP (EPS) reflects the cost of awards that are probable to vest at the end of the performance period.

All LTPP awards granted to our senior management employees have a one-year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model. The model calculates the potential lost value if the employees were able to sell the shares during the lack of marketability period, instead of being required to hold the shares. The model used the same historical stock price volatility and dividend yield assumption used for the Monte Carlo simulation model and an expected dividend yield to compute the discount.
The following assumptions were used to estimate the fair value of awards granted.

 Years Ended October 31,
 202320222021
Stock Option Plan:
Weighted average risk-free interest rate3.9%1.5%0.5%
Dividend yield0.6%0.5%0.7%
Weighted average volatility28%26%26%
Expected life5.5 years5.5 years5.5 years
LTPP:   
Volatility of Agilent shares31%29%30%
Volatility of selected peer-company shares
22%-84%
23%-81%
24%-57%
Pair-wise correlation with selected peers42%41%45%
Post-vest restriction discount for all executive awards7.1%6.5%6.8%

Share-Based Payment Award Activity

Employee Stock Options

The following table summarizes employee stock option award activity of our employees and directors for 2023.

Options
Outstanding 		Weighted
Average
Exercise Price
 (in thousands) 
Outstanding at October 31, 20221,097 $94 
Granted269 $147 
Exercised(249)$41 
Cancelled(37)$142 
Outstanding at October 31, 20231,080 $118 

The options outstanding and exercisable for equity share-based payment awards at October 31, 2023 were as follows:

 Options OutstandingOptions Exercisable
Range of
Exercise Prices		Number
Outstanding		Weighted
Average
Remaining
Contractual
Life		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value		Number
Exercisable		Weighted
Average
Remaining
Contractual
Life		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value
 (in thousands)(in years) (in thousands)(in thousands)(in years) (in thousands)
$40.01 - $50.00
210 1.0$41 13,088 210 1.0$41 13,088 
$100.00- $110.00
311 7.0$110 — 177 7.0$110 — 
$110.01 - $150.00
319 8.8$143 — 40 8.3$136 — 
$150.01 & Over
240 8.0$161 — 80 8.0$161 — 
1,080 6.6$118 $13,088 507 4.8$92 $13,088 

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value, based on the company's closing stock price of $103.37 at October 31, 2023, which would have been received by award holders had all award holders exercised their awards that were in-the-money as of that date. The total number of in-the-money awards exercisable at October 31, 2023 was approximately 0.2 million.
The following table summarizes the aggregate intrinsic value of options exercised and the fair value of options granted in 2023, 2022 and 2021:

Aggregate
Intrinsic Value		Weighted
Average
Exercise
Price		Per Share Value Using Black-Scholes Model
 (in thousands) 
Options exercised in fiscal 2021$34,305 $33 
Black Scholes per share value of options granted during fiscal 2021$26 
Options exercised in fiscal 2022$10,765 $38 
Black Scholes per share value of options granted during fiscal 2022$39 
Options exercised in fiscal 2023$25,303 $41 
Black Scholes per share value of options granted during fiscal 2023$47 

As of October 31, 2023, the unrecognized share-based compensation cost for outstanding stock option awards, net of expected forfeitures, was $9 million. The amount of cash received from the exercise of share-based awards granted was $67 million in 2023, $58 million in 2022 and $55 million in 2021.

Non-Vested Awards

The following table summarizes non-vested award activity in 2023 primarily for our LTPP and restricted stock unit awards.
SharesWeighted
Average
Grant Price
 (in thousands) 
Non-vested at October 31, 20222,103 $114 
Granted864 $146 
Vested(1,096)$90 
Forfeited(181)$134 
Change in LTPP shares in the year due to exceeding performance targets199 $79 
Non-vested at October 31, 20231,889 $136 

As of October 31, 2023, the unrecognized share-based compensation cost for non-vested restricted stock awards net of expected forfeitures was approximately $116 million which is expected to be amortized over a weighted average period of 2.2 years. The total fair value of restricted stock awards vested was $99 million for 2023, $89 million for 2022 and $84 million for 2021.
v3.23.4
INCOME TAXES
 12 Months Ended
Oct. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The domestic and foreign components of income before taxes are:

 Years Ended October 31,
 202320222021
 (in millions)
U.S. operations$614 $858 $876 
Non-U.S. operations725 646 484 
Total income before taxes$1,339 $1,504 $1,360 
The provision for income taxes is comprised of:

 Years Ended October 31,
 202320222021
 (in millions)
U.S. federal taxes:   
Current$117 $173 $122 
Deferred(84)(28)(1)
Non-U.S. taxes:   
Current26 47 (3)
Deferred38 35 14 
State taxes, net of federal benefit:   
Current12 22 17 
Deferred(10)1 1 
Total provision for income taxes$99 $250 $150 


The differences between the U.S. federal statutory income tax rate and our effective tax rate are:

 Years Ended October 31,
 202320222021
 (in millions)
Profit before tax times statutory rate$281 $316 $286 
State income taxes, net of federal benefit2 23 18 
Non-U.S. income taxed at different rates20 (18)5 
Change in unrecognized tax benefits(35)(6)(84)
Foreign-derived intangible income deduction(41)(46)(35)
Realized loss on divestiture of business(104)— — 
Excess tax benefits from stock-based compensation(14)(19)(29)
Other, net(10)— (11)
Provision (benefit) for income taxes$99 $250 $150 
Effective tax rate7.4 %16.6 %11.0 %

For 2023, our income tax expense was $99 million with an effective tax rate of 7.4 percent. For the year ended October 31, 2023, our effective tax rate and the resulting provision for income taxes were impacted by the federal tax benefit of $104 million related to the realized loss on the divestiture of a business. The income taxes for the year ended October 31, 2023, also include the tax benefit of $41 million related to foreign-derived intangible income along with the tax benefit of $30 million related to the release of tax reserves in the U.S. due to the settlement of the audit with the Internal Revenue Service ("IRS") for tax years 2018 and 2019.

For 2022, our income tax expense was $250 million with an effective tax rate of 16.6 percent. For the year ended October 31, 2022, our effective tax rate and the resulting provision for income taxes were impacted by the tax benefit of $46 million related to foreign-derived intangible income.

For 2021, our income tax expense was $150 million with an effective tax rate of 11 percent. For the year ended October 31, 2021, our effective tax rate and the resulting provision for income taxes were impacted by the discrete benefit of $93 million related to the release of tax reserves in various jurisdictions due to audit settlements and the expiration of statutes of limitations. The income taxes for the year ended October 31, 2021, also include the excess tax benefits from stock-based compensation of $29 million.

We have negotiated a tax holiday in Singapore. The tax holiday provides a lower rate of taxation on certain classes of income and requires various thresholds of investments and employment or specific types of income. The tax holiday in Singapore was renegotiated and extended through 2030. As a result of the incentive, the impact of the tax holiday decreased income taxes by $54 million, $53 million, and $35 million in 2023, 2022, and 2021, respectively. The benefit of the tax holiday on net income per share (diluted) was approximately $0.18, $0.18, and $0.11 in 2023, 2022 and 2021, respectively.
The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are:

 Years Ended October 31,
 20232022
 (in millions)
Deferred Tax Assets
Intangibles$102 $62 
Employee benefits, other than retirement36 45 
Net operating loss, capital loss, and credit carryforwards152 157 
Share-based compensation24 23 
Capitalized R&D41 — 
Lease obligations37 29 
Other58 58 
Deferred tax assets$450 $374 
Tax valuation allowance(112)(115)
Deferred tax assets, net of valuation allowance$338 $259 
Deferred Tax Liabilities
Property, plant and equipment$(26)$(11)
Pension benefits and retiree medical benefits(25)(24)
Right-of-use asset(37)(29)
Other(4)(7)
Deferred tax liabilities$(92)$(71)
Net deferred tax assets (liabilities)$246 $188 

Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. As of October 31, 2023, we continued to maintain a valuation allowance of $112 million until sufficient positive evidence exists to support reversal. The valuation allowance is primarily related to deferred tax assets for the states of California and Colorado, along with the net operating losses in the Netherlands and capital losses in Australia.

At October 31, 2023, we had federal, state and foreign net operating loss carryforwards of approximately $13 million, $90 million and $248 million, respectively. The federal and state net operating loss carryforwards are subject to various limitations under Section 382 of the Internal Revenue Code and applicable state tax laws. If not utilized, the federal and state net operating loss carryforwards will begin to expire in 2024. If not utilized, $2 million of the foreign net operating loss carryforwards will begin to expire in 2024. The remaining $246 million of the foreign net operating losses carry forward indefinitely. At October 31, 2023, we had foreign capital loss carryforwards of $107 million. The foreign capital losses carry forward indefinitely. At October 31, 2023, we had state tax credit carryforwards of approximately $88 million. The state tax credits carry forward indefinitely.

The breakdown between long-term deferred tax assets and deferred tax liabilities was as follows:

 October 31,
 20232022
 (in millions)
Long-term deferred tax assets (included within other assets)$284 $246 
Long-term deferred tax liabilities (included within other long-term liabilities)(38)(58)
Total$246 $188 
The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows:
October 31,
20232022
(in millions)
Current income tax assets (included within other current assets)$100 $87 
Long-term income tax assets (included within other assets)3 11 
Current income tax liabilities (included within other accrued liabilities)(73)(51)
Long-term income tax liabilities (included within other long-term liabilities)(162)(216)
Total$(132)$(169)

Uncertain Tax Positions

The aggregate changes in the balances of our gross unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows:

202320222021
 (in millions)
Balance, beginning of year$123 $133 $195 
Additions for tax positions related to the current year5 5 6 
Additions for tax positions from prior years3 — 4 
Reductions for tax positions from prior years(27)(9)— 
Settlements with taxing authorities— — (30)
Statute of limitations expirations(6)(6)(42)
Balance, end of year$98 $123 $133 

As of October 31, 2023, we had $114 million of unrecognized tax benefits, including interest and penalties of which $68 million, if recognized, would affect our effective tax rate.

We recognized tax benefit of $5 million in 2023, tax benefit of $2 million in 2022, and tax benefit of $19 million in 2021, for interest and penalties related to unrecognized tax benefits. Interest and penalties accrued as of October 31, 2023 and 2022 were $16 million and $21 million, respectively.

In the U.S., tax years remain open back to the year 2020 for federal income tax purposes and 2019 for significant states. On October 30, 2023, we reached an agreement with the IRS for tax years 2018 and 2019. The settlement resulted in the recognition of previously unrecognized tax benefits of $30 million. In other major jurisdictions where we conduct business, the tax years generally remain open back to the year 2012.

With these jurisdictions and the U.S., it is reasonably possible that some tax audits may be completed over the next twelve months. However, management is not able to provide a reasonably reliable estimate of the timing of any other future tax payments or change in unrecognized tax benefits, if any.
v3.23.4
NET INCOME (LOSS) PER SHARE
 12 Months Ended
Oct. 31, 2023
Earnings Per Share [Abstract]  
NET INCOME (LOSS) PER SHARE NET INCOME PER SHARE
The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below.
 Years Ended October 31,
 202320222021
 (in millions)
Numerator:   
Net income$1,240 $1,254 $1,210 
Denominators:   
Basic weighted average shares294 299 304 
Potential common shares — stock options and other employee stock plans2 1 3 
Diluted weighted average shares296 300 307 

The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards.

We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share, stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value collectively were greater than the average market price of our common stock because their effect would also be anti-dilutive.

In 2023, 2022 and 2021, we issued share-based awards of approximately 1.5 million, 1.4 million and 2.1 million, respectively.  For the years ended 2023, 2022 and 2021, the impacts of the anti-dilutive potential common shares that were excluded from the calculation of diluted earnings per share were not material.
v3.23.4
INVENTORY
 12 Months Ended
Oct. 31, 2023
Inventory Disclosure [Abstract]  
INVENTORY INVENTORY
Inventory as of October 31, 2023 and 2022 consisted of the following:
 October 31,
 20232022
 (in millions)
Finished goods$570 $555 
Purchased parts and fabricated assemblies461 483 
Inventory$1,031 $1,038 

Inventory-related excess and obsolescence charges of $40 million were recorded in cost of products in 2023, $24 million in 2022 and $29 million in 2021. We record excess and obsolete inventory charges for both inventory on our site as well as inventory at our contract manufacturers and suppliers where we have non-cancelable purchase commitments.
v3.23.4
PROPERTY, PLANT AND EQUIPMENT, NET
 12 Months Ended
Oct. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT, NET PROPERTY, PLANT AND EQUIPMENT, NET
Property, plant and equipment as of October 31, 2023 and 2022, consisted of the following:
 October 31,
 20232022
 (in millions)
Land$60 $59 
Buildings and leasehold improvements1,409 1,255 
Machinery and equipment749 674 
Software275 260 
Total property, plant and equipment2,493 2,248 
Accumulated depreciation and amortization(1,223)(1,148)
Property, plant and equipment, net$1,270 $1,100 

During 2023, we recorded asset impairments of $11 million. During 2022, there were no asset impairments. During 2021, we recorded asset impairments of $2 million. Depreciation expenses were $128 million in 2023, $120 million in 2022 and $122 million in 2021. In 2023 and 2022 we retired approximately $68 million and $48 million, respectively, of assets, the majority of which were fully depreciated and no longer in use.
v3.23.4
LEASES
 12 Months Ended
Oct. 31, 2023
Leases [Abstract]  
Lessee, Operating Leases LEASES
As a lessee, we have various non-cancelable operating lease agreements for office space, warehouses, distribution centers, research and development facilities, manufacturing and production locations as well as vehicles, personal computers and other equipment. Our real estate leases have remaining lease terms of one to thirty years, which represent the non-cancelable periods of the leases and include extension options that we determined are reasonably certain to be exercised. We exclude options that are not reasonably certain to be exercised from our lease terms, ranging from six months to twenty years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms. We often receive incentives from our landlords, such as rent abatement periods, which effectively reduce the total lease payments owed for these leases. Vehicle, personal computer and other equipment operating leases have terms between three and five years.


The components of lease cost for operating leases were as follows:
Year Ended October 31,
202320222021
(in millions)
Operating lease cost$68 $59 $59 
Short-term lease cost2 2 2 
Variable lease cost (a)
16 15 14 
Sublease income(16)(14)(13)
Total lease cost$70 62 62 
(a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes.

In the fourth quarter of fiscal year 2023, we initiated a new restructuring plan ("FY23 Plan") designed to reduce costs and expenses in response to the current macroeconomic conditions. The consolidation of excess facilities under the FY23 Plan resulted in $7 million of accelerated depreciation of our ROU assets.

During fiscal year 2023, we recorded ROU asset impairments of $8 million primarily related to the exit of our Resolution Bioscience business. There were no impairments for fiscal years 2022 and 2021.
Supplemental cash flow information related to leases was as follows:
Year Ended October 31,
202320222021
(in millions)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating leases$56 $53 $57 
Non-cash right of use assets obtained in exchange for operating lease obligations$70 $38 $53 

Supplemental balance sheet information related to leases was as follows:
October 31,
Financial Statement Line Item20232022
(in millions, except lease term and discount rate)
Assets:
Operating lease:
Right of use assetOther assets$154 $150 
Liabilities:
Current
Operating lease liabilitiesOther accrued liabilities$46 $51 
Long-term
Operating lease liabilitiesOther long-term liabilities$118 $101 
Weighted average remaining lease term (in years)
Operating leases8.3 years7.4 years
Weighted average discount rate
Operating leases3.3 %2.4 %

Future minimum rents payable as of October 31, 2023 under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the consolidated balance sheet as follows:
Operating Leases
(in millions)
2024$51 
202532 
202622 
202714 
202811 
Thereafter59 
Total undiscounted future minimum lease payments$189 
Less: amount of lease payments representing interest(25)
Present value of future minimum lease payments$164 
Less: current liabilities(46)
Long-term lease liabilities$118 

As of October 31, 2023, we had no additional significant operating or finance leases that had not yet commenced.

As a lessor, we have contracts for equipment leased to customers primarily in connection with our diagnostics business which include both operating-type lease and sales-type finance lease arrangements. We account for the non-lease component under the revenue recognition ASC 606 guidance and the lease component under the leasing ASC 842 guidance. Equipment lease revenue for operating lease agreements is recognized as visualization kits and reagents are shipped over the life of the lease. The cost of customer leased equipment is recorded within property, plant and equipment, and is netted in the consolidated balance sheet with depreciation over the equipment’s estimated useful life. For an arrangement that has been classified as a
sales-type lease, revenue is recognized when the transfer of control of the underlying leased asset has occurred and the net investment lease recorded which is calculated at the present value of the remaining lease payments due from the lessee.

Revenue allocated to the lease income for both sales-type finance lease and operating lease rental arrangements represents less than one percent of total net revenue in the years ended October 31, 2023, 2022 and 2021, respectively.

As of October 31, 2023, the original cost and net book value of operating leased assets were $30 million and $7 million, respectively. As of October 31, 2023, lease receivables related to sales-type leases were $42 million. As of October 31, 2022, the original cost and net book value of operating leased assets were $29 million and $4 million, respectively. As of October 31, 2022, lease receivables related to sales-type leases were $38 million.
v3.23.4
GOODWILL AND OTHER INTANGIBLE ASSETS
 12 Months Ended
Oct. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2022 and 2023:
Life Sciences and Applied MarketsDiagnostics and GenomicsAgilent CrossLabTotal
 (in millions)
Goodwill as of October 31, 2021$1,743 $1,964 $268 $3,975 
Foreign currency translation impact(19)(11)(12)(42)
Goodwill arising from acquisitions and adjustments19 — — 19 
Goodwill as of October 31, 2022$1,743 $1,953 $256 $3,952 
Foreign currency translation impact4 1 1 6 
Goodwill arising from acquisitions and adjustments— 15 — 15 
Goodwill adjustment related to divestiture of business— (13)— (13)
Goodwill as of October 31, 2023$1,747 $1,956 $257 $3,960 
In connection with the divestiture of our Resolution Bioscience business in the fourth quarter of fiscal year 2023, we received $50 million in cash and recorded a gain on the divestiture of $43 million in other income (expense), net in the consolidated statement of operations which included an adjustment to goodwill of $13 million in our diagnostics and genomics segment. We used the relative fair value approach in determining the adjustment to goodwill.
In addition, we performed a goodwill impairment test, and the results of the analysis indicated that the fair values for all three of our reporting units were in excess of their carrying values by substantial amounts as of September 30, 2023, our annual impairment test date. Based on the results of our quantitative testing, there was no impairment of goodwill for our reporting units in fiscal year 2023. There was no impairment of goodwill in fiscal years 2022 and 2021.
The component parts of other intangible assets at October 31, 2022 and 2023 are shown in the table below:
 Other Intangible Assets
 Gross
Carrying
Amount		Accumulated
Amortization		Net Book
Value
 (in millions)
As of October 31, 2022:   
Purchased technology$1,733 $1,068 $665 
Backlog8 8 — 
Trademark/Tradename196 148 48 
Customer relationships180 105 75 
Third-party technology and licenses32 9 23 
Total amortizable intangible assets$2,149 $1,338 $811 
In-Process R&D10 — 10 
Total$2,159 $1,338 $821 
As of October 31, 2023:   
Purchased technology$1,467 $1,093 $374 
Trademark/Tradename196 163 33 
Customer relationships149 112 37 
Third-party technology and licenses34 13 21 
Total amortizable intangible assets$1,846 $1,381 $465 
In-Process R&D10 — 10 
Total$1,856 $1,381 $475 

In fiscal year 2023, we acquired two businesses for a total purchase price of $51 million. As a result, we recorded additions of $15 million to goodwill and $50 million to other intangible assets in our diagnostics and genomics and life sciences and applied markets segments primarily related to these two acquisitions. During fiscal year 2023, other intangible assets in total increased $2 million due to the impact of foreign currency translation.

In fiscal year 2022, we acquired Polymer Standards Service GmbH (PSS), a provider of solutions in the field of polymer characterization for $41 million. During fiscal year 2022, we recorded additions to goodwill of $19 million and additions to other intangible assets of $35 million related to the acquisition of PSS and advanced artificial intelligence technology. During the year other intangible assets decreased $3 million due to the impact of foreign currency translation.

In general, for United States federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible.

There were no impairments of indefinite-lived intangible assets during fiscal years 2023, 2022 and 2021. During the third quarter of fiscal year 2023, we recorded an impairment of finite-lived intangible assets of $258 million related to the exit of our Resolution Bioscience business in our diagnostics and genomics segment. Of the $258 million, $249 million was recorded in cost of sales and $9 million was recorded in selling, general and administrative expenses on our consolidated statement of operations. During fiscal years 2022 and 2021, there were no impairments of finite-lived intangible assets recorded. During 2023, we also wrote-off the gross carrying amounts of $7 million and the related accumulated amortization of fully amortized intangible assets which were no longer being used.

Amortization expense of intangible assets was $140 million in 2023, $192 million in 2022, and $195 million in 2021.
Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below:
Estimated future amortization expense:
(in millions)
2024$100 
2025$83 
2026$54 
2027$52 
2028$45 
Thereafter$131 
v3.23.4
INVESTMENTS
 12 Months Ended
Oct. 31, 2023
Schedule of Investments [Abstract]  
Investment Holdings, Schedule of Investments INVESTMENTS
The following table summarizes the company's equity investments as of October 31, 2023 and 2022 (net book value):

 October 31,
 20232022
 (in millions)
Long-Term  
Equity investments - without readily determinable fair value$102 $141 
Other investments - with readily determinable fair value26 23 
Trading securities36 31 
Total long-term investments$164 $195 

Equity investments without readily determinable fair value (RDFV) consist of non-marketable equity securities issued by private companies and include VIEs. These investments are accounted for using the measurement alternative at cost adjusting for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer). The adjustments are included in net income in the period in which they occur. Other investments with RDFV consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income.

Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income.

Our investments without RDFV and marketable equity securities with RDFV are subject to periodic impairment review. The impairment analysis requires significant judgment to identify events or circumstances that would likely have a significant adverse effect on the future value of the investment.

Gains and losses reflected in other income (expense), net for our equity investments with RDFV and equity investments without RDFV are summarized below:
Years Ended October 31,
202320222021
( in millions)
Net gain (loss) recognized during the period on equity securities$(41)$(67)$98 
Less: Net gain (loss) on equity securities sold during the period(15)11 6 
Unrealized gain (loss) on equity securities held as of the end of the period$(26)$(78)$92 

Unrealized losses on our equity securities without RDFV were $26 million in 2023. Unrealized gains on our equity securities without RDFV were $6 million and $17 million in 2022 and 2021, respectively.

In 2023, net unrealized gains on our trading securities were $2 million. In 2022 and 2021, net unrealized losses were $7 million and net unrealized gains were $8 million, respectively, on our trading securities.
There were no impairments of investments in 2023, 2022 and 2021.
v3.23.4
FAIR VALUE MEASUREMENTS
 12 Months Ended
Oct. 31, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability.

Fair Value Hierarchy

The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value:

Level 1 — applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 — applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data.

Level 3 — applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2023 were as follows:
  Fair Value Measurement
at October 31, 2023 Using
 October 31,
2023		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$994 $994 $— $— 
Derivative instruments (foreign exchange contracts)19 — 19 — 
Long-term    
Trading securities36 36 — — 
Other investments26 — 26 — 
Total assets measured at fair value$1,075 $1,030 $45 $— 
Liabilities:    
Short-term    
Derivative instruments (foreign exchange contracts)$2 $— $2 $— 
Contingent consideration1 — — 1 
Long-term    
Deferred compensation liability36 — 36 — 
Total liabilities measured at fair value$39 $— $38 $1 

Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2022 were as follows:
  Fair Value Measurement
at October 31, 2022 Using
 October 31,
2022		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$492 $492 $— $— 
Derivative instruments (foreign exchange contracts)31 — 31 — 
Long-term    
Trading securities31 31 — — 
Other investments23 — 23 — 
Total assets measured at fair value$577 $523 $54 $— 
Liabilities:   
Short-term    
Derivative instruments (foreign exchange contracts)$5 $— $5 $— 
Contingent consideration66 — — 66 
Long-term    
Deferred compensation liability31 — 31 — 
Contingent consideration1 — — 1 
Total liabilities measured at fair value$103 $— $36 $67 

Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active
markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable.

Trading securities, which are comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss) within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income.

Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. These shares have been classified as level 2 because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are or can be derived from and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself.

Contingent Consideration. As of October 31, 2023, the fair value of the contingent consideration liability relates to milestone payments in connection with one acquisition.

The contingent consideration liability is our only Level 3 asset or liability. A summary of the Level 3 activity follows:

Contingent Consideration
(in millions)
Balance at October 31, 2021$89 
Additions to contingent consideration3 
Change in fair value (included within selling, general and administrative expenses)(25)
Balance at October 31, 2022$67 
Additions to contingent consideration 5 
Payments(72)
Change in fair value (included within selling, general and administrative expenses)1 
Balance at October 31, 2023$1 

The fair value of the contingent consideration liability as of October 31, 2023 was estimated to be $1 million and was recorded in other accrued liabilities on the consolidated balance sheet. During fiscal year 2023, we made contingent consideration payments totaling $72 million related to the achievement of certain technical milestones associated with our acquisition of Resolution Bioscience and another acquisition.

Resolution Bioscience. In the third quarter of fiscal year 2023, we decided to exit the Resolution Bioscience business and subsequently divested our interest in the business in the fourth quarter of fiscal year 2023. We project that there are no potential future milestone payments related to the Resolution Bioscience business.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

Long-Lived Assets

For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2023, 2022 and 2021:

 Years Ended
October 31,
 202320222021
 (in millions)
Long-lived assets held and used$277 $— $2 

For the year ended October 31, 2023, long-lived assets held and used with a carrying amount of $277 million were written down to fair value of zero, resulting in an impairment charge of $277 million primarily related to the exit of our Resolution Bioscience business in our diagnostics and genomics segment. For the year ended October 31, 2022, there were no
impairments of long-lived assets held and used. For the year ended October 31, 2021, long-lived assets held and used with a carrying value of $2 million were written down to their fair value of zero, resulting in an impairment of $2 million.

Fair values for the impaired long-lived assets during 2023 were measured using level 3 inputs. To determine the fair value of long-lived assets in 2023, we primarily used an estimate of undiscounted future cash flows expected over the life of the primary asset. Since the carrying value was greater than the undiscounted cash flow, the loss was measured by the excess of the carrying amount of the asset over its fair value of zero.

Non-Marketable Equity Securities

For the years ended October 31, 2023, 2022 and 2021, there were no impairments in non-marketable securities without readily determinable fair value.

For the years ended October 31, 2023, 2022 and 2021, net unrealized losses of $26 million, and net unrealized gains of $6 million and $17 million respectively, were included in net income as an adjustment to the carrying value of non-marketable equity securities without readily determinable fair value based on an observable market transaction.

As of October 31, 2023, the cumulative net gain (loss) on our non-marketable equity securities without readily determinable fair values was comprised of $38 million gains and $29 million losses, and the carrying amount was $102 million. As of October 31, 2022, the cumulative net gain (loss) on our non-marketable equity securities without readily determinable fair values was comprised of a $35 million gain and no losses, and the carrying amount was $141 million.

Fair values for the non-marketable securities included in long-term investments on the consolidated balance sheet were measured using Level 3 inputs because they are primarily equity stock issued by private companies without quoted market prices. To estimate the fair value of our non-marketable securities, we use the measurement alternative to record these investments at cost and adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) as and when they occur.
v3.23.4
DERIVATIVES
 12 Months Ended
Oct. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVES DERIVATIVES
We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts and purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates.

Cash Flow Hedges

We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of October 31, 2023, changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss).  Amounts associated with cash flow hedges are reclassified to cost of sales in the consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense), net in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense), net in the consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the years ended October 31, 2023, 2022 and 2021, ineffectiveness and gains and losses recognized in other income (expense), net due to de-designation of cash flow hedge contracts were not significant.

In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest
expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2023 was $3 million.

In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2023 was $3 million.

Net Investment Hedges

We enter into foreign exchange contracts to hedge net investments in foreign operations to mitigate the risk of adverse movements in exchange rates. These foreign exchange contracts are carried at fair value and are designated and qualify as net investment hedges under the criteria prescribed in the authoritative guidance. Changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss)- translation adjustment and are assessed for effectiveness against the underlying exposure every reporting period. If the company’s net investment changes during the year, the hedge relationship will be assessed and de-designated if the hedge notional amount is outside of prescribed tolerance with a gain/loss reclassified from other comprehensive income (loss) to other income (expense) in the current period. For the years ended October 31, 2023, 2022 and 2021 ineffectiveness and the resultant effect of any gains or losses recognized in other income (expense) due to de-designation of the hedge contracts were not significant.

Other Hedges

Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense), net in the consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.

Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties.

A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions.

The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of October 31, 2023, was $1 million. The credit-risk-related contingent features underlying these agreements had not been triggered as of October 31, 2023.
The number of open foreign exchange forward contracts and aggregated notional amounts by designation as of October 31, 2023 were as follows:

 Number of Open Forward
Contracts 		Aggregate Notional Amount
USD
Buy/(Sell)
 ($ in millions)
Derivatives designated as hedging instruments:
Cash Flow Hedges
Foreign exchange forward contracts270$(383)
Net Investment Hedges
Foreign exchange forward contracts3$(11)
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts194$(162)

Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance.


The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2023 and 2022 were as follows:
Fair Values of Derivative Instruments
Asset DerivativesLiability Derivatives
 Fair Value Fair Value
Balance Sheet LocationOctober 31,
2023		October 31,
2022		Balance Sheet LocationOctober 31,
2023		October 31,
2022
(in millions)
Derivatives designated as hedging instruments:     
Cash flow hedges     
Foreign exchange contracts     
Other current assets$15 $23 Other accrued liabilities$1 $2 
Net investment hedges
Foreign exchange contracts
Other current assets$1 $— Other accrued liabilities$— $— 
Derivatives not designated as hedging instruments:     
Foreign exchange contracts     
Other current assets$3 $8 Other accrued liabilities$1 $3 
Total derivatives$19 $31  $2 $5 
The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows:

Years Ended October 31,
202320222021
 (in millions)
Derivatives designated as hedging instruments:   
Cash flow hedges   
Foreign exchange contracts:
Loss reclassified from accumulated other comprehensive income (loss) into interest expense$(2)$(2)$(1)
Gain (loss) recognized in accumulated other comprehensive income (loss)$(4)$56 $2 
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales$2 $36 $(16)
Gain on time value of forward contracts recorded in cost of sales$7 $— $— 
Net investment hedges
Foreign exchange contracts:
Gain (loss) recognized in accumulated other comprehensive income (loss) - translation adjustment$(1)$5 $1 
Gain on time value of forward contracts recorded in other income (expense)— — 1 
Derivatives not designated as hedging instruments:   
Gain recognized in other income (expense), net $3 $10 $— 

At October 31, 2023 the total amount of existing net gain that is expected to be reclassified from accumulated other comprehensive income (loss) is $20 million. Within the next twelve months it is estimated that $12 million of gain included within the net amount of accumulated other comprehensive income (loss) will be reclassified to cost of sales in respect of cash flow hedges.
v3.23.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS
 12 Months Ended
Oct. 31, 2023
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS
General.  We have various defined benefit and defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees.

Agilent provides defined benefits to U.S. employees who meet eligibility criteria under the Agilent Technologies, Inc. Retirement Plan (the "RP").

Effective November 1, 2014, Agilent’s U.S. RP was closed to new entrants including new employees, new transfers to the U.S. payroll and rehires. As of April 30, 2016, benefits under the RP were frozen. Any pension benefit earned in the U.S. Plans through April 30, 2016, remained fully vested and is payable on termination, retirement, death, or permanent disability, based on an eligible participant’s years of credited service, age and other criteria. There are no additional benefit accruals after April 30, 2016.

For eligible service through October 31, 1993, the benefit payable under the Agilent Retirement Plan is reduced by any amounts due to the eligible employee under the Agilent defined contribution Deferred Profit-Sharing Plan (the "DPSP"), which was frozen and closed to new participants as of November 1993.

As of October 31, 2023 and 2022, the fair value of plan assets of the DPSP was $81 million and $93 million, respectively. Note that the projected benefit obligation for the DPSP equals the fair value of plan assets.

Agilent also maintains a Supplemental Benefits Retirement Plan ("SBRP") in the U.S., which is an unfunded non-qualified defined benefit plan to provide supplemental retirement benefits to certain employees that would be provided under the RP but for limitations imposed by the Internal Revenue Code. The RP and the SBRP comprise the "U.S. Plans" in the tables below.
Eligible employees outside the U.S. generally receive retirement benefits under various retirement plans based upon factors such as years of service and/or employee compensation levels. Eligibility is generally determined in accordance with local statutory requirements.

Post-Retirement Medical Benefit Plans. In addition to receiving retirement benefits, Agilent U.S. employees who meet eligibility requirements as of their termination date may participate in the Agilent Technologies, Inc. Health Plan for Retirees. As of January 1, 2020, the Health Plan for Retirees is comprised solely of insured pre-65 HMOs as the self-funded Pre-Medicare Medical Plan was eliminated effective December 31, 2019. The Health Plan for Retirees was closed to new retiree entrants after December 31, 2020.

If eligible, a retiree may receive a fixed amount (different fixed amounts for different groups) under the Retiree Medical Account (“RMA”) or a fixed monthly amount under the Agilent Reimbursement Arrangement (“ARA”).

Any new employee hired on or after November 1, 2014, will not be eligible to participate in the post-retirement medical benefit plans upon retiring.

401(k) and Other Defined Contribution Plans.  Eligible Agilent U.S. employees may participate in the Agilent Technologies, Inc. 401(k) Plan. We match an employee's contributions (both pre-tax and Roth) up to a maximum of 6 percent of an employee's annual eligible compensation, subject to the annual regulatory limit. All matching contributions vest immediately. Effective May 1, 2016 until April 30, 2022, we provided an additional transitional company contribution for certain eligible employees equal to 3 percent, 4 percent or 5 percent of an employee's annual eligible compensation due to the RP benefits being frozen. The maximum employee contribution to the 401(k) Plan is 50 percent of an employee's annual eligible compensation, subject to regulatory limitations. We also sponsor and make contributions to various other defined contribution plans that cover employees outside of the U.S.

Our defined contribution plan expenses included in income from operations were as follows:

Years Ended October 31,
202320222021
(in millions)
Contributions to the 401(k) Plan$47 $46 $43 
Contributions to plans outside the U.S51 47 43 
Total defined contribution plan expense$98 $93 $86 
Components of Net periodic cost.  The service cost component is recorded in cost of sales and operating expenses in the consolidated statement of operations. All other cost components are recorded in other income (expense), net in the consolidated statement of operations. The company uses alternate methods of amortization as allowed by the authoritative guidance which amortizes the actuarial gains and losses on a consistent basis for the years presented. For U.S. Plans, gains and losses are amortized over the average future lifetime of participants using the corridor method. For most Non-U.S. Plans and U.S. Post-Retirement Benefit Plans, gains and losses are amortized over the average remaining future service period or remaining lifetime of participants depending upon the plan, using a separate layer for each year's gains and losses.

For the years ended October 31, 2023, 2022 and 2021, components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of:
 PensionsU.S. Post-Retirement Benefit Plans
 U.S. PlansNon-U.S. Plans
 202320222021202320222021202320222021
 (in millions)
Net periodic benefit cost (benefit)         
Service cost — benefits earned during the period$— $— $— $16 $22 $22 $— $1 $1 
Interest cost on benefit obligation21 14 14 24 9 8 4 2 2 
Expected return on plan assets(19)(27)(29)(36)(43)(49)(4)(6)(6)
Amortization of net actuarial (gain) loss— — 4 (2)25 53 (1)(2)4 
Amortization of prior service benefit— — — — — — (1)(1)(1)
Total periodic benefit cost (benefit)$2 $(13)$(11)$2 $13 $34 $(2)$(6)$— 
Settlement loss$4 $4 $1 $— $— $— $— $— $— 
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss         
Net actuarial (gain) loss$22 $16 $(92)$(13)$(83)$(114)$9 $15 $(30)
Amortization of net actuarial (gain) loss— — (4)2 (25)(53)1 2 (4)
Amortization of prior service benefit— — — — — — 1 1 1 
Loss due to settlement(4)(4)(1)— — — — — — 
Foreign currency— — — 2 11 5 — — — 
Total recognized in other comprehensive (income) loss$18 $12 $(97)$(9)$(97)$(162)$11 $18 $(33)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss$24 $3 $(107)$(7)$(84)$(128)$9 $12 $(33)
Funded Status.    As of October 31, 2023 and 2022, the funded status of the defined benefit and post-retirement benefit plans was:

 U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S.
Post-Retirement
Benefit Plans
 202320222023202220232022
 (in millions)
Change in fair value of plan assets:      
Fair value — beginning of year$396 $551 $748 $1,093 $85 $116 
Actual return on plan assets(8)(122)14 (147)(2)(26)
Employer contributions— — 21 17 — — 
Participants' contributions— — 1 1 — — 
Benefits paid(8)(10)(35)(35)(7)(5)
Settlements(21)(23)— — — — 
Currency impact— — 42 (181)— — 
Fair value — end of year$359 $396 $791 $748 $76 $85 
Change in benefit obligation:      
Benefit obligation — beginning of year$357 $512 $665 $1,100 $65 $84 
Service cost— — 16 22 — 1 
Interest cost21 14 24 9 4 2 
Participants' contributions— — 1 1 — — 
Actuarial (gain) loss(5)(133)(33)(262)3 (17)
Benefits paid(9)(10)(35)(35)(7)(5)
Settlements(21)(26)— — — — 
Currency impact— — 44 (170)— — 
Benefit obligation — end of year$343 $357 $682 $665 $65 $65 
Overfunded (underfunded) status of PBO$16 $39 $109 $83 $11 $20 
Amounts recognized in the consolidated balance sheet consist of:      
Other assets$19 $42 $174 $140 $11 $20 
Employee compensation and benefits(1)(1)— — — — 
Retirement and post-retirement benefits(2)(2)(65)(57)— — 
Total net asset (liability)$16 $39 $109 $83 $11 $20 
Amounts Recognized in Accumulated Other Comprehensive Income (Loss):
Actuarial (gains) losses$66 $48 $43 $52 $4 $(6)
Prior service costs (benefits)— — — — (2)(3)
Total$66 $48 $43 $52 $2 $(9)


The actuarial gains and losses related to the change in plan obligations were a total of $35 million net gain for 2023 and $412 million net gain for 2022. The actuarial net gain that arose in 2023 and 2022 was primarily due to increases in discount rates and changes in other financial and demographic assumptions partially offset by losses due to plan experience.
Investment Policies and Strategies as of October 31, 2023. In the U.S., target asset allocations for our retirement and post-retirement benefit plans were approximately 50 percent to equities and approximately 50 percent to fixed income investments. Our DPSP target asset allocation is approximately 60 percent to equities and approximately 40 percent to fixed income investments. Approximately 1 percent of the retirement and post-retirement plans consists of limited partnerships. The general investment objective for all our plan assets is to obtain the optimum rate of investment return on the total investment portfolio consistent with the assumption of a reasonable level of risk. Specific investment objectives for the plans' portfolios are to: maintain and enhance the purchasing power of the plans' assets; achieve investment returns consistent with the level of risk being taken; and earn performance rates of return in accordance with the benchmarks adopted for each asset class. Outside the U.S., our target asset allocation (excluding annuity contracts in the U.K.) ranges from zero to 60 percent to equities, from 38 percent to 100 percent to fixed income investments, and from zero to 25 percent to real estate, depending on the plan. All plans' assets are broadly diversified. Due to fluctuations in equity and bond markets, our actual allocations of plan assets at October 31, 2023, may differ from the target allocation. Our policy is to bring the actual allocation in line with the target allocation.

Equity securities include exchange-traded common stock and preferred stock of companies from broadly diversified industries. Fixed income securities include a global portfolio of corporate bonds of companies from diversified industries, government securities, mortgage-backed securities, asset-backed securities, derivative instruments and other. Real estate securities include holdings of managed investment funds which invest primarily in the equity instruments of real estate investment trusts and other similar real estate investments. Other investments include a group trust consisting primarily of private equity partnerships. Portions of the cash and cash equivalent, equity, and fixed income investments are held in commingled funds that are valued using Net Asset Value (“NAV”) as the practical expedient. In addition, some of the investments valued using NAV as the practical expedient may have limits on their redemption to weekly or monthly and/or may require prior written notice specified by each fund. In December 2021, we entered into an insurance buy-in contract for a portion of benefit obligations under the U.K. defined benefit plan which was funded from existing pension plan assets with no adjustment made to the benefit obligations. It has been classified as an “Annuity Contract” since the insurance buy-in contract is similar to an annuity contract. It matches cash flows with future benefit payments for listed pensioners as of the contract date with the obligation remaining with the plan. This contract is issued by a third-party insurance company with no affiliation to us.

Fair Value. The measurement of the fair value of pension and post-retirement plan assets uses the valuation methodologies and the inputs as described in Note 12, "Fair Value Measurements".

Cash and Cash Equivalents - Cash and cash equivalents consist of short-term investment funds. The funds also invest in short-term domestic fixed income securities and other securities with debt-like characteristics emphasizing short-term maturities and quality. Some of our cash and cash equivalents are held in commingled funds. Other cash and cash equivalents are generally classified as Level 2 investments.

Equity - This consists of equity securities which have quoted prices in active markets and has been classified as Level 1 investments.

Fixed Income - Some of the fixed income securities are not actively traded and are valued at quoted prices based on the terms of the security and comparison to similar securities traded on an active market; these are classified as Level 2 investments. Securities which have quoted prices in active markets are classified as Level 1 investments.

Real Estate - Real estate securities include holdings of managed investment funds which invest primarily in the equity instruments of real estate investment trust and other similar real estate investments. Since the existing securities have quoted prices in active markets, it has been classified as level 1 and grouped with equity.

Annuity Contract – This consists of the U.K. insurance buy-in contract. Since it is valued on an insurer pricing basis, which reflects the purchase price adjusted for changes in discount rates and other actuarial assumptions which approximates fair value, it has been classified as level 3.

Other Investments - Other investments also include partnership investments where, due to their private nature, pricing inputs are not readily observable. Asset valuations are developed by the general partners that manage the partnerships. These valuations are based on proprietary appraisals, application of public market multiples to private company cash flows, utilization of market transactions that provide valuation information for comparable companies and other methods. Holdings of limited partnerships are classified as Level 3.
Agilent has adopted the accounting guidance related to the presentation of certain investments using the NAV practical expedient. The accounting guidance exempts investments using this practical expedient from categorization within the fair value hierarchy.


The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2023 and 2022.
  Fair Value Measurement
at October 31, 2023 Using
 October 31,
2023		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$2 $— $— $— $2 
Equity182 44 — — 138 
Fixed Income174 — — — 174 
Other Investments1 — — 1 — 
Total assets measured at fair value$359 $44 $— $1 $314 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
  Fair Value Measurement
at October 31, 2022 Using
 October 31,
2022		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$1 $— $— $— $1 
Equity194 49 — — 145 
Fixed Income199 — — — 199 
Other Investments2 — — 2 — 
Total assets measured at fair value$396 $49 $— $2 $345 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2023 and 2022:
 Years Ended
October 31.
 20232022
Balance, beginning of year$2 $2 
Realized gains/(losses)— — 
Unrealized gains/(losses)— — 
Purchases, sales, issuances, and settlements(1)— 
Transfers in (out)— — 
Balance, end of year$1 $2 
The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2023 and 2022.
  Fair Value Measurement
at October 31, 2023 Using
 October 31,
2023		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$— $— $— $— $— 
Equity39 10 — — 29 
Fixed Income36 — — — 36 
Other Investments1 — — 1 — 
Total assets measured at fair value$76 $10 $— $1 $65 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

  Fair Value Measurement
at October 31, 2022 Using
 October 31,
2022		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$— $— $— $— $— 
Equity42 10 — — 32 
Fixed Income42 — — — 42 
Other Investments1 — — 1 — 
Total assets measured at fair value$85 $10 $— $1 $74 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.


For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2023 and 2022:
 Years Ended
October 31,
 20232022
Balance, beginning of year$1 $1 
Realized gains/(losses)— — 
Unrealized gains/(losses)— — 
Purchases, sales, issuances, and settlements— — 
Transfers in (out)— — 
Balance, end of year$1 $1 
The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2023 and 2022:

  Fair Value Measurement
at October 31, 2023 Using
 October 31,
2023		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$17 $1 $16 $— $— 
Equity367 266 — — 101 
Fixed Income321 113 113 — 95 
Annuity Contract86 — — 86 — 
Total assets measured at fair value$791 $380 $129 $86 $196 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

  Fair Value Measurement
at October 31, 2022 Using
 October 31,
2022		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$22 $— $22 $— $— 
Equity360 264 — — 96 
Fixed Income274 83 98 — 93 
Annuity Contract92 — — 92 — 
Total assets measured at fair value$748 $347 $120 $92 $189 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
.

For non-U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2023 and 2022:
 Years Ended
October 31,
 20232022
Balance, beginning of year$92 $— 
Unrealized losses(5)(39)
Purchases, sales, issuances, and settlements(6)(5)
Transfers in (out)— 159 
Currency impact5 (23)
Balance, end of year$86 $92 
The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2023 or 2022.
 20232022
 Benefit
Obligation		 Benefit
Obligation		 
 Fair Value of
Plan Assets		Fair Value of
Plan Assets
 PBOPBO
 (in millions)
U.S. defined benefit plans where PBO exceeds the fair value of plan assets $3 $— $3 $— 
U.S. defined benefit plans where fair value of plan assets exceeds PBO 340 359 354 396 
Total$343 $359 $357 $396 
Non-U.S. defined benefit plans where PBO exceeds the fair value of plan assets $197 $132 $172 $114 
Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO 485 659 493 634 
Total$682 $791 $665 $748 
 ABO ABO 
U.S. defined benefit plans where ABO exceeds the fair value of plan assets$3 $— $3 $— 
U.S. defined benefit plans where the fair value of plan assets exceeds ABO340 359 354 396 
Total$343 $359 $357 $396 
Non-U.S. defined benefit plans where ABO exceeds the fair value of plan assets $192 $132 $167 $114 
Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO480 659 485 634 
Total$672 $791 $652 $748 

Contributions and Estimated Future Benefit Payments.  During fiscal year 2024, we expect to make no contributions to the U.S. defined benefit plans and the Post-Retirement Medical Plans. We expect to contribute $18 million to plans outside the U.S. The following table presents expected future benefit payments for the next 10 years:

U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S. Post-Retirement
Benefit Plans
 (in millions)
2024$33 $35 $7 
2025$31 $36 $7 
2026$31 $37 $8 
2027$32 $37 $8 
2028$32 $39 $8 
2029 - 2033$142 $202 $33 

Assumptions.  The assumptions used to determine the benefit obligations and net periodic cost (benefit) for our defined benefit and post-retirement benefit plans are presented in the tables below. The expected long-term return on assets below represents an estimate of long-term returns on investment portfolios consisting of a mixture of equities, fixed income and alternative investments in proportion to the asset allocations of each of our plans. We consider long-term rates of return, which are weighted based on the asset classes (both historical and forecasted) in which we expect our pension and post-retirement funds to be invested. Discount rates reflect the current rate at which pension and post-retirement obligations could be settled based on the measurement dates of the plans - October 31. The U.S. discount rates at October 31, 2023 and 2022, were
determined based on the results of matching expected plan benefit payments with cash flows from a hypothetically constructed bond portfolio. The non-U.S. rates were generally based on published rates for high-quality corporate bonds. The range of assumptions that were used for the non-U.S. defined benefit plans reflects the different economic environments within various countries.

Assumptions used to calculate the net periodic cost (benefit) in each year were as follows:

 For years ended October 31,
 202320222021
U.S. defined benefit plans:   
Discount rate6.00%2.75%2.75%
Expected long-term return on assets5.00%5.00%7.00%
Non-U.S. defined benefit plans:   
Discount rate
1.50-4.77%
0.29-1.76%
0.07-1.54%
Average increase in compensation levels
2.00-3.25%
2.00-3.50%
2.00-3.00%
Expected long-term return on assets
3.25-5.50%
2.75-5.50%
4.00-5.50%
Interest crediting rate for cash balance plans
0.50-2.10%
0.30-0.50%
0.10-0.50%
U.S. post-retirement benefits plans:   
Discount rate6.00%2.75%2.50%
Expected long-term return on assets5.00%5.00%7.00%
Current medical cost trend rate7.00%6.00%6.25%
Ultimate medical cost trend rate4.75%4.50%4.50%
Medical cost trend rate decreases to ultimate rate in year202920272029

Assumptions used to calculate the benefit obligation were as follows:

 As of the Years Ending October 31,
 20232022
U.S. defined benefit plans:  
Discount rate6.50%6.00%
Non-U.S. defined benefit plans:  
Discount rate
1.78-5.63%
1.50-4.77%
Average increase in compensation levels
2.00-3.25%
2.00-3.25%
Interest crediting rate for cash balance plans
0.50-1.80%
0.50-2.10%
U.S. post-retirement benefits plans:  
Discount rate6.60%6.00%
Current medical cost trend rate6.50%7.00%
Ultimate medical cost trend rate4.75%4.75%
Medical cost trend rate decreases to ultimate rate in year20292029
v3.23.4
RESTRUCTURING AND OTHER RELATED COSTS
 12 Months Ended
Oct. 31, 2023
Restructuring and Related Activities [Abstract]  
Restructuring and Other Related Costs Disclosure RESTRUCTURING AND OTHER RELATED COSTS
In the fourth quarter of fiscal year 2023, we initiated a new restructuring plan ("FY23 Plan") designed to reduce costs and expenses in response to the current macroeconomic conditions. The plan includes a reduction of our total headcount by approximately 400 regular employees, representing approximately 2 percent of our global workforce, and the consolidation of our excess facilities, including some site closures.

In connection with this plan, we have recorded approximately $46 million in restructuring and other related costs in fiscal year 2023. These costs include severance and other personnel costs associated with the workforce reduction. The consolidation of excess facilities includes accelerated depreciation expenses of ROU and machinery and equipment assets, and other facilities-related costs. The timing and scope of the workforce reductions will vary based on local legal requirements.
These actions impact all three of our business segments. The costs associated with this restructuring plan have not been allocated to our business segments' results; however, each business segment will benefit from the future cost savings from these actions. When completed, the restructuring program is expected to result in the reduction in annual cost of sales and operating expenses over the three business segments. While the majority of the workforce reduction will be completed in the first quarter of 2024, we expect to substantially complete the remaining restructuring activities by the end of fiscal year 2024.

A summary of total restructuring activity is shown in the table below:

Workforce
Reduction		Consolidation of Excess FacilitiesTotal
(in millions)
Balance at October 31, 2022$— $— $— 
Income statement expense33 13 46 
Accelerated share-based compensation expense(1)— (1)
Accelerated depreciation expenses of ROU and machinery and equipment— (8)(8)
Cash payments(1)— (1)
Balance at October 31, 2023$31 $5 $36 

The restructuring and other related costs, which totaled $36 million at October 31, 2023, are recorded in other accrued liabilities on the consolidated balance sheet and reflect estimated future cash outlays.

A summary of the charges in the consolidated statement of operations resulting from the restructuring plan is shown below:


Year Ended
October 31,
2023
(in millions)
Cost of products and services$11 
Research and Development6 
Selling, general and administrative29 
Total restructuring costs$46 
v3.23.4
GUARANTEES
 12 Months Ended
Oct. 31, 2023
Guarantees [Abstract]  
GUARANTEES GUARANTEES
Standard Warranty

We accrue for standard warranty costs based on historical trends in actual warranty charges over the past 12 months. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product.
A summary of the standard warranty accrual activity is shown in the table below.

 October 31,
 20232022
 (in millions)
Standard warranty accrual, beginning balance$30 $30 
Accruals for warranties including change in estimates57 50 
Settlements made during the period(58)(50)
Standard warranty accrual, ending balance$29 $30 
Accruals for warranties due within one year$29 $30 


Bank Guarantees

Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately $39 million and $37 million as of October 31, 2023 and 2022, respectively. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss.

Indemnifications in Connection with Transactions

In connection with various divestitures, acquisitions, spin-offs and other transactions, we have agreed to indemnify certain parties, their affiliates and/or other related parties against certain damages and expenses that might occur in the future. These indemnifications may cover a variety of liabilities, including, but not limited to, employee, tax, environmental, intellectual property, litigation and other liabilities related to the business conducted prior to the date of the transaction. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2023.

Indemnifications to Officers and Directors

Our corporate bylaws require that we indemnify our officers and directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Agilent and such other entities, including service with respect to employee benefit plans. In addition, we have entered into separate indemnification agreements with each director and each board-appointed officer of Agilent which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in the bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated. Historically, we have not made payments related to these obligations, and the fair value for these indemnification obligations was not material as of October 31, 2023.

Other Indemnifications

As is customary in our industry and as provided for in local law in the U.S. and other jurisdictions, many of our standard contracts provide remedies to our customers and others with whom we enter into contracts, such as defense, settlement, or payment of judgment for intellectual property claims related to the use of our products. From time to time, we indemnify customers, as well as our suppliers, contractors, lessors, lessees, companies that purchase our businesses or assets and others with whom we enter into contracts, against combinations of loss, expense, or liability arising from various triggering events related to the sale and the use of our products and services, the use of their goods and services, the use of facilities and state of our owned facilities, the state of the assets and businesses that we sell and other matters covered by such contracts, usually up to a specified maximum amount. In addition, from time to time we also provide protection to these parties against claims related to
undiscovered liabilities, additional product liability or environmental obligations. In our experience, claims made under such indemnifications are rare and the associated estimated fair value of the liability was not material as of October 31, 2023.

In connection with the sale of several of our businesses, we have agreed to indemnify the buyers of such businesses, their respective affiliates and other related parties against certain damages that they might incur in the future. The continuing indemnifications primarily cover damages relating to liabilities of the businesses that Agilent retained and did not transfer to the buyers, as well as other specified items. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2023.
v3.23.4
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Oct. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
17.   COMMITMENTS AND CONTINGENCIES

Other Purchase Commitments.  Typically, we can cancel contracts with professional services suppliers without penalties. For those contracts that are not cancelable without penalties, there are termination fees and costs or commitments for continued spending that we are obligated to pay to a supplier under each contract's termination period before such contract can be cancelled. Our contractual obligations with these suppliers under "other purchase commitments" were approximately $123 million.

Contingencies: We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.
v3.23.4
SHORT-TERM DEBT
 12 Months Ended
Oct. 31, 2023
Short-Term Debt [Abstract]  
SHORT-TERM DEBT SHORT-TERM DEBT
Credit Facilities

On June 7, 2023, we entered into a new credit agreement with a group of financial institutions which provides for a $1.5 billion five-year unsecured credit facility that will expire on June 7, 2028, and an incremental revolving credit facility in an aggregate amount of up to $750 million. The credit facility replaced the existing credit facility which was terminated on the closing date of the new facility. During the year ended October 31, 2023, we borrowed and repaid $360 million under the credit facility. As of both October 31, 2023 and 2022, we had no borrowings outstanding under both the credit facility and the incremental revolving credit facility. We were in compliance with the covenants for the credit facility during the year ended October 31, 2023.

On June 2, 2023, we entered into an Uncommitted Money Market Line Credit agreement with Societe Generale which provides for an aggregate borrowing capacity of $300 million. The credit facility is an uncommitted short-term cash advance facility where each request must be at least $1 million. The interest rate is set by the lender at the time of the borrowing and is fixed for the duration of the advance. During the year ended October 31, 2023, we borrowed and repaid $61 million. As of October 31, 2023, we had no borrowings outstanding under the credit facility.

Commercial Paper
Under our U.S. commercial paper program, we may issue and sell unsecured, short-term promissory notes in the aggregate principal amount not to exceed $1.5 billion with up to 397-day maturities. At any point in time, the company intends to maintain available commitments under its revolving credit facility in an amount at least equal to the amount of the commercial paper notes outstanding. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The proceeds from issuances under the program may be used for general corporate purposes. During the year ended October 31, 2023, we borrowed $1.67 billion and repaid $1.70 billion. As of October 31, 2023, we had no borrowings outstanding under our U.S. commercial paper program. As of October 31, 2022, we had borrowings of $35 million outstanding under the U.S. commercial paper program and had a weighted average annual interest rate of 3.54 percent.
v3.23.4
LONG-TERM DEBT
 12 Months Ended
Oct. 31, 2023
Debt Disclosure [Abstract]  
LONG-TERM DEBT LONG-TERM DEBT
Term Loan Facility

On April 15, 2022, we entered into a term loan agreement with a group of financial institutions, which provided for a $600 million delayed draw term loan that will mature on April 15, 2025. As of October 31, 2023 and 2022, we had $600 million borrowings outstanding under the term loan facility and had weighted average interest rates of 6.22 percent and 3.98 percent, respectively. Loans under the term loan agreement bear interest, at our option, either at: (i) the alternate base rate, as defined in the term loan agreement, plus the applicable margin for such loans or (ii) adjusted term SOFR, as defined in the term loan agreement, plus the applicable margin for such loans. The term loan agreement contains customary representations and warranties as well as customary affirmative and negative covenants. We were in compliance with the covenants for the term loan during the year ended October 31, 2023.

On May 4, 2022, we used the proceeds from the term loan facility and repaid the $600 million outstanding aggregate principal amount of our 3.875% 2023 senior notes. The total redemption price of approximately $609 million was computed in accordance with the terms of the 2023 senior notes as the present value of the remaining scheduled payments of principal and unpaid interest on the notes being redeemed. In May 2022, we recorded a loss on extinguishment of debt of $9 million in other income (expense), net in the consolidated statement of operations. In addition, $7 million of accrued interest, up to but not including the applicable redemption date, was paid.

On December 14, 2023, we prepaid $120 million of our outstanding $600 million term loan.


Senior Notes

The following table summarizes the company's long-term senior notes:

 October 31, 2023October 31, 2022
 Amortized
Principal		Amortized
Principal
 (in millions)
2026 Senior Notes299 299 
2029 Senior Notes496 495 
2030 Senior Notes496 496 
2031 Senior Notes844 843 
Total Senior Notes$2,135 $2,133 


2026 Senior Notes

On September 22, 2016, the company issued aggregate principal amount of $300 million in senior notes ("2026 senior notes"). The 2026 senior notes were issued at 99.624% of their principal amount. The notes will mature on September 22, 2026 and bear interest at a fixed rate of 3.05% per annum. The interest is payable semi-annually on March 22nd and September 22nd of each year and payments commenced March 22, 2017.

In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2023 was $(3) million.
2029 Senior Notes

On September 16, 2019, the company issued an aggregate principal amount of $500 million in senior notes ("2029 senior notes"). The 2029 senior notes were issued at 99.316% of their principal amount. The notes will mature on September 15, 2029, and bear interest at a fixed rate of 2.75% per annum. The interest is payable semi-annually on March 15th and September 15th of each year and payments commenced on March 15, 2020.

In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2023 was $(3) million.

2030 Senior Notes

On June 4, 2020, we issued an aggregate principal amount of $500 million in senior notes ("2030 senior notes"). The 2030 senior notes were issued at 99.812% of their principal amount. The 2030 senior notes will mature on June 4, 2030, and bear interest at a fixed rate of 2.10% per annum. The interest is payable semi-annually on June 4th and December 4th of each year and payments commenced on December 4, 2020.

2031 Senior Notes

On March 12, 2021, we issued an aggregate principal amount of $850 million in senior notes ("2031 senior notes"). The 2031 senior notes were issued at 99.822% of their principal amount. The 2031 senior notes will mature on March 12, 2031, and bear interest at a fixed rate of 2.30% per annum. The interest is payable semi-annually on March 12th and September 12th of each year and payments commenced on September 12, 2021.

All outstanding senior notes listed above are unsecured and rank equally in right of payment with all of Agilent's other senior unsecured indebtedness.
v3.23.4
STOCKHOLDERS' EQUITY
 12 Months Ended
Oct. 31, 2023
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS EQUITY STOCKHOLDERS' EQUITY
Stock Repurchase Program

On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 share repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the year ended October 31, 2021, we repurchased and retired 3.1 million shares for $365 million under this authorization. Effective February 18, 2021, the 2019 repurchase program was terminated and replaced by the new share repurchase program. The remaining authorization under the 2019 repurchase plan of $193 million expired on February 18, 2021.

On February 16, 2021 we announced that our board of directors had approved a new share repurchase program (the "2021 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2021 repurchase program authorizes the purchase of up to $2.0 billion, excluding excise taxes, of our common stock at the company's discretion and has no fixed termination date. The 2021 repurchase program which became effective on February 18, 2021, replaced and terminated the 2019 repurchase program on that date. The 2021 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the year ended October 31, 2021, we repurchased and retired 3.0 million shares for $423 million under this authorization. During the year ended October 31, 2022, we repurchased and retired 8.4 million shares for $1,139 million under this authorization. During the year ended October 31, 2023 we repurchased and retired 661,739 shares for $99 million, excluding excise taxes, under this authorization. On March 1, 2023, the 2021 repurchase program was terminated and the remaining authorization of $339 million expired.

On January 9, 2023, we announced that our board of directors had approved a share repurchase program (the "2023 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the
company's employee equity incentive programs. The 2023 repurchase program authorizes the purchase of up to $2.0 billion, excluding excise taxes, of our common stock at the company's discretion and has no fixed termination date. The 2023 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. The 2023 repurchase program commenced on March 1, 2023, and also terminated and replaced the 2021 repurchase program. During the year ended October 31, 2023 we repurchased and retired 3.9 million shares for $476 million, excluding excise taxes, under this authorization. As of October 31, 2023, we had remaining authorization to repurchase up to approximately $1,524 million of our common stock under the 2023 repurchase program.

The Inflation Reduction Act of 2022, which was enacted into law on August 16, 2022, imposed a nondeductible 1% excise tax on the net value of certain stock repurchases made after December 31, 2022. As a result, we recorded the applicable excise tax of $3.2 million during the year ended October 31, 2023 as an incremental cost of the shares repurchased and a corresponding liability for the excise tax payable in other accrued liabilities on our consolidated balance sheet.

Cash Dividends on Shares of Common Stock

During the year ended October 31, 2023, cash dividends of $0.900 per share, or $265 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2022, cash dividends of $0.840 per share, or $250 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2021, cash dividends of $0.776 per share, or $236 million were declared and paid on the company's outstanding common stock.

On November 15, 2023, we declared a quarterly dividend of $0.236 per share of common stock, or approximately $69 million which will be paid on January 24, 2024, to shareholders of record as of the close of business on January 2, 2024. The timing and amounts of any future dividends are subject to determination and approval by our board of directors.

Accumulated Other Comprehensive Income (Loss)
Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2023 and 2022 were as follows:
Net defined benefit pension cost and post retirement plan costs
Foreign currency translationPrior service creditsActuarial LossesUnrealized gains (losses) on derivativesTotal
(in millions)
As of October 31, 2021$(185)$124 $(224)$3 $(282)
Other comprehensive income (loss) before reclassifications(162)— 50 56 (56)
Amounts reclassified out of accumulated other comprehensive income (loss)— (1)28 (34)(7)
Tax (expense) benefit12 — (9)(5)(2)
Other comprehensive income (loss)(150)(1)69 17 (65)
As of October 31, 2022$(335)$123 $(155)$20 $(347)
Other comprehensive income (loss) before reclassifications33 — (17)(4)12 
Amounts reclassified out of accumulated other comprehensive income (loss)— (1)2 — 1 
Tax benefit1 — 5 1 7 
Other comprehensive income (loss)34 (1)(10)(3)20 
As of October 31, 2023$(301)$122 $(165)$17 $(327)
Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2023 and 2022 were as follows (in millions):
Details about Accumulated Other
Comprehensive Income components		Amounts Reclassified
from Other Comprehensive Income		Affected line item in
statement of operations
20232022
Unrealized gains on derivatives$2 $36 Cost of products
Unrealized losses on derivatives(2)(2)Interest expense
— 34 Total before income tax
— (8)Provision for income tax
— 26 Total net of income tax
Net defined benefit pension cost and post retirement plan costs:
Actuarial net loss(2)(28)Other (income) expense
Prior service benefit1 1 Other (income) expense
(1)(27)Total before income tax
— 7 Benefit for income tax
(1)(20)Total net of income tax
Total reclassifications for the period$(1)$6 

Amounts in parentheses indicate reductions to income and increases to other comprehensive income.

Reclassifications of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost (see Note 14, "Retirement Plans and Post Retirement Pension Plans").
v3.23.4
SEGMENT INFORMATION
 12 Months Ended
Oct. 31, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Description of Segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.
We have three business segments comprised of life sciences and applied markets, diagnostics and genomics and Agilent CrossLab, each of which comprises a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments.
A description of our three reportable segments is as follows:

Our life sciences and applied markets business provides application-focused solutions that include instruments, consumables and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies. Our consumables portfolio is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries to supplies. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies.
Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business is a contract and development manufacturing organization that provides services related to and the production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in a class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential tissue pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business provides clinical flow cytometry reagents for routine cancer diagnostics. This business also provides bulk antibodies as raw materials and associated assay development services to IVD manufacturers, biotechnology and pharmaceutical companies. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples. Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques including NGS, utilized in clinical and life science research applications.

The Agilent CrossLab business spans the entire lab with its extensive services portfolio, which is designed to improve customer outcomes. The majority of the portfolio is vendor neutral, meaning we can serve and supply customers regardless of their instrument purchase choices. The services portfolio include repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting and various other custom services to support the customers' laboratory operations. Custom services are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements.

A significant portion of the segments' expenses arises from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses, costs of centralized research and development and joint sales and marketing costs. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate certain costs to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Unallocated costs consist of asset impairments, amortization of acquisition-related intangible assets, acquisition and integration costs, changes in the fair value of acquisition-related contingent consideration, transformational initiatives expenses, restructuring and other related costs, business exit and divestiture costs and certain other charges. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations, in-sourcing or outsourcing of activities.
The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments.
The following tables reflect segment results under our management reporting system after excluding certain unallocated costs as noted in the reconciliations below:
Years Ended October 31,
202320222021
(in millions)
Net Revenue:
Life Sciences and Applied Markets$3,856 $4,007 $3,663 
Diagnostics and Genomics1,409 1,389 1,296 
Agilent CrossLab1,568 1,452 1,360 
Total net revenue$6,833 $6,848 $6,319 
Income from Operations:
Life Sciences and Applied Markets$1,116 $1,186 $1,017 
Diagnostics and Genomics296 301 273 
Agilent CrossLab463 370 323 
Total reportable segment income from operations 1,875 1,857 1,613 
Share-Based Compensation Expense:
Life Sciences and Applied Markets$66 $69 $60 
Diagnostics and Genomics22 25 22 
Agilent CrossLab24 26 24 
Unallocated share-based compensation expenses (1)
— 6 5 
Total share-based compensation expense$112 $126 $111 
Depreciation Expense:
Life Sciences and Applied Markets$63 $59 $60 
Diagnostics and Genomics40 39 39 
Agilent CrossLab25 22 23 
Total depreciation expense$128 $120 $122 
(1) Share-based compensation expense amounts not allocated to the segments relate to accelerated share-based compensation expense from workforce reduction and from acquisition of businesses.

Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, prepaid expenses, long-term investments, deferred tax assets, right-of use assets and other assets.
    The following table reflects segment assets and capital expenditures under our management reporting system.
October 31,
20232022
(in millions)
Assets:
Life Sciences and Applied Markets$3,820 $3,955 
Diagnostics and Genomics3,307 3,489 
Agilent CrossLab897 869 
Total reportable segment assets$8,024 $8,313 
Capital Expenditures:
Life Sciences and Applied Markets$70 $77 
Diagnostics and Genomics206 181 
Agilent CrossLab22 33 
Total capital expenditures$298 $291 

Major Customers.    No customer represented 10 percent or more of our total net revenue in 2023, 2022 or 2021.

          The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes:
 Years Ended October 31,
 202320222021
 (in millions)
Total reportable segments' income from operations$1,875 $1,857 $1,613 
Unallocated Costs
Amortization of intangible assets related to business combinations(139)(191)(194)
Acquisition and integration costs(16)(25)(41)
Transformational initiatives(25)(30)(37)
Asset impairments(277)— (2)
Business exit and divestiture costs — (7)(5)
Change in fair value of contingent consideration(1)25 21 
Restructuring and other related costs(46)— — 
Other (21)(11)(8)
Total unallocated costs(525)(239)(266)
Income from operations1,350 1,618 1,347 
Interest income51 9 2 
Interest expense(95)(84)(81)
Other income (expense, net33 (39)92 
Income before taxes$1,339 $1,504 $1,360 

    The following table reconciles segment assets to Agilent's total assets:
October 31,
20232022
(in millions)
Total reportable segments' assets$8,024 $8,313 
Cash and cash equivalents1,590 1,053 
Prepaid expenses139 119 
Long-term investments164 195 
Long-term and other receivables127 134 
Deferred tax assets284 246 
Right of use assets154 150 
Others281 322 
Total assets$10,763 $10,532 
The other category primarily includes over funded pension plans which are not allocated to the segments.

The following table presents summarized information for net revenue by geographic region. Revenues from external customers are generally attributed to countries based upon the customers' location.

Years Ended October 31,
202320222021
 (in millions)
Net revenue:   
United States$2,410 $2,385 $2,159 
China including Hong Kong1,383 1,499 1,273 
Rest of the world3,040 2,964 2,887 
Total net revenue6,833 6,848 6,319 

The following table presents summarized information for long-lived assets by geographic region. Long lived assets consist of property, plant, and equipment, right-of-use assets, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of Asia and the rest of Europe.
October 31,
20232022
 (in millions)
Long-lived Assets:
United States$1,188 $1,080 
Germany192 151 
Rest of World471 492 
Total Long-lived Assets$1,851 $1,723 
v3.23.4
SUBSEQUENT EVENTS
 12 Months Ended
Oct. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events SUBSEQUENT EVENT
Segment Reporting Changes. In December 2023, we decided to re-organize our operating segments and move our cell analysis business, which currently is included in our life science and applied markets segment, to our diagnostics and genomics operating segment. Following this re-organization, we will continue to have three businesses - life sciences and applied markets, diagnostics and genomics and Agilent CrossLab- each of which will comprise a reportable segment. All historical segment financial information will be recast to conform to this new reporting structure in our financial statements and accompanying notes, beginning with our Form 10-Q filing for the first quarter of fiscal year 2024. There will be no change to our Agilent CrossLab business segment.
v3.23.4
Schedule II Valuation and Qualifying Accounts
 12 Months Ended
Oct. 31, 2023
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts
SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS

Column AColumn BColumn CColumn DColumn E
DescriptionBalance at
Beginning
of Period		Additions Charged to
Expenses or
Other Accounts*		Deductions Credited to Expenses or Other Accounts**Balance at
End of
Period
 (in millions)
2023    
Tax valuation allowance$115 $1 $(4)$112 
2022    
Tax valuation allowance$120 $7 $(12)$115 
2021    
Tax valuation allowance$132 $5 $(17)$120 

* Additions include current year additions charged to expenses and current year build due to increases in net deferred tax assets, return to provision true-ups, other adjustments and other comprehensive income impact to deferred taxes.
** Deductions include current year releases credited to expenses and current year reductions due to decreases in net deferred tax assets, return to provision true-ups, other adjustments and other comprehensive income impact to deferred taxes.
v3.23.4
Pay vs Performance Disclosure - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Pay vs Performance Disclosure      
Net Income $ 1,240 $ 1,254 $ 1,210
v3.23.4
Insider Trading Arrangements
 3 Months Ended
Oct. 31, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.23.4
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Oct. 31, 2023
Accounting Policies [Abstract]  
Business Description and Basis of Presentation
Overview.  Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Announced Exit and Subsequent Divestiture of Resolution Bioscience Business. During the third quarter of fiscal year 2023, we made the decision to exit the Resolution Bioscience business within our diagnostics and genomics segment and recorded a long-lived asset impairment charge of $270 million. In the fourth quarter of fiscal year 2023, we received an unsolicited offer and entered into an agreement to divest the Resolution Bioscience business for $50 million. As a result, we recorded a gain on the divestiture of $43 million in other income (expense), net in the consolidated statement of operations, which included an adjustment to goodwill of $13 million.

Basis of Presentation.  The accompanying consolidated financial statements have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year.
Principles of Consolidation
Principles of Consolidation.  The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates
Use of Estimates.  The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement plan assumptions, restructuring and accounting for income taxes.

Restructuring. The main components of our restructuring plan are related to workforce reductions, consolidation of excess leased facilities and site closures. Workforce reduction charges are accrued when payment of benefits becomes probable that the employees are entitled to the severance and the amounts can be estimated. Consolidation of facilities costs primarily consists of accelerated depreciation of right-of-use assets classified as held and used. In accordance with the accounting guidance, it was determined that certain assets had been abandoned, and an assessment was made of the remaining useful lives and potential alternative uses. If the amounts and timing of cash flows from restructuring activities are significantly different from what we have estimated, the actual amounts of restructuring and other related charges could be materially different, either higher or lower, than those we have recorded.
Risk and Uncertainties Risks and Uncertainties. We are subject to risks common to companies in the analytical instrument industry, such as global economic and financial market conditions, fluctuations in foreign currency exchange rates and fluctuations in customer demand, among others.
Revenue Recognition
Revenue Recognition.  We enter into contracts to sell products, services or combinations of products and services. Products may include hardware or software and services may include one-time service events or services performed over time.

We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers, (“ASC 606’’). See also Note 3, "Revenue" for additional information on revenue recognition.

Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled in exchange for
those products or services, the transaction price. For equipment, consumables, and most software licenses, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. For products that transfer control over time, revenue is recognized as the performance obligation is satisfied. Product over time revenue is assessed against the following criteria: the performance creates an asset that the customer controls as the asset is created; the asset has no alternative use; and we have an enforceable right to payment. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded.

Service revenue includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. Revenue for these contracts is recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls not included in a support contract are recognized to revenue at the time a service is performed.

We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis.

Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue.

For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per geographic region for each performance obligation. Standalone selling prices are determined for each distinct good or service in the contract, and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations.

A portion of our revenue relates to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance.

Deferred Revenue.  Contract liabilities (deferred revenue) primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements (performance obligations) to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either in current liabilities in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation.

Sales Taxes.  Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue.

Shipping and Handling Costs.  Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented.
Research and Development
Research and Development.  Costs related to research, design and development of our products are charged to research and development expense as they are incurred.
Advertising
Advertising.  Advertising costs are generally expensed as incurred and amounted to $54 million in 2023, $66 million in 2022 and $63 million in 2021.
Taxes on Income
Taxes on Income.  Income tax expense or benefit is based on income or loss before taxes. Deferred tax assets and liabilities are recognized principally for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. See Note 5, "Income Taxes" for more information.
Net Income (Loss) Per Share
Net Income Per Share.  Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense are assumed proceeds to be used to repurchase hypothetical shares. See Note 6, "Net Income Per Share".
Cash, Cash Equivalents and Short-Term Investments and Restricted Cash and Restricted Cash Equivalents
Cash, Cash Equivalents and Short-Term Investments.  We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value.

As of October 31, 2023, approximately $1,287 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries. Our cash and cash equivalents mainly consist of short-term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds.

We classify equity investments as short-term investments based on their nature and our intent and ability to exit within a year or less. As of October 31, 2023, we had no short-term investments.

Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows:
October 31,
202320222021
(in millions)
Cash and cash equivalents$1,590 $1,053 $1,484 
Restricted cash included in other assets3 3 6 
Total cash, cash equivalents and restricted cash$1,593 $1,056 $1,490 
Accounts Receivable, net
Accounts Receivable, net.  Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable have been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2023 and 2022 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of estimated product returns which are not material.
Concentration of Credit Risk
Concentration of Credit Risk.  Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, equity investments with readily determinable fair value securities, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents or short-term investments. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis.
Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount, and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of accounts receivable as of October 31, 2023, or 2022.
Inventory
Inventory.  Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates and assumptions about future demand, economic conditions and actual usage, which require management judgment. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of inventory levels, sales trends and forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory and to estimate and record reserves for excess, slow-moving and obsolete inventory.
Property, Plant and Equipment
Property, Plant and Equipment.  Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over 3 years to 10 years. We use the straight-line method to depreciate assets.
Capitalized Software
Capitalized Software.  We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over 3 years to 5 years once development is complete.
Leases
Leases. We determine whether an arrangement is, or contains, a lease at inception. We record the present value of operating lease payments as right-of-use ("ROU") assets and lease liabilities on the consolidated balance sheet. Where we are the lessee, ROU assets represent the company’s right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of operating lease liabilities as either current or non-current is based on the expected timing of payments due under our obligations. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rates, we have used a number of factors including the company's credit rating, the lease term and the currency swap rate. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet and lease expense for these leases is recognized on a straight-line basis over the lease term. Lease expense for operating leases with an initial term of more than twelve months is recognized on a straight-line basis over the lease term as an operating expense. We have lease agreements which require payments for lease and non-lease components. We have elected to account for these payments as a single lease component.

A portion of our revenue relates to lease arrangements where Agilent is the lessor. Standalone lease arrangements are outside the scope of Accounting Standard Codification ("ASC") Topic 606, Revenue Contracts with Customers, and are therefore accounted for in accordance with ASC Topic 842, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type finance lease using the current lease classification guidance. In a lease arrangement that is a multiple-element arrangement that contains equipment leases and the supply of consumables, the revenue associated with the instrument rental is treated under the lease accounting standard ASC 842, whereas the revenue associated with the consumables, the non-lease component, is recognized in accordance with the ASC 606 revenue standard.
   See also Note 9, "Leases" for additional information about our leases.
Acquisitions
Acquisitions. Agilent accounts for the acquisition of a business using the acquisition method of accounting, and we allocate the fair value of the purchase price to the tangible assets acquired, liabilities assumed, and intangible assets acquired, including in-process research and development (“IPR&D”), based on their estimated fair values. The excess value of the cost of an acquired business over the fair value of the assets acquired and liabilities assumed is recognized as goodwill. The fair value
of IPR&D is initially capitalized as an intangible asset with an indefinite life. When an IPR&D project is completed, the IPR&D is reclassified as an amortizable purchased intangible asset and amortized to costs of revenues over the asset’s estimated useful life.
Our determination of the fair value of the intangible assets acquired involves the use of significant estimates and assumptions. Specifically, our determination of the fair value of the developed product technology and IPR&D acquired involve significant estimates and assumptions related to revenue growth rates and discount rates. Our determination of the fair value of customer relationships acquired involved significant estimates and assumptions related to revenue growth rates, discount rates, and customer attrition rates. Our determination of the fair value of the tradename acquired involved the use of significant estimates and assumptions related to revenue growth rates, royalty rates and discount rates. The company believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use. Actual results could differ materially from these estimates.
Goodwill and Purchased Intangible Assets
Goodwill and Purchased Intangible Assets. We assess our goodwill and purchased intangible assets for impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Under the authoritative guidance, we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the quantitative test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e., greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required.

The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers.

If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, then we are required to perform a quantitative impairment test on goodwill to identify and measure the amount of a goodwill impairment loss to be recognized. A goodwill impairment loss, if any, is measured as the amount by which a reporting unit's carrying value, including goodwill, exceeds its fair value, not to exceed the carrying amount of goodwill. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units.

In fiscal year 2023, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a quantitative test for goodwill impairment of the three reporting units as of September 30, 2023, our annual impairment test date. Based on the results of our quantitative testing, there was no impairment of goodwill as of September 30, 2023. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2023, 2022 and 2021.

Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years. IPR&D is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned.

Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e., greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2023. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair values of these indefinite-lived intangible assets are greater than their respective carrying values. Each quarter we review the events and
circumstances to determine if impairment of indefinite-lived intangible assets is indicated. During the year ended October 31, 2023, 2022 and 2021, there were no impairments of indefinite-lived intangible assets.
Impairment of Long-Lived Assets Impairment of Long-Lived Assets.  We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. During the year ended October 31, 2023, we recorded an impairment charge of long-lived assets including intangible assets of $277 million primarily related to the exit of our Resolution Bioscience business. During the year ended October 31, 2022, there were no impairments of other long-lived assets or intangible assets. During the year ended October 31, 2021, we recorded an impairment charge of long-lived assets of $2 million.
Variable Interest Entity
Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). We evaluate our investments in privately held companies on an ongoing basis. We have determined that as of October 31, 2023 and 2022, there were no VIEs required to be consolidated in our consolidated financial statements because we do not have a controlling financial interest in any of the VIEs in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs and vice-versa, based on changes in facts and circumstances including changes in contractual arrangements and capital structure.

As of October 31, 2023 and 2022, the total carrying value of investments and loans in privately held companies considered as VIEs was $82 million and $87 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are classified as long-term investments and the loans are classified within other current assets and other assets (depending upon tenure of loan) on the consolidated balance sheet.
Investments
Investments.  Equity investments without readily determinable fair value consist of non-marketable equity securities (typically investments in privately-held companies). These investments are accounted for using the measurement alternative at cost, and we adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) included in net income as and when it occurs. Equity investments with readily determinable fair value consist of marketable equity securities which were reclassified from non-marketable equity securities following the commencement of public market trading of the issuers and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. There are no equity investments with readily determinable fair value at October 31, 2023 and 2022. Other investments with readily determinable fair value consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Trading securities, which are comprised of mutual funds, bonds and other similar instruments and deferred compensation liabilities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. There are no equity method investments as of October 31, 2023 and 2022. The company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.
Fair Value of Financial Instruments
Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of short-term and long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. As of October 31, 2023, and October 31, 2022, the fair value of the term loan approximates its carrying value. As of October 31, 2023, the fair value of our senior notes was $1,747 million with a carrying value of $2,135 million. This compares to the fair value of our senior notes of $1,754 million with a carrying value of $2,133 million as of October 31, 2022. The change in the fair value compared to carrying value in the year ended October 31, 2023, is primarily due to increased market interest rates. The fair value was calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign
exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 12, "Fair Value Measurements" for additional information on the fair value of financial instruments and contingent consideration.
Warranty
Warranty.  Our standard warranty terms typically extend for one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 16, "Guarantees".
Employee Compensation and Benefits
Employee Compensation and Benefits.  Amounts owed to employees, such as accrued salary, bonuses and vacation benefits are accounted for within employee compensation and benefits. The total amount of accrued vacation benefit was $120 million and $123 million as of October 31, 2023, and 2022, respectively.
Retirement and Post-Retirement Plans
Retirement and Post-Retirement Plans. We have various defined benefit and defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Assumptions used to determine the benefit obligations and the expense for these plans are derived annually. See Note 14, “Retirement plans and post-retirement pension plans” for additional information.
Retirement of Treasury Shares
Retirement of Treasury Shares. Upon the formal retirement of treasury shares, we deduct the par value of the retired treasury shares from common stock and allocate the excess of cost over par as a deduction to additional paid-in capital, based on the pro-rata portion of additional paid-in-capital, and the remaining excess as a deduction to retained earnings. All retired treasury shares revert to the status of authorized but unissued shares.
Share-Based Compensation
Share-Based Compensation.  For the years ended 2023, 2022 and 2021, we accounted for share-based awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant date fair value method of accounting. Under the fair value method, we recorded compensation expense for all share-based awards of $112 million in 2023, $126 million in 2022 and $111 million in 2021. See Note 4, "Share-based Compensation" for additional information.
Derivative Instruments
Derivative Instruments.  Agilent is exposed to global foreign currency exchange rate and interest rate risks in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts, interest rate swaps and interest rate locks to manage financial exposures resulting from changes in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the company's fixed-rate debt. To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk otherwise inherent in the amount and duration of the hedged exposures and comply with established risk management policies. Foreign exchange hedging contracts generally mature within twelve months, interest rate swaps mature at the same time as the maturity of the debt and interest rate locks mature at the same time as the issuance of debt. In order to manage foreign currency exposures in a few limited jurisdictions, we may enter into foreign exchange contracts that do not qualify for hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the parent company. We do not use derivative financial instruments for trading or speculative purposes.

All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are designated and qualify as a cash flow hedge, changes in the value of the effective portion of the derivative instrument are recognized in accumulated comprehensive income (loss), a component of stockholders' equity. For derivative instruments that are designated and qualify as a net investment hedge, changes in the value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss) - translation adjustment. Amounts associated with cash flow hedges are reclassified and recognized in income when either the forecasted transaction occurs or it becomes probable the forecasted transaction will not occur. Derivatives not designated as hedging instruments are recorded on the balance sheet at their fair value and changes in the fair values are recorded in the income statement in the current period. Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet. Changes in the fair value of the ineffective portion of derivative instruments are recognized in earnings in the current period. The impact of the ineffectiveness measurement in 2023, 2022 and 2021 was not material. Cash flows from derivative instruments are classified in the statement of cash flows in the same category as the cash flows from the hedged or economically hedged item, primarily in operating activities.
Foreign Currency Translation
Foreign Currency Translation.  We translate and remeasure balance sheet and income statement items into U.S. dollars. For those subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using monthly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity.
For those subsidiaries that operate in a U.S. dollar functional environment, foreign currency assets and liabilities are remeasured into U.S. dollars at current exchange rates except for non-monetary assets and capital accounts which are remeasured at historical exchange rates. Revenue and expenses are generally remeasured at monthly exchange rates which approximate average exchange rates in effect during each period. Gains or losses from foreign currency remeasurement are included in consolidated net income. Net gains or losses resulting from foreign currency transactions, including hedging gains and losses, are reported in other income (expense), net and were $2 million gain for 2023, $6 million loss for 2022 and $4 million loss for 2021.
v3.23.4
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Oct. 31, 2023
Accounting Policies [Abstract]  
Restricted Cash and Cash Equivalents
Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows:
October 31,
202320222021
(in millions)
Cash and cash equivalents$1,590 $1,053 $1,484 
Restricted cash included in other assets3 3 6 
Total cash, cash equivalents and restricted cash$1,593 $1,056 $1,490 
v3.23.4
REVENUE (Tables)
 12 Months Ended
Oct. 31, 2023
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:

Life Sciences and Applied MarketsAgilent CrossLabDiagnostics and GenomicsTotal
(in millions)
Year Ended October 31, 2023:
Americas$1,284 $634 $814 $2,732 
Europe920 417 417 1,754 
Asia Pacific1,652 517 178 2,347 
Total$3,856 $1,568 $1,409 $6,833 
Year Ended October 31, 2022:
Americas$1,331 $567 $784 $2,682 
Europe907 382 410 1,699 
Asia Pacific1,769 503 195 2,467 
Total$4,007 $1,452 $1,389 $6,848 
Year Ended October 31, 2021:
Americas$1,199 $510 $695 $2,404 
Europe893 378 417 1,688 
Asia Pacific1,571 472 184 2,227 
Total$3,663 $1,360 $1,296 $6,319 

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
Years Ended October 31,
202320222021
(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical$2,433 2,515 $2,224 
Chemicals and Advanced Materials1,543 1,521 1,328 
Diagnostics and Clinical966 963 938 
Food628 617 601 
Academia and Government601 576 576 
Environmental and Forensics662 656 652 
Total$6,833 $6,848 $6,319 
Revenue by Type
Instrumentation$2,742 2,907 $2,657 
Non-instrumentation and other4,091 3,941 3,662 
Total$6,833 $6,848 $6,319 
Contract with Customer, Asset and Liability
The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2022 and 2023:

Contract
Liabilities
(in millions)
Ending balance as of October 31, 2021$519 
Net revenue deferred in the period437 
Revenue recognized that was included in the contract liability balance at the beginning of the period(372)
Change in deferrals from customer cash advances, net of revenue recognized11 
Currency translation and other adjustments(38)
Ending balance as of October 31, 2022$557 
Net revenue deferred in the period488 
Revenue recognized that was included in the contract liability balance at the beginning of the period(409)
Change in deferrals from customer cash advances, net of revenue recognized(28)
Currency translation and other adjustments8 
Ending balance as of October 31, 2023$616 
v3.23.4
SHARE-BASED COMPENSATION (Tables)
 12 Months Ended
Oct. 31, 2023
Share-Based Payment Arrangement, Noncash Expense [Abstract]  
Allocated Share-based compensation expense disclosure
The impact on our results for share-based compensation was as follows:

Years Ended October 31,
202320222021
(in millions)
Cost of products and services$34 $30 $26 
Research and development13 14 12 
Selling, general and administrative65 82 73 
Total share-based compensation expense$112 $126 $111 
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions
The following assumptions were used to estimate the fair value of awards granted.

 Years Ended October 31,
 202320222021
Stock Option Plan:
Weighted average risk-free interest rate3.9%1.5%0.5%
Dividend yield0.6%0.5%0.7%
Weighted average volatility28%26%26%
Expected life5.5 years5.5 years5.5 years
LTPP:   
Volatility of Agilent shares31%29%30%
Volatility of selected peer-company shares
22%-84%
23%-81%
24%-57%
Pair-wise correlation with selected peers42%41%45%
Post-vest restriction discount for all executive awards7.1%6.5%6.8%
Summary of stock option award activity
The following table summarizes employee stock option award activity of our employees and directors for 2023.

Options
Outstanding 		Weighted
Average
Exercise Price
 (in thousands) 
Outstanding at October 31, 20221,097 $94 
Granted269 $147 
Exercised(249)$41 
Cancelled(37)$142 
Outstanding at October 31, 20231,080 $118 
Schedule of share-based compensation, shares authorized under stock option plans, by exercise price range
The options outstanding and exercisable for equity share-based payment awards at October 31, 2023 were as follows:

 Options OutstandingOptions Exercisable
Range of
Exercise Prices		Number
Outstanding		Weighted
Average
Remaining
Contractual
Life		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value		Number
Exercisable		Weighted
Average
Remaining
Contractual
Life		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value
 (in thousands)(in years) (in thousands)(in thousands)(in years) (in thousands)
$40.01 - $50.00
210 1.0$41 13,088 210 1.0$41 13,088 
$100.00- $110.00
311 7.0$110 — 177 7.0$110 — 
$110.01 - $150.00
319 8.8$143 — 40 8.3$136 — 
$150.01 & Over
240 8.0$161 — 80 8.0$161 — 
1,080 6.6$118 $13,088 507 4.8$92 $13,088 
Schedule of Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value
The following table summarizes the aggregate intrinsic value of options exercised and the fair value of options granted in 2023, 2022 and 2021:

Aggregate
Intrinsic Value		Weighted
Average
Exercise
Price		Per Share Value Using Black-Scholes Model
 (in thousands) 
Options exercised in fiscal 2021$34,305 $33 
Black Scholes per share value of options granted during fiscal 2021$26 
Options exercised in fiscal 2022$10,765 $38 
Black Scholes per share value of options granted during fiscal 2022$39 
Options exercised in fiscal 2023$25,303 $41 
Black Scholes per share value of options granted during fiscal 2023$47 
Share-Based Payment Arrangement, Activity
The following table summarizes non-vested award activity in 2023 primarily for our LTPP and restricted stock unit awards.
SharesWeighted
Average
Grant Price
 (in thousands) 
Non-vested at October 31, 20222,103 $114 
Granted864 $146 
Vested(1,096)$90 
Forfeited(181)$134 
Change in LTPP shares in the year due to exceeding performance targets199 $79 
Non-vested at October 31, 20231,889 $136 
v3.23.4
INCOME TAXES (Tables)
 12 Months Ended
Oct. 31, 2023
Income Tax Disclosure [Abstract]  
Domestic and Foreign Components of Income before Taxes
The domestic and foreign components of income before taxes are:

 Years Ended October 31,
 202320222021
 (in millions)
U.S. operations$614 $858 $876 
Non-U.S. operations725 646 484 
Total income before taxes$1,339 $1,504 $1,360 
Provision for income taxes
The provision for income taxes is comprised of:

 Years Ended October 31,
 202320222021
 (in millions)
U.S. federal taxes:   
Current$117 $173 $122 
Deferred(84)(28)(1)
Non-U.S. taxes:   
Current26 47 (3)
Deferred38 35 14 
State taxes, net of federal benefit:   
Current12 22 17 
Deferred(10)1 1 
Total provision for income taxes$99 $250 $150 
Tax rate reconciliation, U.S. federal statutory rate to effective tax rate from operations
The differences between the U.S. federal statutory income tax rate and our effective tax rate are:

 Years Ended October 31,
 202320222021
 (in millions)
Profit before tax times statutory rate$281 $316 $286 
State income taxes, net of federal benefit2 23 18 
Non-U.S. income taxed at different rates20 (18)5 
Change in unrecognized tax benefits(35)(6)(84)
Foreign-derived intangible income deduction(41)(46)(35)
Realized loss on divestiture of business(104)— — 
Excess tax benefits from stock-based compensation(14)(19)(29)
Other, net(10)— (11)
Provision (benefit) for income taxes$99 $250 $150 
Effective tax rate7.4 %16.6 %11.0 %
Significant components of deferred tax assets and deferred tax liabilities
The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are:

 Years Ended October 31,
 20232022
 (in millions)
Deferred Tax Assets
Intangibles$102 $62 
Employee benefits, other than retirement36 45 
Net operating loss, capital loss, and credit carryforwards152 157 
Share-based compensation24 23 
Capitalized R&D41 — 
Lease obligations37 29 
Other58 58 
Deferred tax assets$450 $374 
Tax valuation allowance(112)(115)
Deferred tax assets, net of valuation allowance$338 $259 
Deferred Tax Liabilities
Property, plant and equipment$(26)$(11)
Pension benefits and retiree medical benefits(25)(24)
Right-of-use asset(37)(29)
Other(4)(7)
Deferred tax liabilities$(92)$(71)
Net deferred tax assets (liabilities)$246 $188 
The breakdown between long-term deferred tax assets and deferred tax liabilities was as follows:

 October 31,
 20232022
 (in millions)
Long-term deferred tax assets (included within other assets)$284 $246 
Long-term deferred tax liabilities (included within other long-term liabilities)(38)(58)
Total$246 $188 
Current and Long Term Tax Assets and Liabilities [Table Text Block]
The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows:
October 31,
20232022
(in millions)
Current income tax assets (included within other current assets)$100 $87 
Long-term income tax assets (included within other assets)3 11 
Current income tax liabilities (included within other accrued liabilities)(73)(51)
Long-term income tax liabilities (included within other long-term liabilities)(162)(216)
Total$(132)$(169)
Aggregate Changes in Gross Unrecognized Tax Benefits
The aggregate changes in the balances of our gross unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows:

202320222021
 (in millions)
Balance, beginning of year$123 $133 $195 
Additions for tax positions related to the current year5 5 6 
Additions for tax positions from prior years3 — 4 
Reductions for tax positions from prior years(27)(9)— 
Settlements with taxing authorities— — (30)
Statute of limitations expirations(6)(6)(42)
Balance, end of year$98 $123 $133 
v3.23.4
NET INCOME (LOSS) PER SHARE (Tables)
 12 Months Ended
Oct. 31, 2023
Earnings Per Share [Abstract]  
Reconciliation of the numerators and denominators of the basic and diluted net income per share
The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below.
 Years Ended October 31,
 202320222021
 (in millions)
Numerator:   
Net income$1,240 $1,254 $1,210 
Denominators:   
Basic weighted average shares294 299 304 
Potential common shares — stock options and other employee stock plans2 1 3 
Diluted weighted average shares296 300 307 
v3.23.4
INVENTORY (Tables)
 12 Months Ended
Oct. 31, 2023
Inventory Disclosure [Abstract]  
Inventory
Inventory as of October 31, 2023 and 2022 consisted of the following:
 October 31,
 20232022
 (in millions)
Finished goods$570 $555 
Purchased parts and fabricated assemblies461 483 
Inventory$1,031 $1,038 
v3.23.4
PROPERTY, PLANT AND EQUIPMENT, NET (Tables)
 12 Months Ended
Oct. 31, 2023
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
Property, plant and equipment as of October 31, 2023 and 2022, consisted of the following:
 October 31,
 20232022
 (in millions)
Land$60 $59 
Buildings and leasehold improvements1,409 1,255 
Machinery and equipment749 674 
Software275 260 
Total property, plant and equipment2,493 2,248 
Accumulated depreciation and amortization(1,223)(1,148)
Property, plant and equipment, net$1,270 $1,100 
v3.23.4
LEASES (Tables)
 12 Months Ended
Oct. 31, 2023
Leases [Abstract]  
Lease, Cost
The components of lease cost for operating leases were as follows:
Year Ended October 31,
202320222021
(in millions)
Operating lease cost$68 $59 $59 
Short-term lease cost2 2 2 
Variable lease cost (a)
16 15 14 
Sublease income(16)(14)(13)
Total lease cost$70 62 62 
(a) Variable lease cost includes cancelable leases, non-fixed maintenance costs and non-recoverable transaction taxes.

In the fourth quarter of fiscal year 2023, we initiated a new restructuring plan ("FY23 Plan") designed to reduce costs and expenses in response to the current macroeconomic conditions. The consolidation of excess facilities under the FY23 Plan resulted in $7 million of accelerated depreciation of our ROU assets.

During fiscal year 2023, we recorded ROU asset impairments of $8 million primarily related to the exit of our Resolution Bioscience business. There were no impairments for fiscal years 2022 and 2021.
Supplemental cash flow information related to leases was as follows:
Year Ended October 31,
202320222021
(in millions)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating leases$56 $53 $57 
Non-cash right of use assets obtained in exchange for operating lease obligations$70 $38 $53 

Supplemental balance sheet information related to leases was as follows:
October 31,
Financial Statement Line Item20232022
(in millions, except lease term and discount rate)
Assets:
Operating lease:
Right of use assetOther assets$154 $150 
Liabilities:
Current
Operating lease liabilitiesOther accrued liabilities$46 $51 
Long-term
Operating lease liabilitiesOther long-term liabilities$118 $101 
Weighted average remaining lease term (in years)
Operating leases8.3 years7.4 years
Weighted average discount rate
Operating leases3.3 %2.4 %
Schedule of Future Minimum Rent Payments
Future minimum rents payable as of October 31, 2023 under non-cancelable leases with initial terms exceeding one year reconcile to lease liabilities included in the consolidated balance sheet as follows:
Operating Leases
(in millions)
2024$51 
202532 
202622 
202714 
202811 
Thereafter59 
Total undiscounted future minimum lease payments$189 
Less: amount of lease payments representing interest(25)
Present value of future minimum lease payments$164 
Less: current liabilities(46)
Long-term lease liabilities$118 
v3.23.4
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 12 Months Ended
Oct. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill balances and movements for each reportable segments during the period
The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2022 and 2023:
Life Sciences and Applied MarketsDiagnostics and GenomicsAgilent CrossLabTotal
 (in millions)
Goodwill as of October 31, 2021$1,743 $1,964 $268 $3,975 
Foreign currency translation impact(19)(11)(12)(42)
Goodwill arising from acquisitions and adjustments19 — — 19 
Goodwill as of October 31, 2022$1,743 $1,953 $256 $3,952 
Foreign currency translation impact4 1 1 6 
Goodwill arising from acquisitions and adjustments— 15 — 15 
Goodwill adjustment related to divestiture of business— (13)— (13)
Goodwill as of October 31, 2023$1,747 $1,956 $257 $3,960 
Schedule of Acquired Finite-Lived Intangible Assets by Major Class
The component parts of other intangible assets at October 31, 2022 and 2023 are shown in the table below:
 Other Intangible Assets
 Gross
Carrying
Amount		Accumulated
Amortization		Net Book
Value
 (in millions)
As of October 31, 2022:   
Purchased technology$1,733 $1,068 $665 
Backlog8 8 — 
Trademark/Tradename196 148 48 
Customer relationships180 105 75 
Third-party technology and licenses32 9 23 
Total amortizable intangible assets$2,149 $1,338 $811 
In-Process R&D10 — 10 
Total$2,159 $1,338 $821 
As of October 31, 2023:   
Purchased technology$1,467 $1,093 $374 
Trademark/Tradename196 163 33 
Customer relationships149 112 37 
Third-party technology and licenses34 13 21 
Total amortizable intangible assets$1,846 $1,381 $465 
In-Process R&D10 — 10 
Total$1,856 $1,381 $475 
Future Amortization expense for the next five years and thereafter
Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below:
Estimated future amortization expense:
(in millions)
2024$100 
2025$83 
2026$54 
2027$52 
2028$45 
Thereafter$131 
v3.23.4
INVESTMENTS (Tables)
 12 Months Ended
Oct. 31, 2023
Schedule of Investments [Abstract]  
Investment
The following table summarizes the company's equity investments as of October 31, 2023 and 2022 (net book value):

 October 31,
 20232022
 (in millions)
Long-Term  
Equity investments - without readily determinable fair value$102 $141 
Other investments - with readily determinable fair value26 23 
Trading securities36 31 
Total long-term investments$164 $195 
Gain (Loss) on Securities
Gains and losses reflected in other income (expense), net for our equity investments with RDFV and equity investments without RDFV are summarized below:
Years Ended October 31,
202320222021
( in millions)
Net gain (loss) recognized during the period on equity securities$(41)$(67)$98 
Less: Net gain (loss) on equity securities sold during the period(15)11 6 
Unrealized gain (loss) on equity securities held as of the end of the period$(26)$(78)$92 
v3.23.4
FAIR VALUE MEASUREMENTS (Tables)
 12 Months Ended
Oct. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Assets And Liabilities Measured On Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2023 were as follows:
  Fair Value Measurement
at October 31, 2023 Using
 October 31,
2023		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$994 $994 $— $— 
Derivative instruments (foreign exchange contracts)19 — 19 — 
Long-term    
Trading securities36 36 — — 
Other investments26 — 26 — 
Total assets measured at fair value$1,075 $1,030 $45 $— 
Liabilities:    
Short-term    
Derivative instruments (foreign exchange contracts)$2 $— $2 $— 
Contingent consideration1 — — 1 
Long-term    
Deferred compensation liability36 — 36 — 
Total liabilities measured at fair value$39 $— $38 $1 

Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2022 were as follows:
  Fair Value Measurement
at October 31, 2022 Using
 October 31,
2022		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
 (in millions)
Assets:    
Short-term    
Cash equivalents (money market funds)$492 $492 $— $— 
Derivative instruments (foreign exchange contracts)31 — 31 — 
Long-term    
Trading securities31 31 — — 
Other investments23 — 23 — 
Total assets measured at fair value$577 $523 $54 $— 
Liabilities:   
Short-term    
Derivative instruments (foreign exchange contracts)$5 $— $5 $— 
Contingent consideration66 — — 66 
Long-term    
Deferred compensation liability31 — 31 — 
Contingent consideration1 — — 1 
Total liabilities measured at fair value$103 $— $36 $67 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
The contingent consideration liability is our only Level 3 asset or liability. A summary of the Level 3 activity follows:

Contingent Consideration
(in millions)
Balance at October 31, 2021$89 
Additions to contingent consideration3 
Change in fair value (included within selling, general and administrative expenses)(25)
Balance at October 31, 2022$67 
Additions to contingent consideration 5 
Payments(72)
Change in fair value (included within selling, general and administrative expenses)1 
Balance at October 31, 2023$1 
Impairment of Long-lived assets included in net income
For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2023, 2022 and 2021:

 Years Ended
October 31,
 202320222021
 (in millions)
Long-lived assets held and used$277 $— $2 
v3.23.4
DERIVATIVES (Tables)
 12 Months Ended
Oct. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Aggregated notional amounts by designation
The number of open foreign exchange forward contracts and aggregated notional amounts by designation as of October 31, 2023 were as follows:

 Number of Open Forward
Contracts 		Aggregate Notional Amount
USD
Buy/(Sell)
 ($ in millions)
Derivatives designated as hedging instruments:
Cash Flow Hedges
Foreign exchange forward contracts270$(383)
Net Investment Hedges
Foreign exchange forward contracts3$(11)
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts194$(162)
Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2023 and 2022 were as follows:
Fair Values of Derivative Instruments
Asset DerivativesLiability Derivatives
 Fair Value Fair Value
Balance Sheet LocationOctober 31,
2023		October 31,
2022		Balance Sheet LocationOctober 31,
2023		October 31,
2022
(in millions)
Derivatives designated as hedging instruments:     
Cash flow hedges     
Foreign exchange contracts     
Other current assets$15 $23 Other accrued liabilities$1 $2 
Net investment hedges
Foreign exchange contracts
Other current assets$1 $— Other accrued liabilities$— $— 
Derivatives not designated as hedging instruments:     
Foreign exchange contracts     
Other current assets$3 $8 Other accrued liabilities$1 $3 
Total derivatives$19 $31  $2 $5 
Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations
The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows:

Years Ended October 31,
202320222021
 (in millions)
Derivatives designated as hedging instruments:   
Cash flow hedges   
Foreign exchange contracts:
Loss reclassified from accumulated other comprehensive income (loss) into interest expense$(2)$(2)$(1)
Gain (loss) recognized in accumulated other comprehensive income (loss)$(4)$56 $2 
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales$2 $36 $(16)
Gain on time value of forward contracts recorded in cost of sales$7 $— $— 
Net investment hedges
Foreign exchange contracts:
Gain (loss) recognized in accumulated other comprehensive income (loss) - translation adjustment$(1)$5 $1 
Gain on time value of forward contracts recorded in other income (expense)— — 1 
Derivatives not designated as hedging instruments:   
Gain recognized in other income (expense), net $3 $10 $— 
v3.23.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)
 12 Months Ended
Oct. 31, 2023
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
Defined Contribution Plan Disclosures
Our defined contribution plan expenses included in income from operations were as follows:

Years Ended October 31,
202320222021
(in millions)
Contributions to the 401(k) Plan$47 $46 $43 
Contributions to plans outside the U.S51 47 43 
Total defined contribution plan expense$98 $93 $86 
Schedule of Net Benefit Costs
For the years ended October 31, 2023, 2022 and 2021, components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of:
 PensionsU.S. Post-Retirement Benefit Plans
 U.S. PlansNon-U.S. Plans
 202320222021202320222021202320222021
 (in millions)
Net periodic benefit cost (benefit)         
Service cost — benefits earned during the period$— $— $— $16 $22 $22 $— $1 $1 
Interest cost on benefit obligation21 14 14 24 9 8 4 2 2 
Expected return on plan assets(19)(27)(29)(36)(43)(49)(4)(6)(6)
Amortization of net actuarial (gain) loss— — 4 (2)25 53 (1)(2)4 
Amortization of prior service benefit— — — — — — (1)(1)(1)
Total periodic benefit cost (benefit)$2 $(13)$(11)$2 $13 $34 $(2)$(6)$— 
Settlement loss$4 $4 $1 $— $— $— $— $— $— 
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss         
Net actuarial (gain) loss$22 $16 $(92)$(13)$(83)$(114)$9 $15 $(30)
Amortization of net actuarial (gain) loss— — (4)2 (25)(53)1 2 (4)
Amortization of prior service benefit— — — — — — 1 1 1 
Loss due to settlement(4)(4)(1)— — — — — — 
Foreign currency— — — 2 11 5 — — — 
Total recognized in other comprehensive (income) loss$18 $12 $(97)$(9)$(97)$(162)$11 $18 $(33)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss$24 $3 $(107)$(7)$(84)$(128)$9 $12 $(33)
Schedule of Funded status of Defined Benefit and Post-Retirement Benefit plans
Funded Status.    As of October 31, 2023 and 2022, the funded status of the defined benefit and post-retirement benefit plans was:

 U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S.
Post-Retirement
Benefit Plans
 202320222023202220232022
 (in millions)
Change in fair value of plan assets:      
Fair value — beginning of year$396 $551 $748 $1,093 $85 $116 
Actual return on plan assets(8)(122)14 (147)(2)(26)
Employer contributions— — 21 17 — — 
Participants' contributions— — 1 1 — — 
Benefits paid(8)(10)(35)(35)(7)(5)
Settlements(21)(23)— — — — 
Currency impact— — 42 (181)— — 
Fair value — end of year$359 $396 $791 $748 $76 $85 
Change in benefit obligation:      
Benefit obligation — beginning of year$357 $512 $665 $1,100 $65 $84 
Service cost— — 16 22 — 1 
Interest cost21 14 24 9 4 2 
Participants' contributions— — 1 1 — — 
Actuarial (gain) loss(5)(133)(33)(262)3 (17)
Benefits paid(9)(10)(35)(35)(7)(5)
Settlements(21)(26)— — — — 
Currency impact— — 44 (170)— — 
Benefit obligation — end of year$343 $357 $682 $665 $65 $65 
Overfunded (underfunded) status of PBO$16 $39 $109 $83 $11 $20 
Amounts recognized in the consolidated balance sheet
Amounts recognized in the consolidated balance sheet consist of:      
Other assets$19 $42 $174 $140 $11 $20 
Employee compensation and benefits(1)(1)— — — — 
Retirement and post-retirement benefits(2)(2)(65)(57)— — 
Total net asset (liability)$16 $39 $109 $83 $11 $20 
Amounts recognized in accumulated other comprehensive income (loss)
Amounts Recognized in Accumulated Other Comprehensive Income (Loss):
Actuarial (gains) losses$66 $48 $43 $52 $4 $(6)
Prior service costs (benefits)— — — — (2)(3)
Total$66 $48 $43 $52 $2 $(9)
Schedule of Allocation of Plan Assets
The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2023 and 2022.
  Fair Value Measurement
at October 31, 2023 Using
 October 31,
2023		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$2 $— $— $— $2 
Equity182 44 — — 138 
Fixed Income174 — — — 174 
Other Investments1 — — 1 — 
Total assets measured at fair value$359 $44 $— $1 $314 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
  Fair Value Measurement
at October 31, 2022 Using
 October 31,
2022		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$1 $— $— $— $1 
Equity194 49 — — 145 
Fixed Income199 — — — 199 
Other Investments2 — — 2 — 
Total assets measured at fair value$396 $49 $— $2 $345 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2023 and 2022.
  Fair Value Measurement
at October 31, 2023 Using
 October 31,
2023		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$— $— $— $— $— 
Equity39 10 — — 29 
Fixed Income36 — — — 36 
Other Investments1 — — 1 — 
Total assets measured at fair value$76 $10 $— $1 $65 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

  Fair Value Measurement
at October 31, 2022 Using
 October 31,
2022		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$— $— $— $— $— 
Equity42 10 — — 32 
Fixed Income42 — — — 42 
Other Investments1 — — 1 — 
Total assets measured at fair value$85 $10 $— $1 $74 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2023 and 2022:

  Fair Value Measurement
at October 31, 2023 Using
 October 31,
2023		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$17 $1 $16 $— $— 
Equity367 266 — — 101 
Fixed Income321 113 113 — 95 
Annuity Contract86 — — 86 — 
Total assets measured at fair value$791 $380 $129 $86 $196 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

  Fair Value Measurement
at October 31, 2022 Using
 October 31,
2022		Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Not Subject to Leveling (1)
 (in millions)
Cash and Cash Equivalents$22 $— $22 $— $— 
Equity360 264 — — 96 
Fixed Income274 83 98 — 93 
Annuity Contract92 — — 92 — 
Total assets measured at fair value$748 $347 $120 $92 $189 
(1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
.
Defined benefit plans assets measured at fair value using significant unobservable inputs (level 3)
For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2023 and 2022:
 Years Ended
October 31.
 20232022
Balance, beginning of year$2 $2 
Realized gains/(losses)— — 
Unrealized gains/(losses)— — 
Purchases, sales, issuances, and settlements(1)— 
Transfers in (out)— — 
Balance, end of year$1 $2 
For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2023 and 2022:
 Years Ended
October 31,
 20232022
Balance, beginning of year$1 $1 
Realized gains/(losses)— — 
Unrealized gains/(losses)— — 
Purchases, sales, issuances, and settlements— — 
Transfers in (out)— — 
Balance, end of year$1 $1 
For non-U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2023 and 2022:
 Years Ended
October 31,
 20232022
Balance, beginning of year$92 $— 
Unrealized losses(5)(39)
Purchases, sales, issuances, and settlements(6)(5)
Transfers in (out)— 159 
Currency impact5 (23)
Balance, end of year$86 $92 
Combined projected benefit obligation, accumulated benefit obligations and fair value of plan assets
The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2023 or 2022.
 20232022
 Benefit
Obligation		 Benefit
Obligation		 
 Fair Value of
Plan Assets		Fair Value of
Plan Assets
 PBOPBO
 (in millions)
U.S. defined benefit plans where PBO exceeds the fair value of plan assets $3 $— $3 $— 
U.S. defined benefit plans where fair value of plan assets exceeds PBO 340 359 354 396 
Total$343 $359 $357 $396 
Non-U.S. defined benefit plans where PBO exceeds the fair value of plan assets $197 $132 $172 $114 
Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO 485 659 493 634 
Total$682 $791 $665 $748 
 ABO ABO 
U.S. defined benefit plans where ABO exceeds the fair value of plan assets$3 $— $3 $— 
U.S. defined benefit plans where the fair value of plan assets exceeds ABO340 359 354 396 
Total$343 $359 $357 $396 
Non-U.S. defined benefit plans where ABO exceeds the fair value of plan assets $192 $132 $167 $114 
Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO480 659 485 634 
Total$672 $791 $652 $748 
Schedule of expected benefit payments The following table presents expected future benefit payments for the next 10 years:
U.S. Defined
Benefit Plans		Non-U.S. Defined
Benefit Plans		U.S. Post-Retirement
Benefit Plans
 (in millions)
2024$33 $35 $7 
2025$31 $36 $7 
2026$31 $37 $8 
2027$32 $37 $8 
2028$32 $39 $8 
2029 - 2033$142 $202 $33 
Assumptions used to calculate the net periodic cost and benefit obligation
Assumptions used to calculate the net periodic cost (benefit) in each year were as follows:

 For years ended October 31,
 202320222021
U.S. defined benefit plans:   
Discount rate6.00%2.75%2.75%
Expected long-term return on assets5.00%5.00%7.00%
Non-U.S. defined benefit plans:   
Discount rate
1.50-4.77%
0.29-1.76%
0.07-1.54%
Average increase in compensation levels
2.00-3.25%
2.00-3.50%
2.00-3.00%
Expected long-term return on assets
3.25-5.50%
2.75-5.50%
4.00-5.50%
Interest crediting rate for cash balance plans
0.50-2.10%
0.30-0.50%
0.10-0.50%
U.S. post-retirement benefits plans:   
Discount rate6.00%2.75%2.50%
Expected long-term return on assets5.00%5.00%7.00%
Current medical cost trend rate7.00%6.00%6.25%
Ultimate medical cost trend rate4.75%4.50%4.50%
Medical cost trend rate decreases to ultimate rate in year202920272029

Assumptions used to calculate the benefit obligation were as follows:

 As of the Years Ending October 31,
 20232022
U.S. defined benefit plans:  
Discount rate6.50%6.00%
Non-U.S. defined benefit plans:  
Discount rate
1.78-5.63%
1.50-4.77%
Average increase in compensation levels
2.00-3.25%
2.00-3.25%
Interest crediting rate for cash balance plans
0.50-1.80%
0.50-2.10%
U.S. post-retirement benefits plans:  
Discount rate6.60%6.00%
Current medical cost trend rate6.50%7.00%
Ultimate medical cost trend rate4.75%4.75%
Medical cost trend rate decreases to ultimate rate in year20292029
v3.23.4
RESTRUCTURING AND OTHER RELATED COSTS (Tables)
 12 Months Ended
Oct. 31, 2023
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring Reserve by Type of Cost
A summary of total restructuring activity is shown in the table below:

Workforce
Reduction		Consolidation of Excess FacilitiesTotal
(in millions)
Balance at October 31, 2022$— $— $— 
Income statement expense33 13 46 
Accelerated share-based compensation expense(1)— (1)
Accelerated depreciation expenses of ROU and machinery and equipment— (8)(8)
Cash payments(1)— (1)
Balance at October 31, 2023$31 $5 $36 
Restructuring and related costs by statement of operations caption
A summary of the charges in the consolidated statement of operations resulting from the restructuring plan is shown below:


Year Ended
October 31,
2023
(in millions)
Cost of products and services$11 
Research and Development6 
Selling, general and administrative29 
Total restructuring costs$46 
v3.23.4
GUARANTEES (Tables)
 12 Months Ended
Oct. 31, 2023
Guarantees [Abstract]  
Standard Warranty
A summary of the standard warranty accrual activity is shown in the table below.

 October 31,
 20232022
 (in millions)
Standard warranty accrual, beginning balance$30 $30 
Accruals for warranties including change in estimates57 50 
Settlements made during the period(58)(50)
Standard warranty accrual, ending balance$29 $30 
Accruals for warranties due within one year$29 $30 
v3.23.4
LONG-TERM DEBT (Tables)
 12 Months Ended
Oct. 31, 2023
Debt Disclosure [Abstract]  
Long-term debt - Senior Notes
The following table summarizes the company's long-term senior notes:

 October 31, 2023October 31, 2022
 Amortized
Principal		Amortized
Principal
 (in millions)
2026 Senior Notes299 299 
2029 Senior Notes496 495 
2030 Senior Notes496 496 
2031 Senior Notes844 843 
Total Senior Notes$2,135 $2,133 
v3.23.4
STOCKHOLDERS' EQUITY (Tables)
 12 Months Ended
Oct. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss)
Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2023 and 2022 were as follows:
Net defined benefit pension cost and post retirement plan costs
Foreign currency translationPrior service creditsActuarial LossesUnrealized gains (losses) on derivativesTotal
(in millions)
As of October 31, 2021$(185)$124 $(224)$3 $(282)
Other comprehensive income (loss) before reclassifications(162)— 50 56 (56)
Amounts reclassified out of accumulated other comprehensive income (loss)— (1)28 (34)(7)
Tax (expense) benefit12 — (9)(5)(2)
Other comprehensive income (loss)(150)(1)69 17 (65)
As of October 31, 2022$(335)$123 $(155)$20 $(347)
Other comprehensive income (loss) before reclassifications33 — (17)(4)12 
Amounts reclassified out of accumulated other comprehensive income (loss)— (1)2 — 1 
Tax benefit1 — 5 1 7 
Other comprehensive income (loss)34 (1)(10)(3)20 
As of October 31, 2023$(301)$122 $(165)$17 $(327)
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]
Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2023 and 2022 were as follows (in millions):
Details about Accumulated Other
Comprehensive Income components		Amounts Reclassified
from Other Comprehensive Income		Affected line item in
statement of operations
20232022
Unrealized gains on derivatives$2 $36 Cost of products
Unrealized losses on derivatives(2)(2)Interest expense
— 34 Total before income tax
— (8)Provision for income tax
— 26 Total net of income tax
Net defined benefit pension cost and post retirement plan costs:
Actuarial net loss(2)(28)Other (income) expense
Prior service benefit1 1 Other (income) expense
(1)(27)Total before income tax
— 7 Benefit for income tax
(1)(20)Total net of income tax
Total reclassifications for the period$(1)$6 
v3.23.4
SEGMENT INFORMATION (Tables)
 12 Months Ended
Oct. 31, 2023
Revenue from External Customer [Line Items]  
Segment profitability
The following tables reflect segment results under our management reporting system after excluding certain unallocated costs as noted in the reconciliations below:
Years Ended October 31,
202320222021
(in millions)
Net Revenue:
Life Sciences and Applied Markets$3,856 $4,007 $3,663 
Diagnostics and Genomics1,409 1,389 1,296 
Agilent CrossLab1,568 1,452 1,360 
Total net revenue$6,833 $6,848 $6,319 
Income from Operations:
Life Sciences and Applied Markets$1,116 $1,186 $1,017 
Diagnostics and Genomics296 301 273 
Agilent CrossLab463 370 323 
Total reportable segment income from operations 1,875 1,857 1,613 
Share-Based Compensation Expense:
Life Sciences and Applied Markets$66 $69 $60 
Diagnostics and Genomics22 25 22 
Agilent CrossLab24 26 24 
Unallocated share-based compensation expenses (1)
— 6 5 
Total share-based compensation expense$112 $126 $111 
Depreciation Expense:
Life Sciences and Applied Markets$63 $59 $60 
Diagnostics and Genomics40 39 39 
Agilent CrossLab25 22 23 
Total depreciation expense$128 $120 $122 
(1) Share-based compensation expense amounts not allocated to the segments relate to accelerated share-based compensation expense from workforce reduction and from acquisition of businesses.

Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, prepaid expenses, long-term investments, deferred tax assets, right-of use assets and other assets.
    The following table reflects segment assets and capital expenditures under our management reporting system.
October 31,
20232022
(in millions)
Assets:
Life Sciences and Applied Markets$3,820 $3,955 
Diagnostics and Genomics3,307 3,489 
Agilent CrossLab897 869 
Total reportable segment assets$8,024 $8,313 
Capital Expenditures:
Life Sciences and Applied Markets$70 $77 
Diagnostics and Genomics206 181 
Agilent CrossLab22 33 
Total capital expenditures$298 $291 
Reconciliation of Reportable Segment Income from Operations to Consolidated Income before taxes.
          The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes:
 Years Ended October 31,
 202320222021
 (in millions)
Total reportable segments' income from operations$1,875 $1,857 $1,613 
Unallocated Costs
Amortization of intangible assets related to business combinations(139)(191)(194)
Acquisition and integration costs(16)(25)(41)
Transformational initiatives(25)(30)(37)
Asset impairments(277)— (2)
Business exit and divestiture costs — (7)(5)
Change in fair value of contingent consideration(1)25 21 
Restructuring and other related costs(46)— — 
Other (21)(11)(8)
Total unallocated costs(525)(239)(266)
Income from operations1,350 1,618 1,347 
Interest income51 9 2 
Interest expense(95)(84)(81)
Other income (expense, net33 (39)92 
Income before taxes$1,339 $1,504 $1,360 
Reconciliation of Assets from Segment to Consolidated
    The following table reconciles segment assets to Agilent's total assets:
October 31,
20232022
(in millions)
Total reportable segments' assets$8,024 $8,313 
Cash and cash equivalents1,590 1,053 
Prepaid expenses139 119 
Long-term investments164 195 
Long-term and other receivables127 134 
Deferred tax assets284 246 
Right of use assets154 150 
Others281 322 
Total assets$10,763 $10,532 
The other category primarily includes over funded pension plans which are not allocated to the segments.
Revenue and assets by geographic areas The following table presents summarized information for net revenue by geographic region. Revenues from external customers are generally attributed to countries based upon the customers' location.
Years Ended October 31,
202320222021
 (in millions)
Net revenue:   
United States$2,410 $2,385 $2,159 
China including Hong Kong1,383 1,499 1,273 
Rest of the world3,040 2,964 2,887 
Total net revenue6,833 6,848 6,319 

The following table presents summarized information for long-lived assets by geographic region. Long lived assets consist of property, plant, and equipment, right-of-use assets, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of Asia and the rest of Europe.
October 31,
20232022
 (in millions)
Long-lived Assets:
United States$1,188 $1,080 
Germany192 151 
Rest of World471 492 
Total Long-lived Assets$1,851 $1,723 
v3.23.4
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Oct. 31, 2020
Gain (Loss) on Disposition of Assets [Abstract]        
Proceeds from Divestiture of Businesses $ 50 $ 0 $ 0  
Net gain on Divestiture of Business 43 0 0  
Goodwill adjustment related to divestiture of business (13)      
Advertising Expense        
Advertising costs expensed as incurred 54 66 63  
Cash and Cash Equivalents        
Short-term Investments 0 0    
Cash and cash equivalents 1,590 1,053 1,484  
Restricted Cash 3 3 6  
Cash, cash equivalents and restricted cash 1,593 1,056 1,490 $ 1,447
Goodwill and Intangible Assets        
Goodwill impairment 0 0 0  
Impairment of indefinite-lived intangible assets 0 0 0  
Long -Lived Assets        
Impairment of Long-Lived Assets 277 0 2  
Variable Interest Entity        
Assets 10,763 10,532    
Fair Value Disclosures        
Equity Method Investments 0 0    
Carrying Value of Senior Notes 2,735 2,733    
Employee Compensation and Benefits        
Employee compensation and benefits accrued 120 123    
Share-based Payment Arrangement, Noncash Expense [Abstract]        
Share-based compensation expense 112 126 111  
Foreign Currency Translation        
Foreign currency translation net gain (Ioss) 2 (6) $ (4)  
Senior Notes        
Fair Value Disclosures        
Carrying Value of Senior Notes $ 2,135 $ 2,133    
Accounts Receivable        
Accounts Receivable        
Percent of Accounts receivable from a single customer No single customer accounted for more than 10 percent of accounts receivable No single customer accounted for more than 10 percent of accounts receivable    
Quoted Prices in Active Markets for Identical Assets (Level 1) | Senior Notes        
Foreign Currency Translation        
Long-term Debt, Fair Value $ 1,747 $ 1,754    
Variable Interest Entity, Not Primary Beneficiary        
Variable Interest Entity        
Assets 82 $ 87    
Non-US        
Cash and Cash Equivalents        
Cash and cash equivalents 1,287      
Resolution Bioscience, Inc.        
Gain (Loss) on Disposition of Assets [Abstract]        
Net gain on Divestiture of Business 43      
Long -Lived Assets        
Long lived assets held for sale Impairment $ 270      
Minimum        
Goodwill and Intangible Assets        
Finite Lived Intangible Assets Useful Life 6 months      
Minimum | Machinery and Equipment        
Property, Plant and Equipment [Abstract]        
Property, Plant and Equipment, Useful Life 3 years      
Minimum | Software Development        
Property, Plant and Equipment [Abstract]        
Property, Plant and Equipment, Useful Life 3 years      
Maximum        
Goodwill and Intangible Assets        
Finite Lived Intangible Assets Useful Life 15 years      
Maximum | Machinery and Equipment        
Property, Plant and Equipment [Abstract]        
Property, Plant and Equipment, Useful Life 10 years      
Maximum | Software Development        
Property, Plant and Equipment [Abstract]        
Property, Plant and Equipment, Useful Life 5 years      
Diagnostics and Genomics        
Gain (Loss) on Disposition of Assets [Abstract]        
Goodwill adjustment related to divestiture of business $ (13)      
v3.23.4
REVENUE - Revenue by Region (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Disaggregation of Revenue [Line Items]      
Net revenue $ 6,833 $ 6,848 $ 6,319
Americas      
Disaggregation of Revenue [Line Items]      
Net revenue 2,732 2,682 2,404
Europe      
Disaggregation of Revenue [Line Items]      
Net revenue 1,754 1,699 1,688
Asia Pacific      
Disaggregation of Revenue [Line Items]      
Net revenue 2,347 2,467 2,227
Life Sciences and Applied Markets      
Disaggregation of Revenue [Line Items]      
Net revenue 3,856 4,007 3,663
Life Sciences and Applied Markets | Americas      
Disaggregation of Revenue [Line Items]      
Net revenue 1,284 1,331 1,199
Life Sciences and Applied Markets | Europe      
Disaggregation of Revenue [Line Items]      
Net revenue 920 907 893
Life Sciences and Applied Markets | Asia Pacific      
Disaggregation of Revenue [Line Items]      
Net revenue 1,652 1,769 1,571
Diagnostics and Genomics      
Disaggregation of Revenue [Line Items]      
Net revenue 1,409 1,389 1,296
Diagnostics and Genomics | Americas      
Disaggregation of Revenue [Line Items]      
Net revenue 814 784 695
Diagnostics and Genomics | Europe      
Disaggregation of Revenue [Line Items]      
Net revenue 417 410 417
Diagnostics and Genomics | Asia Pacific      
Disaggregation of Revenue [Line Items]      
Net revenue 178 195 184
Agilent CrossLab      
Disaggregation of Revenue [Line Items]      
Net revenue 1,568 1,452 1,360
Agilent CrossLab | Americas      
Disaggregation of Revenue [Line Items]      
Net revenue 634 567 510
Agilent CrossLab | Europe      
Disaggregation of Revenue [Line Items]      
Net revenue 417 382 378
Agilent CrossLab | Asia Pacific      
Disaggregation of Revenue [Line Items]      
Net revenue $ 517 $ 503 $ 472
v3.23.4
REVENUE - Revenue by End Markets (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Disaggregation of Revenue [Line Items]      
Net revenue $ 6,833 $ 6,848 $ 6,319
Pharmaceutical and Biopharmaceutical Market      
Disaggregation of Revenue [Line Items]      
Net revenue 2,433 2,515 2,224
Chemical and Advanced Materials Market      
Disaggregation of Revenue [Line Items]      
Net revenue 1,543 1,521 1,328
Diagnostics and Clinical Market      
Disaggregation of Revenue [Line Items]      
Net revenue 966 963 938
Food Market      
Disaggregation of Revenue [Line Items]      
Net revenue 628 617 601
Academia and Government Market      
Disaggregation of Revenue [Line Items]      
Net revenue 601 576 576
Environmental and Forensics Market      
Disaggregation of Revenue [Line Items]      
Net revenue $ 662 $ 656 $ 652
v3.23.4
REVENUE - Revenue by Type (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Disaggregation of Revenue [Line Items]      
Net revenue $ 6,833 $ 6,848 $ 6,319
Instrumentation      
Disaggregation of Revenue [Line Items]      
Net revenue 2,742 2,907 2,657
Non-Instrumentation and Other      
Disaggregation of Revenue [Line Items]      
Net revenue $ 4,091 $ 3,941 $ 3,662
v3.23.4
REVENUE - Contract Balances (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Contract Assets $ 252 $ 275
Contract Liability beginning balance 557 519
Net revenue deferred in the period 488 437
Revenue recognized that was included in the contract liability balance at the beginning of the period (409) (372)
Change in deferrals from customer cash advances, net of revenue recognized (28) 11
Currency translation and other adjustments 8 (38)
Contract Liability ending balance 616 $ 557
Revenue, Remaining Performance Obligation, Amount $ 331  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-31    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 12 months  
v3.23.4
SHARE-BASED COMPENSATION General Disclosures (Details) - USD ($)
$ in Millions
 12 Months Ended
Nov. 07, 2023
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Employee stock purchase plan [Abstract]        
Compensation percentage maximum eligible contribution to purchase shares of common stock   10.00%    
Maximum number of shares authorized for issuance under the ESPP (in shares)   31,000,000    
Number of shares purchased under ESPP (in shares)   487,735 469,701 462,237
Aggregate Value stock issued under Employee Stock Purchase Plan   $ 57 $ 54 $ 46
Incentive compensation plans [Abstract]        
Common stock available for future awards under the 2018 Stock Plan (in shares)   19,519,780    
Subsequent Event        
Employee stock purchase plan [Abstract]        
Number of shares purchased under ESPP (in shares) 324,092      
Aggregate Value stock issued under Employee Stock Purchase Plan $ 28      
Employee Stock Purchase Plan        
Employee stock purchase plan [Abstract]        
Percent of market price   85.00%    
Incentive compensation plans [Abstract]        
Common stock available for future awards under the 2018 Stock Plan (in shares)   24,277,203    
Share-based Payment Arrangement, Option        
Employee stock purchase plan [Abstract]        
Percent of market price   100.00%    
Incentive compensation plans [Abstract]        
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period   10 years    
Percentage which rate options generally vest per year (in hundredths)   25.00%    
Number of years from the date of grant generally vest (in years)   4 years    
Restricted Stock Units (RSUs)        
Incentive compensation plans [Abstract]        
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period   10 years    
Percentage which rate options generally vest per year (in hundredths)   25.00%    
Number of years from the date of grant generally vest (in years)   4 years    
Long-Term Performance Plan        
Incentive compensation plans [Abstract]        
Number of years from the date of grant generally vest (in years)   3 years    
Long-Term Performance Plan | Minimum        
Incentive compensation plans [Abstract]        
Percentage which rate options generally vest per year (in hundredths)   0.00%    
Long-Term Performance Plan | Maximum        
Incentive compensation plans [Abstract]        
Percentage which rate options generally vest per year (in hundredths)   200.00%    
v3.23.4
SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Share-based compensation disclosures      
Share-based compensation expense $ 112 $ 126 $ 111
Cost of Product and Services      
Share-based compensation disclosures      
Share-based compensation expense 34 30 26
Research and Development      
Share-based compensation disclosures      
Share-based compensation expense 13 14 12
Selling, General and Administrative      
Share-based compensation disclosures      
Share-based compensation expense 65 82 $ 73
Inventories      
Share-based Payment Arrangement, Expensed and Capitalized, Amount      
Share-based compensation expense $ 0 $ 0  
v3.23.4
SHARE-BASED COMPENSATION-Fair Value Assumptions (Details)
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted average risk-free interest rate 3.90% 1.50% 0.50%
Dividend Yield 0.60% 0.50% 0.70%
Weighted Average Volatility 28.00% 26.00% 26.00%
Expected life 5 years 6 months 5 years 6 months 5 years 6 months
Percent of market price 100.00%    
Long-Term Performance Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Volatility of Agilent shares (in hundreths) 31.00% 29.00% 30.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 22.00% 23.00% 24.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 84.00% 81.00% 57.00%
Pair-wise correlation with selected peers (in hundredths) 42.00% 41.00% 45.00%
LTPP & RSU      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Post-vest restriction discount for all executive awards 7.10% 6.50% 6.80%
v3.23.4
SHARE-BASED COMPENSATION Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]      
Outstanding, beginning balance (in shares) 1,097    
Granted (in shares) 269    
Exercised (in shares) (249)    
Cancelled (in shares) (37)    
Outstanding, ending balance (in shares) 1,080 1,097  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]      
Outstanding, Weighted Average option Exercise Price $ 118 $ 94  
Options, Grants in Period, Weighted Average Exercise Price 147    
Weighted-average exercise price per share, exercised (in dollars per share) 41 $ 38 $ 33
Weighted-average exercise price per share, cancelled, expired and forfeited (in dollars per shares) $ 142    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value $ 25,303,000 $ 10,765,000 $ 34,305,000
Black Scholes per share value of options granted during fiscal year $ 47 $ 39 $ 26
Issuance of common stock under employee stock plans $ 67,000,000 $ 58,000,000 $ 55,000,000
Unrecognized share-based compensation expense - Stock Options $ 9,000,000    
v3.23.4
SHARE-BASED COMPENSATION Shares Authorized by Exercise Price Range (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]    
Weighted Average Remaining Contractual Life (in years) 6 years 7 months 6 days  
Aggregate Intrinsic Value - Options outstanding $ 13,088  
Number Exercisable (in shares) 200  
Weighted Average Remaining Contractual Life (in years) 4 years 9 months 18 days  
Weighted Average Exercise Price (in dollars per share) $ 92  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $ 13,088  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number 507  
Aggregate instrinsic value of options [Abstract]    
Share Price $ 103.37  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 1,080 1,097
Outstanding, Weighted Average option Exercise Price $ 118 $ 94
Range of Exercise Prices - $40.01 - $50.00    
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]    
Minimum price of options outstanding in the period (in dollars per share) 40.01  
Maximum price of options outstanding, end of the period (in dollars per share) $ 50.00  
Number Outstanding (in shares) 210  
Weighted Average Remaining Contractual Life (in years) 1 year  
Weighted Average Exercise Price (in dollars per share) $ 41  
Aggregate Intrinsic Value - Options outstanding $ 13,088  
Number Exercisable (in shares) 210  
Weighted Average Remaining Contractual Life (in years) 1 year  
Weighted Average Exercise Price (in dollars per share) $ 41  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $ 13,088  
Range of Exercise Prices $100.00 - $110.00    
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]    
Minimum price of options outstanding in the period (in dollars per share) $ 100.00  
Maximum price of options outstanding, end of the period (in dollars per share) $ 110.00  
Number Outstanding (in shares) 311  
Weighted Average Remaining Contractual Life (in years) 7 years  
Weighted Average Exercise Price (in dollars per share) $ 110  
Aggregate Intrinsic Value - Options outstanding $ 0  
Number Exercisable (in shares) 177  
Weighted Average Remaining Contractual Life (in years) 7 years  
Weighted Average Exercise Price (in dollars per share) $ 110  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $ 0  
Range of Exercise Prices - $110.01 - $150.00    
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]    
Minimum price of options outstanding in the period (in dollars per share) $ 110.01  
Maximum price of options outstanding, end of the period (in dollars per share) $ 150.00  
Number Outstanding (in shares) 319  
Weighted Average Remaining Contractual Life (in years) 8 years 9 months 18 days  
Weighted Average Exercise Price (in dollars per share) $ 143  
Aggregate Intrinsic Value - Options outstanding $ 0  
Number Exercisable (in shares) 40  
Weighted Average Remaining Contractual Life (in years) 8 years 3 months 18 days  
Weighted Average Exercise Price (in dollars per share) $ 136  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $ 0  
Range of Exercise Prices - $150.01 & over    
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]    
Minimum price of options outstanding in the period (in dollars per share) $ 150.01  
Number Outstanding (in shares) 240  
Weighted Average Remaining Contractual Life (in years) 8 years  
Weighted Average Exercise Price (in dollars per share) $ 161  
Aggregate Intrinsic Value - Options outstanding $ 0  
Number Exercisable (in shares) 80  
Weighted Average Remaining Contractual Life (in years) 8 years  
Weighted Average Exercise Price (in dollars per share) $ 161  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $ 0  
v3.23.4
SHARE-BASED COMPENSATION Non-vested award activity disclosure (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Non-vested beginning (in shares) 2,103    
Granted (in shares) 864    
Vested (in shares) (1,096)    
Forfeited (in shares) (181)    
Change in LTPP shares vested in the year- Weighted Average Grant Date Fair Value $ 79    
Change in LTPP shares vested in the year due to performance conditions 199    
Non-vested ending (in shares) 1,889 2,103  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]      
Non-vested at beginning of period -Weighted Average Grant Price (in dollars per share) $ 114    
Granted - Weighted Average Grant Price (in dollars per share) 146    
Vested- Weighted Average Grant Price (in dollars per share) 90    
Foreited- Weighted Average Grant Price (in dollars per share) 134    
Non-vested at end of period -Weighted Average Grant Price (in dollars per share) $ 136 $ 114  
Unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures $ 116    
Weighted-average period non-vested restricted stock awards are expected to be amortized over (in years) 2 years 2 months 12 days    
Total fair value of restricted stock awards vested $ 99 $ 89 $ 84
v3.23.4
INCOME TAXES INCOME TAXES- Provision (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Income before income tax      
U.S. operations $ 614 $ 858 $ 876
Non-U.S. operations 725 646 484
Income before taxes 1,339 1,504 1,360
Provision (benefit) for income taxes      
U.S. federal taxes - current 117 173 122
U.S. federal taxes - deferred (84) (28) (1)
Non-U.S. taxes - current 26 47 (3)
Non-U.S. taxes - deferred 38 35 14
State taxes, net of federal benefit - current 12 22 17
State taxes, net of federal benefit - deferred (10) 1 1
Provision for income taxes $ 99 $ 250 $ 150
v3.23.4
INCOME TAXES Effective tax rate (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Income Tax Disclosure [Abstract]      
Profit before tax times statutory rate $ 281 $ 316 $ 286
State income taxes, net of federal benefit 2 23 18
Non-U.S. income taxed at different rates 20 (18) 5
Change in unrecognized tax benefits) (35) (6) (84)
Foreign-derived intangible income deduction (41) (46) (35)
Realized loss on divestiture (104) 0 0
Excess tax benefits from stock-based compensation (14) (19) (29)
Other, net (10) 0 (11)
Provision for income taxes $ 99 $ 250 $ 150
Effective tax rate (in hundredths) 7.40% 16.60% 11.00%
Effective Income Tax Rate Reconciliation, Tax Settlement, Amount $ 30   $ 93
v3.23.4
INCOME TAXES INCOME TAXES Tax holidays (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Income Tax Holiday [Line Items]      
Impact of the income tax holidays $ 54 $ 53 $ 35
Benefit of income tax holidays on net income per share $ 0.18 $ 0.18 $ 0.11
v3.23.4
INCOME TAXES INCOME TAXES - Deferred Taxes and other (Details) - USD ($)
$ in Millions
Oct. 31, 2023
Oct. 31, 2022
Components of Deferred Tax Assets    
Intangibles $ 102 $ 62
Employee benefits, other than retirement 36 45
Net operating loss, capital loss and credit carryforwards 152 157
Share-based compensation 24 23
Capitalized Research and Development Costs 41 0
Lease obligations 37 29
Other 58 58
Subtotal 450 374
Tax valuation allowance (112) (115)
Deferred tax assets 338 259
Components of Deferred Tax Liabilities    
Property, plant and equipment (26) (11)
Pension benefits and retiree medical benefits (25) (24)
Right-of-use asset (37) (29)
Other (4) (7)
Deferred tax liability (92) (71)
Deferred Tax Assets, Net 246 188
Long Term Deferred Tax Assets And Liabilities [Abstract]    
Long-term deferred tax assets ( included within other assets) 338 259
Deferred Tax Assets, Net 246 188
Other Noncurrent Assets [Member]    
Components of Deferred Tax Assets    
Deferred tax assets 284 246
Long Term Deferred Tax Assets And Liabilities [Abstract]    
Long-term deferred tax assets ( included within other assets) 284 246
Other Noncurrent Liabilities    
Long Term Deferred Tax Assets And Liabilities [Abstract]    
Long-term deferred tax liabilities ( included within other long-term liabilities) $ 38 $ 58
v3.23.4
INCOME TAXES - Carryforwards (Details)
$ in Millions
Oct. 31, 2023
USD ($)
Net Operating loss carryforwards  
Federal net operating loss carryforwards $ 13
State net operating loss carryforwards 90
Foreign net operating loss carryforwards 248
Foreign  
Net Operating loss carryforwards  
Net operating loss carryforwards, subject to expiration 2
Net operating loss carryforwards, not subject to expiration 246
Domestic  
Capital Loss Carryforward  
Capital loss carryforwards 107
State  
Tax Credit Carryforwards  
Tax credit carryforwards $ 88
v3.23.4
INCOME TAXES - Current and long-term income tax assets and liabilities (Details) - USD ($)
$ in Millions
Oct. 31, 2023
Oct. 31, 2022
Income Tax Disclosure [Abstract]    
Current income tax assets (included within other current assets) $ 100 $ 87
Long-term income tax assets (included within other assets) 3 11
Current income tax liabilities (included within other accrued liabilities) (73) (51)
Long-term income tax liabilities (included within other long-term liabilities) (162) (216)
Total $ 132 $ 169
v3.23.4
INCOME TAXES INCOME TAXES - Uncertain Tax Positions (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Unrecognized Tax Benefits Rollforward      
Balance, beginning of year $ 123 $ 133 $ 195
Additions for tax positions related to the current year 5 5 6
Additions for tax positions from prior years 3 0 4
Reductions for tax positions from prior years 27 9 0
Settlements with taxing authorities 0 0 (30)
Statute of limitations expirations 6 6 42
Balance, end of year 98 123 133
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]      
Unrecognized Tax Benefits that Would Impact Effective Tax Rate 68    
Interest and penalties accrued related to unrecognized tax benefits accrued and reported 16 21  
Unrecognized Tax Benefits, including interest and penalties 114    
Provision (benefit) for income taxes 99 250 150
Tax Interest and Penalties      
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]      
Provision (benefit) for income taxes $ (5) $ (2) $ (19)
v3.23.4
NET INCOME (LOSS) PER SHARE (Details) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Numerator:      
Net Income $ 1,240 $ 1,254 $ 1,210
Denominator:      
Basic weighted average shares 294.0 299.0 304.0
Potential common shares - stock options and other employeee stock plans 2.0 1.0 3.0
Diluted weighted average shares 296.0 300.0 307.0
Share-based awards issued      
Total number of share-based awards issued (in shares) 1.5 1.4 2.1
v3.23.4
INVENTORY (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Inventory [Line Items]      
Finished goods $ 570 $ 555  
Purchased parts and fabricated assemblies 461 483  
Inventory 1,031 1,038  
Inventory-related excess and obsolescence charges $ 40 $ 24 $ 29
v3.23.4
PROPERTY, PLANT AND EQUIPMENT, NET (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Property, Plant and Equipment [Line Items]      
Land $ 60 $ 59  
Buildings and leasehold improvements 1,409 1,255  
Machinery and equipment 749 674  
Software 275 260  
Total property, plant and equipment 2,493 2,248  
Accumulated depreciation and amortization (1,223) (1,148)  
Property, plant and equipment, net 1,270 1,100  
Asset impairment charges 11 0 $ 2
Depreciation expense 128 120 $ 122
Property, Plant and Equipment, Disposals $ 68 $ 48  
v3.23.4
LEASES - Lease Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Leases [Abstract]      
Operating Lease, Cost $ 68 $ 59 $ 59
Short-term Lease, Cost 2 2 2
Variable Lease, Cost 16 15 14
Sublease Income (16) (14) (13)
Total Lease, Cost 70 $ 62 $ 62
Accelerated Depreciation 7    
Operating Lease, Impairment Loss $ 8    
v3.23.4
LEASES - Supplemental Cash Flow Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Leases [Abstract]      
Operating cash flow from operating leases $ 56 $ 53 $ 57
Non-cash right of use assets obtained in exchange for operating lease obligations $ 70 $ 38 $ 53
v3.23.4
LEASES - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
Oct. 31, 2023
Oct. 31, 2022
Lessee, Lease, Description [Line Items]    
Right-of-use asset $ 154 $ 150
Operating lease liabilities - Current 46 51
Operating lease liabilities - Long-term $ 118 $ 101
Operating Lease, Weighted Average Remaining Lease Term 8 years 3 months 18 days 7 years 4 months 24 days
Operating Lease, Weighted Average Discount Rate, Percent 3.30% 2.40%
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other assets Other assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current Other Liabilities, Current
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Noncurrent Other Liabilities, Noncurrent
v3.23.4
LEASES - Maturities of Lease Liabilities (Details) - USD ($)
$ in Millions
Oct. 31, 2023
Oct. 31, 2022
Future Minimum Lease Payment Due    
2024 $ 51  
2025 32  
2026 22  
2027 14  
2028 11  
Thereafter 59  
Total undiscounted future minimum lease payments 189  
Less: amount of lease payments representing interest $ (25)  
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current, Other Liabilities, Noncurrent  
Present value of future minimum lease payments $ 164  
Less: Current liabilities (46) $ (51)
Long-term lease liabilities $ 118 $ 101
v3.23.4
LEASES - Textual (Details) - USD ($)
$ in Millions
Oct. 31, 2023
Oct. 31, 2022
Leases [Abstract]    
Lessor Asset under Operating Lease, original cost $ 30 $ 29
Lessor Asset under Operating Lease, Net book Value 7 4
Sales-type Lease, Lease Receivable $ 42 $ 38
v3.23.4
GOODWILL AND OTHER INTANGIBLE ASSETS Roll forward (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Goodwill - Rollforward    
Beginning Balance $ 3,952 $ 3,975
Foreign currency translation impact 6 (42)
Goodwill arising from acquisitions 15 19
Goodwill adjustment related to divestiture of business (13)  
Ending Balance 3,960 3,952
Life Sciences and Applied Markets    
Goodwill - Rollforward    
Beginning Balance 1,743 1,743
Foreign currency translation impact 4 (19)
Goodwill arising from acquisitions 0 19
Goodwill adjustment related to divestiture of business 0  
Ending Balance 1,747 1,743
Diagnostics and Genomics    
Goodwill - Rollforward    
Beginning Balance 1,953 1,964
Foreign currency translation impact 1 (11)
Goodwill arising from acquisitions 15 0
Goodwill adjustment related to divestiture of business (13)  
Ending Balance 1,956 1,953
Agilent CrossLab    
Goodwill - Rollforward    
Beginning Balance 256 268
Foreign currency translation impact 1 (12)
Goodwill arising from acquisitions 0 0
Goodwill adjustment related to divestiture of business 0  
Ending Balance $ 257 $ 256
v3.23.4
GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Other Intangibles (Details) - USD ($)
$ in Millions
Oct. 31, 2023
Oct. 31, 2022
Schedule of Other Intangible Assets By Major Class [Abstract]    
Gross Carrying Amount $ 1,846 $ 2,149
Accumulated Amortization 1,381 1,338
Other intangible assets, net 475 821
Total amortizable intangible assets 465 811
Gross Book Value 1,856 2,159
In-Process R&D 10 10
Purchased technology    
Schedule of Other Intangible Assets By Major Class [Abstract]    
Gross Carrying Amount 1,467 1,733
Accumulated Amortization 1,093 1,068
Other intangible assets, net 374 665
Backlog    
Schedule of Other Intangible Assets By Major Class [Abstract]    
Gross Carrying Amount   8
Accumulated Amortization   8
Other intangible assets, net   0
Trademark/Tradename    
Schedule of Other Intangible Assets By Major Class [Abstract]    
Gross Carrying Amount 196 196
Accumulated Amortization 163 148
Other intangible assets, net 33 48
Customer Relationships    
Schedule of Other Intangible Assets By Major Class [Abstract]    
Gross Carrying Amount 149 180
Accumulated Amortization 112 105
Other intangible assets, net 37 75
Third-Party Technology and Licenses [Member]    
Schedule of Other Intangible Assets By Major Class [Abstract]    
Gross Carrying Amount 34 32
Accumulated Amortization 13 9
Other intangible assets, net $ 21 $ 23
v3.23.4
GOODWILL AND OTHER INTANGIBLE ASSETS Text (Details)
$ in Millions
 12 Months Ended
Oct. 31, 2023
USD ($)
numberOfCustomers
Oct. 31, 2022
USD ($)
Oct. 31, 2021
USD ($)
Intangible Assets, Including Goodwill)      
Goodwill Additions $ 15 $ 19  
Additions and adjustments to other intangibles 50    
Foreign exchange translation impact to other intangible assets 2 (3)  
Goodwill and Intangible Asset Impairment [Abstract]      
Goodwill impairment 0 0 $ 0
Impairment of finite-lived intangible assets 0 0 0
Impairment of indefinite-lived intangible assets 0 0 0
Business Acquisition      
Intangible assets written-off 7    
Net gain on Divestiture of Business 43 0 0
Proceeds from Divestiture of Businesses 50 0 $ 0
Diagnostics and Genomics      
Intangible Assets, Including Goodwill)      
Goodwill Additions 15 0  
Life Sciences and Applied Markets      
Intangible Assets, Including Goodwill)      
Goodwill Additions 0 19  
Agilent CrossLab      
Intangible Assets, Including Goodwill)      
Goodwill Additions 0 0  
Resolution Bioscience, Inc.      
Goodwill and Intangible Asset Impairment [Abstract]      
Impairment of finite-lived intangible assets 258    
Business Acquisition      
Net gain on Divestiture of Business 43    
Resolution Bioscience, Inc. | Cost of Product and Services      
Goodwill and Intangible Asset Impairment [Abstract]      
Impairment of finite-lived intangible assets $ 249    
Business Acquisition      
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of revenue    
Resolution Bioscience, Inc. | Selling, General and Administrative      
Goodwill and Intangible Asset Impairment [Abstract]      
Impairment of finite-lived intangible assets $ 9    
Business Acquisition      
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative    
Polymer Standards Service GmbH      
Intangible Assets, Including Goodwill)      
Goodwill Additions   19  
Additions and adjustments to other intangibles   35  
Business Acquisition      
Purchase price for acquisition   $ 41  
Acquisition of businesses      
Business Acquisition      
Number of Businesses Acquired | numberOfCustomers 2    
Purchase price for acquisition $ 51    
v3.23.4
GOODWILL AND OTHER INTANGIBLE ASSETS Amortization Expense and Future Amortization Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Future Amortization Expense Schedule      
2024 $ 100    
2025 83    
2026 54    
2027 52    
2028 45    
Thereafter 131    
Amortization Expense      
Amortization of intangible assets during the period $ 140 $ 192 $ 195
v3.23.4
INVESTMENTS (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Long-Term [Abstract]      
Equity investments - without readily determinable fair value $ 102 $ 141  
Other investments - with readily determinable fair value 26 23  
Trading securities 36 31  
Long-term investments 164 195  
Amounts included in other income (expense), net [Abstract]      
Net gain (loss) on equity securities (41) (67) $ 98
Net gain (loss) on equity securities sold during the period (15) 11 6
Unrealized gain (loss) on equity securities (26) (78) 92
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount   6 17
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 26    
Trading, Unrealized Gain (Loss) 2 (7) 8
Other than Temporary Impairment Losses, Investments $ 0 $ 0 $ 0
v3.23.4
FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - USD ($)
$ in Millions
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Assets, Long-term [Abstract]      
Trading securities $ 36 $ 31  
Total assets measured at fair value 0   $ 0
Liabilities, Long-term [Abstract]      
Contingent Consideration 1 67 $ 89
Fair Value, Recurring      
Assets, Long-term [Abstract]      
Total assets measured at fair value 1,075 577  
Liabilities, Short-term [Abstract]      
Derivative instruments (foreign exchange contracts) $ 2 $ 5  
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current Other Liabilities, Current  
Liabilities, Long-term [Abstract]      
Total liabilities measured at fair value $ 39 $ 103  
Fair Value, Recurring | Other Current Liabilities      
Liabilities, Long-term [Abstract]      
Contingent Consideration 1 66  
Fair Value, Recurring | Other Noncurrent Liabilities      
Liabilities, Long-term [Abstract]      
Contingent Consideration   1  
Deferred compensation liability 36 31  
Fair Value, Recurring | Other Current Assets [Member]      
Assets, Short-term [Abstract]      
Cash equivalents (money market funds) 994 492  
Derivative instruments (foreign exchange contracts) 19 31  
Fair Value, Recurring | Other Noncurrent Assets [Member]      
Assets, Long-term [Abstract]      
Trading securities 36 31  
Other investments 26 23  
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)      
Assets, Long-term [Abstract]      
Total assets measured at fair value 1,030 523  
Liabilities, Short-term [Abstract]      
Derivative instruments (foreign exchange contracts) $ 0 $ 0  
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current Other Liabilities, Current  
Liabilities, Long-term [Abstract]      
Total liabilities measured at fair value $ 0 $ 0  
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Liabilities      
Liabilities, Long-term [Abstract]      
Contingent Consideration 0 0  
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Noncurrent Liabilities      
Liabilities, Long-term [Abstract]      
Contingent Consideration   0  
Deferred compensation liability 0 0  
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Assets [Member]      
Assets, Short-term [Abstract]      
Cash equivalents (money market funds) 994 492  
Derivative instruments (foreign exchange contracts) 0 0  
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Noncurrent Assets [Member]      
Assets, Long-term [Abstract]      
Trading securities 36 31  
Other investments 0 0  
Fair Value, Recurring | Significant Other Observable Inputs (Level 2)      
Assets, Long-term [Abstract]      
Total assets measured at fair value 45 54  
Liabilities, Short-term [Abstract]      
Derivative instruments (foreign exchange contracts) $ 2 $ 5  
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current Other Liabilities, Current  
Liabilities, Long-term [Abstract]      
Total liabilities measured at fair value $ 38 $ 36  
Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | Other Current Liabilities      
Liabilities, Long-term [Abstract]      
Contingent Consideration 0 0  
Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | Other Noncurrent Liabilities      
Liabilities, Long-term [Abstract]      
Contingent Consideration   0  
Deferred compensation liability 36 31  
Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | Other Current Assets [Member]      
Assets, Short-term [Abstract]      
Cash equivalents (money market funds) 0 0  
Derivative instruments (foreign exchange contracts) 19 31  
Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | Other Noncurrent Assets [Member]      
Assets, Long-term [Abstract]      
Trading securities 0 0  
Other investments 26 23  
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)      
Assets, Long-term [Abstract]      
Total assets measured at fair value 0 0  
Liabilities, Short-term [Abstract]      
Derivative instruments (foreign exchange contracts) $ 0 $ 0  
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current Other Liabilities, Current  
Liabilities, Long-term [Abstract]      
Contingent Consideration $ 1    
Total liabilities measured at fair value   $ 67  
Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | Other Current Liabilities      
Liabilities, Long-term [Abstract]      
Contingent Consideration 1 66  
Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | Other Noncurrent Liabilities      
Liabilities, Long-term [Abstract]      
Contingent Consideration   1  
Deferred compensation liability 0 0  
Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | Other Current Assets [Member]      
Assets, Short-term [Abstract]      
Cash equivalents (money market funds) 0 0  
Derivative instruments (foreign exchange contracts) 0 0  
Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | Other Noncurrent Assets [Member]      
Assets, Long-term [Abstract]      
Trading securities 0 0  
Other investments $ 0 $ 0  
v3.23.4
FAIR VALUE MEASUREMENTS - Contingent Consideration (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 1 $ 67 $ 89
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 5 3  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 1 (25)  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements (72)    
Fair Value, Recurring | Other Current Liabilities      
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 1 66  
Fair Value, Recurring | Other Noncurrent Liabilities      
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value   1  
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring      
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 1    
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Other Current Liabilities      
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 1 66  
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Other Noncurrent Liabilities      
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value   $ 1  
v3.23.4
FAIR VALUE MEASUREMENTS FAIR VALUE MEASURMENTS - Fair value of assets and liabilities measured on non recurring (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Carrying value of long-lived asset $ 277   $ 2
Long-lived assets held for use impairment $ 277 $ 0 $ 2
Long lived assets, held for use, location not disclosed impairment charge impairment charge impairment charge
Fair value of assets, nonrecurring $ 0   $ 0
Impairments in non-marketable securities without readily determinable fair value $ 0 $ 0 $ 0
v3.23.4
FAIR VALUE MEASUREMENTS - Non marketable securities (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Fair Value Disclosures [Abstract]      
Impairments in non-marketable securities without readily determinable fair value $ 0 $ 0 $ 0
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 26    
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount   6 $ 17
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount 38 35  
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount 29 0  
Equity investments - without readily determinable fair value $ 102 $ 141  
v3.23.4
DERIVATIVES (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 06, 2019
Sep. 15, 2016
Sep. 15, 2016
Oct. 31, 2023
Aug. 01, 2019
Feb. 01, 2016
Treasury Lock            
Derivative Contracts [Abstract]            
Derivative, Notional Amount         $ 250  
Aggregate fair value , net liability position       $ 1    
Senior Notes 2026 | Interest Rate Swap [Member] | Cash Flow Hedges | Derivatives Designated as Hedging Instrument            
Derivative Contracts [Abstract]            
Derivative, Notional Amount           $ 300
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred   $ (10) $ (10) (3)    
Senior Notes 2029 | Treasury Lock | Cash Flow Hedges | Derivatives Designated as Hedging Instrument            
Derivative Contracts [Abstract]            
Derivative, Notional Amount         $ 250  
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred $ (6)     $ (3)    
v3.23.4
DERIVATIVES, Disclosures and derivative instrument aggregated notional amounts by currency and designations (Details) - Forward Contracts Buy/(Sell)
Oct. 31, 2023
USD ($)
contracts
Designated as Hedging Instrument | Cash Flow Hedges  
Derivative [Line Items]  
Number of Foreign Currency Derivatives Held | contracts 270
Designated as Hedging Instrument | Cash Flow Hedges | Sell  
Derivative [Line Items]  
Derivative, Notional Amount $ 383,000,000
Designated as Hedging Instrument | Net Investment Hedging  
Derivative [Line Items]  
Number of Foreign Currency Derivatives Held 3
Designated as Hedging Instrument | Net Investment Hedging | Sell  
Derivative [Line Items]  
Derivative, Notional Amount $ 11,000,000
Derivatives Not Designated as Hedging Instruments  
Derivative [Line Items]  
Number of Foreign Currency Derivatives Held | contracts 194
Derivatives Not Designated as Hedging Instruments | Sell  
Derivative [Line Items]  
Derivative, Notional Amount $ 162,000,000
v3.23.4
DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) - USD ($)
$ in Millions
Oct. 31, 2023
Oct. 31, 2022
Derivative, Fair Value, Net [Abstract]    
Derivative Asset, Fair Value $ 19 $ 31
Derivative Liability, Fair Value 2 5
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Other Current Assets [Member]    
Derivative, Fair Value, Net [Abstract]    
Derivative Asset, Fair Value 3 8
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Accrued Liabilities [Member]    
Derivative, Fair Value, Net [Abstract]    
Derivative Liability, Fair Value 1 3
Cash Flow Hedges | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts | Other Current Assets [Member]    
Derivative, Fair Value, Net [Abstract]    
Derivative Asset, Fair Value 15 23
Cash Flow Hedges | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts | Accrued Liabilities [Member]    
Derivative, Fair Value, Net [Abstract]    
Derivative Liability, Fair Value 1 2
Net Investment Hedging | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts | Other Current Assets [Member]    
Derivative, Fair Value, Net [Abstract]    
Derivative Asset, Fair Value 1 0
Net Investment Hedging | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts | Accrued Liabilities [Member]    
Derivative, Fair Value, Net [Abstract]    
Derivative Liability, Fair Value $ 0 $ 0
v3.23.4
DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Derivatives Not Designated as Hedging Instruments      
Derivative [Line Items]      
Gain (loss) recognized in other income (expense), net within continuing operations $ 3 $ 10 $ 0
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other income (expense), net Other income (expense), net Other income (expense), net
Cash Flow Hedges      
Derivative [Line Items]      
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months $ 20    
Cash Flow Hedges | Cost of Sales [Member]      
Derivative [Line Items]      
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months 12    
Cash Flow Hedges | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts      
Derivative [Line Items]      
Gain(loss reclassified from accumulated other comprehensive income (loss) into cost of sales 2 $ 36 $ (16)
Gain (loss) recognized in other income (expense), net within continuing operations $ 7 $ 0 $ 0
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of revenue Cost of revenue Cost of revenue
Derivative Instrument, Gain Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration] Costs and Expenses Costs and Expenses Costs and Expenses
Cash Flow Hedges | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts | Accumulated Other Comprehensive Loss      
Derivative [Line Items]      
Other comprehensive income (loss) before reclassifications $ (4) $ 56 $ 2
Cash Flow Hedges | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts | Interest Expense      
Derivative [Line Items]      
Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net (2) (2) (1)
Net Investment Hedging | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts      
Derivative [Line Items]      
Gain (loss) recognized in other income (expense), net within continuing operations $ 0 $ 0 $ 1
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other income (expense), net Other income (expense), net Other income (expense), net
Net Investment Hedging | Derivatives Designated as Hedging Instrument | Foreign Exchange Contracts | Accumulated Other Comprehensive Loss      
Derivative [Line Items]      
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax $ (1) $ 5 $ 1
v3.23.4
RETIREMENT PLANS AND POST RETIEMENT PENSION PLANS - Deferred Profit Sharing Plan (Details) - Deferred Profit Sharing - USD ($)
$ in Millions
Oct. 31, 2023
Oct. 31, 2022
Defined Benefit Plan Disclosure [Line Items]    
Fair Value of Plan Assets $ 81 $ 93
Projected Benefit Obligation $ 81 $ 93
v3.23.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Defined Contribution (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Defined Contribution Plan Disclosure [Line Items]      
Maximum employer matching contribution in the 401(k) plan (in hundredths) 6.00%    
Maximum employee contribution to 401(k) 50.00%    
Defined contribution plan expense $ 98 $ 93 $ 86
401(k) Additional company contribution      
Defined Contribution Plan Disclosure [Line Items]      
Transitional company contribution to employee 401(k) 4.00%    
401(k) Additional company contribution | 3 Percent      
Defined Contribution Plan Disclosure [Line Items]      
Transitional company contribution to employee 401(k) 3.00%    
401(k) Additional company contribution | 5 Percent      
Defined Contribution Plan Disclosure [Line Items]      
Transitional company contribution to employee 401(k) 5.00%    
Foreign Plan      
Defined Contribution Plan Disclosure [Line Items]      
Defined contribution plan expense $ 51 47 43
UNITED STATES      
Defined Contribution Plan Disclosure [Line Items]      
Defined contribution plan expense $ 47 $ 46 $ 43
v3.23.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Components of Net Periodic Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]      
Amortization of net actuarial gain (loss) $ 2 $ 28  
Amortization of prior service benefit (1) (1)  
Pension Plan | UNITED STATES      
Net periodic benefit cost (benefit) [Abstract]      
Service cost - benefits earned during the period 0 0 $ 0
Interest cost on benefit obligation 21 14 14
Defined Benefit Plan, Expected Return (Loss) on Plan Assets (19) (27) (29)
Amortization of actuarial gain (loss) 0 0 4
Amortization of prior service benefit 0 0 0
Total periodic benefit cost (benefit) 2 (13) (11)
Settlement loss (4) (4) (1)
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]      
Net actuarial (gain) loss 22 16 (92)
Amortization of net actuarial gain (loss) 0 0 (4)
Amortization of prior service benefit 0 0 0
Settlement and Curtailment Gain (Loss), before Tax (4) (4) (1)
Foreign Currency 0 0 0
Total recognized in other comprehensive (income) loss 18 12 (97)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss 24 3 (107)
Pension Plan | Foreign Plan      
Net periodic benefit cost (benefit) [Abstract]      
Service cost - benefits earned during the period 16 22 22
Interest cost on benefit obligation 24 9 8
Defined Benefit Plan, Expected Return (Loss) on Plan Assets (36) (43) (49)
Amortization of actuarial gain (loss) (2) 25 53
Amortization of prior service benefit 0 0 0
Total periodic benefit cost (benefit) 2 13 34
Settlement loss 0 0 0
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]      
Net actuarial (gain) loss (13) (83) (114)
Amortization of net actuarial gain (loss) 2 (25) (53)
Amortization of prior service benefit 0 0 0
Settlement and Curtailment Gain (Loss), before Tax 0 0 0
Foreign Currency 2 11 5
Total recognized in other comprehensive (income) loss (9) (97) (162)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss (7) (84) (128)
Post-Retirement Benefit Plan | UNITED STATES      
Net periodic benefit cost (benefit) [Abstract]      
Service cost - benefits earned during the period 0 1 1
Interest cost on benefit obligation 4 2 2
Defined Benefit Plan, Expected Return (Loss) on Plan Assets (4) (6) (6)
Amortization of actuarial gain (loss) (1) (2) 4
Amortization of prior service benefit (1) (1) (1)
Total periodic benefit cost (benefit) (2) (6) 0
Settlement loss 0 0 0
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]      
Net actuarial (gain) loss 9 15 (30)
Amortization of net actuarial gain (loss) 1 2 (4)
Amortization of prior service benefit 1 1 1
Settlement and Curtailment Gain (Loss), before Tax 0 0 0
Foreign Currency 0 0 0
Total recognized in other comprehensive (income) loss 11 18 (33)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss $ 9 $ 12 $ (33)
v3.23.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Funded Status (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Change in benefit obligation: [Roll Forward]      
Actuarial gain (loss) $ 35 $ (412)  
Foreign Plan | Pension Plan      
Change in fair value of plan assets: [Roll Forward]      
Fair Value Balance, beginning of year 748 1,093  
Actual return on plan assets 14 (147)  
Employer contributions 21 17  
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 1 1  
Benefits paid 35 35  
Settlements 0 0  
Currency impact 42 (181)  
Fair Value Balance, end of year 791 748 $ 1,093
Change in benefit obligation: [Roll Forward]      
Benefit Obligation Balance, Beginning of year 665 1,100  
Service cost 16 22 22
Interest cost 24 9 8
Participant's contributions 1 1  
Actuarial gain (loss) 33 262  
Benefits paid 35 35  
Settlement 0 0  
Currency impact 44 (170)  
Benefit Obligation Balance, end of year 682 665 1,100
Funded status of plan [Abstract]      
Funded status of plan 109 83  
Actuarial (gains) losses 43 52  
Prior service costs (benefits) 0 0  
Total 43 52  
UNITED STATES | Pension Plan      
Change in fair value of plan assets: [Roll Forward]      
Fair Value Balance, beginning of year 396 551  
Actual return on plan assets (8) (122)  
Employer contributions 0 0  
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 0 0  
Benefits paid 8 10  
Settlements (21) (23)  
Currency impact 0 0  
Fair Value Balance, end of year 359 396 551
Change in benefit obligation: [Roll Forward]      
Benefit Obligation Balance, Beginning of year 357 512  
Service cost 0 0 0
Interest cost 21 14 14
Participant's contributions 0 0  
Actuarial gain (loss) 5 133  
Benefits paid 9 10  
Settlement (21) (26)  
Currency impact 0 0  
Benefit Obligation Balance, end of year 343 357 512
Funded status of plan [Abstract]      
Funded status of plan 16 39  
Actuarial (gains) losses 66 48  
Prior service costs (benefits) 0 0  
Total 66 48  
UNITED STATES | Post-Retirement Benefit Plan      
Change in fair value of plan assets: [Roll Forward]      
Fair Value Balance, beginning of year 85 116  
Actual return on plan assets (2) (26)  
Employer contributions 0 0  
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 0 0  
Benefits paid 7 5  
Settlements 0 0  
Currency impact 0 0  
Fair Value Balance, end of year 76 85 116
Change in benefit obligation: [Roll Forward]      
Benefit Obligation Balance, Beginning of year 65 84  
Service cost 0 1 1
Interest cost 4 2 2
Participant's contributions 0 0  
Actuarial gain (loss) (3) 17  
Benefits paid 7 5  
Settlement 0 0  
Currency impact 0 0  
Benefit Obligation Balance, end of year 65 65 $ 84
Funded status of plan [Abstract]      
Funded status of plan 11 20  
Actuarial (gains) losses 4 (6)  
Prior service costs (benefits) (2) (3)  
Total 2 (9)  
Other Assets | Foreign Plan | Pension Plan      
Funded status of plan [Abstract]      
Funded status of plan 174 140  
Other Assets | UNITED STATES | Pension Plan      
Funded status of plan [Abstract]      
Funded status of plan 19 42  
Other Assets | UNITED STATES | Post-Retirement Benefit Plan      
Funded status of plan [Abstract]      
Funded status of plan 11 20  
Employee compensation and benefits [Member] | Foreign Plan | Pension Plan      
Funded status of plan [Abstract]      
Funded status of plan 0 0  
Employee compensation and benefits [Member] | UNITED STATES | Pension Plan      
Funded status of plan [Abstract]      
Funded status of plan (1) (1)  
Employee compensation and benefits [Member] | UNITED STATES | Post-Retirement Benefit Plan      
Funded status of plan [Abstract]      
Funded status of plan 0 0  
Retirement and post-retirement benefits | Foreign Plan | Pension Plan      
Funded status of plan [Abstract]      
Funded status of plan (65) (57)  
Retirement and post-retirement benefits | UNITED STATES | Pension Plan      
Funded status of plan [Abstract]      
Funded status of plan (2) (2)  
Retirement and post-retirement benefits | UNITED STATES | Post-Retirement Benefit Plan      
Funded status of plan [Abstract]      
Funded status of plan $ 0 $ 0  
v3.23.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS , Target Allocations (Details)
Oct. 31, 2023
Foreign Plan | Pension Plan | Minimum | Equity Securities  
Defined Benefit Plan Disclosure [Line Items]  
Target Allocation Percentage of Plan Assets 0.00%
Foreign Plan | Pension Plan | Minimum | Fixed Income Securities  
Defined Benefit Plan Disclosure [Line Items]  
Target Allocation Percentage of Plan Assets 38.00%
Foreign Plan | Pension Plan | Minimum | Real Estate  
Defined Benefit Plan Disclosure [Line Items]  
Target Allocation Percentage of Plan Assets 0.00%
Foreign Plan | Pension Plan | Maximum | Equity Securities  
Defined Benefit Plan Disclosure [Line Items]  
Target Allocation Percentage of Plan Assets 60.00%
Foreign Plan | Pension Plan | Maximum | Fixed Income Securities  
Defined Benefit Plan Disclosure [Line Items]  
Target Allocation Percentage of Plan Assets 100.00%
Foreign Plan | Pension Plan | Maximum | Real Estate  
Defined Benefit Plan Disclosure [Line Items]  
Target Allocation Percentage of Plan Assets 25.00%
UNITED STATES | Deferred Profit Sharing | Equity Securities  
Defined Benefit Plan Disclosure [Line Items]  
Target Allocation Percentage of Plan Assets 60.00%
UNITED STATES | Deferred Profit Sharing | Fixed Income Securities  
Defined Benefit Plan Disclosure [Line Items]  
Target Allocation Percentage of Plan Assets 40.00%
UNITED STATES | Pension Plan | Equity Securities  
Defined Benefit Plan Disclosure [Line Items]  
Target Allocation Percentage of Plan Assets 50.00%
UNITED STATES | Pension Plan | Fixed Income Securities  
Defined Benefit Plan Disclosure [Line Items]  
Target Allocation Percentage of Plan Assets 50.00%
UNITED STATES | Pension Plan | Other Investments  
Defined Benefit Plan Disclosure [Line Items]  
Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments 1.00%
UNITED STATES | Other Postretirement Benefits Plan | Equity Securities  
Defined Benefit Plan Disclosure [Line Items]  
Target Allocation Percentage of Plan Assets 50.00%
UNITED STATES | Other Postretirement Benefits Plan | Fixed Income Securities  
Defined Benefit Plan Disclosure [Line Items]  
Target Allocation Percentage of Plan Assets 50.00%
UNITED STATES | Other Postretirement Benefits Plan | Other Investments  
Defined Benefit Plan Disclosure [Line Items]  
Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments 1.00%
v3.23.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Fair Value of Plan Assets (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Pension Plan | Foreign Plan      
Fair value of plan assets [Abstract]      
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets $ 197 $ 172  
Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets. 132 114  
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]      
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) 42 (181)  
Projected benefit obligation and fair value of plan assets [Abstract]      
Total projected benefit obligation - aggregate benefit obligation 682 665  
Defined Benefit obligation where Fair Value exceeds Pension benefit obligation 485 493  
Fair Value of plan assets where fair value exceeds pension benefit obligation 659 634  
Benefit Obligation 682 665 $ 1,100
Accumulated benefit obligation and fair value of plan assets      
Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation 192 167  
Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets 132 114  
Accumulated Benefit Obligation where Fair Value of plan Assets exceeds ABO 480 485  
Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds ABO. 659 634  
Defined Benefit Plan, Accumulated Benefit Obligation 672 652  
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year 18    
Fair Value of Plan Assets 791 748 1,093
Pension Plan | Foreign Plan | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 17 22  
Pension Plan | Foreign Plan | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 367 360  
Pension Plan | Foreign Plan | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 321 274  
Pension Plan | Foreign Plan | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   92  
Pension Plan | Foreign Plan | Other Contract      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 86    
Pension Plan | Foreign Plan | Quoted Prices in Active Markets for Identical Assets (Level 1)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 380 347  
Pension Plan | Foreign Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 1 0  
Pension Plan | Foreign Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 266 264  
Pension Plan | Foreign Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 113 83  
Pension Plan | Foreign Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   0  
Pension Plan | Foreign Plan | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Contract      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0    
Pension Plan | Foreign Plan | Significant Unobservable Inputs (Level 3)      
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]      
Unrealized gains/(losses) 5 (39)  
Purchases, sales, issuances, and settlements (6) (5)  
Transfers in (out) 0 159  
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) 5 (23)  
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 86 92 0
Pension Plan | Foreign Plan | Significant Unobservable Inputs (Level 3) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Foreign Plan | Significant Unobservable Inputs (Level 3) | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Foreign Plan | Significant Unobservable Inputs (Level 3) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Foreign Plan | Significant Unobservable Inputs (Level 3) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   92  
Pension Plan | Foreign Plan | Significant Unobservable Inputs (Level 3) | Other Contract      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 86    
Pension Plan | Foreign Plan | Significant Other Observable Inputs (Level 2)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 129 120  
Pension Plan | Foreign Plan | Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 16 22  
Pension Plan | Foreign Plan | Significant Other Observable Inputs (Level 2) | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Foreign Plan | Significant Other Observable Inputs (Level 2) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 113 98  
Pension Plan | Foreign Plan | Significant Other Observable Inputs (Level 2) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   0  
Pension Plan | Foreign Plan | Significant Other Observable Inputs (Level 2) | Other Contract      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0    
Pension Plan | Foreign Plan | Fair Value Measured at Net Asset Value Per Share      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 196 189  
Pension Plan | Foreign Plan | Fair Value Measured at Net Asset Value Per Share | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | Foreign Plan | Fair Value Measured at Net Asset Value Per Share | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 101 96  
Pension Plan | Foreign Plan | Fair Value Measured at Net Asset Value Per Share | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 95 93  
Pension Plan | Foreign Plan | Fair Value Measured at Net Asset Value Per Share | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   0  
Pension Plan | Foreign Plan | Fair Value Measured at Net Asset Value Per Share | Other Contract      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0    
Pension Plan | UNITED STATES      
Fair value of plan assets [Abstract]      
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets 3 3  
Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets. 0 0  
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]      
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) 0 0  
Projected benefit obligation and fair value of plan assets [Abstract]      
Defined Benefit obligation where Fair Value exceeds Pension benefit obligation 340 354  
Fair Value of plan assets where fair value exceeds pension benefit obligation 359 396  
Benefit Obligation 343 357 512
Accumulated benefit obligation and fair value of plan assets      
Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation 3 3  
Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets 0 0  
Accumulated Benefit Obligation where Fair Value of plan Assets exceeds ABO 340 354  
Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds ABO. 359 396  
Defined Benefit Plan, Accumulated Benefit Obligation 343 357  
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year 0    
Fair Value of Plan Assets 359 396 551
Assets for Plan Benefits, Defined Benefit Plan 359    
Pension Plan | UNITED STATES | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 2 1  
Pension Plan | UNITED STATES | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 182 194  
Pension Plan | UNITED STATES | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 174 199  
Pension Plan | UNITED STATES | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 1 2  
Pension Plan | UNITED STATES | Quoted Prices in Active Markets for Identical Assets (Level 1)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   49  
Assets for Plan Benefits, Defined Benefit Plan 44    
Pension Plan | UNITED STATES | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | UNITED STATES | Quoted Prices in Active Markets for Identical Assets (Level 1) | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 44 49  
Pension Plan | UNITED STATES | Quoted Prices in Active Markets for Identical Assets (Level 1) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | UNITED STATES | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | UNITED STATES | Significant Unobservable Inputs (Level 3)      
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]      
Realized gains/(losses) 0 0  
Unrealized gains/(losses) 0 0  
Purchases, sales, issuances, and settlements (1) 0  
Transfers in (out) 0 0  
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 1 2 2
Assets for Plan Benefits, Defined Benefit Plan 1    
Pension Plan | UNITED STATES | Significant Unobservable Inputs (Level 3) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | UNITED STATES | Significant Unobservable Inputs (Level 3) | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   0  
Pension Plan | UNITED STATES | Significant Unobservable Inputs (Level 3) | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0    
Pension Plan | UNITED STATES | Significant Unobservable Inputs (Level 3) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | UNITED STATES | Significant Unobservable Inputs (Level 3) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 1 2  
Pension Plan | UNITED STATES | Significant Other Observable Inputs (Level 2)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   0  
Assets for Plan Benefits, Defined Benefit Plan 0    
Pension Plan | UNITED STATES | Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | UNITED STATES | Significant Other Observable Inputs (Level 2) | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   0  
Pension Plan | UNITED STATES | Significant Other Observable Inputs (Level 2) | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0    
Pension Plan | UNITED STATES | Significant Other Observable Inputs (Level 2) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | UNITED STATES | Significant Other Observable Inputs (Level 2) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Pension Plan | UNITED STATES | Fair Value Measured at Net Asset Value Per Share      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   345  
Assets for Plan Benefits, Defined Benefit Plan 314    
Pension Plan | UNITED STATES | Fair Value Measured at Net Asset Value Per Share | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 2 1  
Pension Plan | UNITED STATES | Fair Value Measured at Net Asset Value Per Share | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets   145  
Pension Plan | UNITED STATES | Fair Value Measured at Net Asset Value Per Share | Defined Benefit Plan, Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 138    
Pension Plan | UNITED STATES | Fair Value Measured at Net Asset Value Per Share | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 174 199  
Pension Plan | UNITED STATES | Fair Value Measured at Net Asset Value Per Share | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES      
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]      
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) 0 0  
Projected benefit obligation and fair value of plan assets [Abstract]      
Benefit Obligation 65 65 84
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 76 85 116
Post-Retirement Benefit Plan | UNITED STATES | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 39 42  
Post-Retirement Benefit Plan | UNITED STATES | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 36 42  
Post-Retirement Benefit Plan | UNITED STATES | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 1 1  
Post-Retirement Benefit Plan | UNITED STATES | Quoted Prices in Active Markets for Identical Assets (Level 1)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 10 10  
Post-Retirement Benefit Plan | UNITED STATES | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 10 10  
Post-Retirement Benefit Plan | UNITED STATES | Quoted Prices in Active Markets for Identical Assets (Level 1) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Significant Unobservable Inputs (Level 3)      
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]      
Realized gains/(losses) 0 0  
Unrealized gains/(losses) 0 0  
Purchases, sales, issuances, and settlements 0 0  
Transfers in (out) 0 0  
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 1 1 $ 1
Post-Retirement Benefit Plan | UNITED STATES | Significant Unobservable Inputs (Level 3) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Significant Unobservable Inputs (Level 3) | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Significant Unobservable Inputs (Level 3) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Significant Unobservable Inputs (Level 3) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 1 1  
Post-Retirement Benefit Plan | UNITED STATES | Significant Other Observable Inputs (Level 2)      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Significant Other Observable Inputs (Level 2) | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Significant Other Observable Inputs (Level 2) | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Significant Other Observable Inputs (Level 2) | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Fair Value Measured at Net Asset Value Per Share      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 65 74  
Post-Retirement Benefit Plan | UNITED STATES | Fair Value Measured at Net Asset Value Per Share | Cash and Cash Equivalents      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 0 0  
Post-Retirement Benefit Plan | UNITED STATES | Fair Value Measured at Net Asset Value Per Share | Equity Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 29 32  
Post-Retirement Benefit Plan | UNITED STATES | Fair Value Measured at Net Asset Value Per Share | Fixed Income Securities      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets 36 42  
Post-Retirement Benefit Plan | UNITED STATES | Fair Value Measured at Net Asset Value Per Share | Other Investments      
Accumulated benefit obligation and fair value of plan assets      
Fair Value of Plan Assets $ 0 $ 0  
v3.23.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Expected Benefit Payments (Details)
$ in Millions
Oct. 31, 2023
USD ($)
Pension Plan | Foreign Plan  
Defined Benefit Plan Disclosure [Line Items]  
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year $ 18
Future benefit payments [Abstract]  
2022 35
2023 36
2024 37
2025 37
2026 39
2027 - 2031 202
Pension Plan | UNITED STATES  
Defined Benefit Plan Disclosure [Line Items]  
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year 0
Future benefit payments [Abstract]  
2022 33
2023 31
2024 31
2025 32
2026 32
2027 - 2031 142
Post-Retirement Benefit Plan | UNITED STATES  
Future benefit payments [Abstract]  
2022 7
2023 7
2024 8
2025 8
2026 8
2027 - 2031 33
Other Postretirement Benefits Plan | UNITED STATES  
Defined Benefit Plan Disclosure [Line Items]  
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year $ 0
v3.23.4
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Assumptions (Details)
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Oct. 31, 2020
Foreign Plan | Pension Plan | Minimum        
Assumptions used to calculate the net periodic cost        
Discount rate (in hundredths) 1.50% 0.29% 0.07%  
Average increase in compensation levels (in hundredths) 2.00% 2.00% 2.00%  
Expected long-term return on assets (in hundredths) 3.25% 2.75% 4.00%  
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate 0.50% 0.30% 0.10%  
Assumptions used to calculate the benefit obligation        
Discount rate (in hundredths) 1.78% 1.50%    
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 2.00% 2.00%    
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate 0.50% 0.50%    
Foreign Plan | Pension Plan | Maximum        
Assumptions used to calculate the net periodic cost        
Discount rate (in hundredths) 4.77% 1.76% 1.54%  
Average increase in compensation levels (in hundredths) 3.25% 3.50% 3.00%  
Expected long-term return on assets (in hundredths) 5.50% 5.50% 5.50%  
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate 2.10% 0.50% 0.50%  
Assumptions used to calculate the benefit obligation        
Discount rate (in hundredths) 5.63% 4.77%    
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 3.25% 3.25%    
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate 1.80% 2.10%    
UNITED STATES | Pension Plan        
Assumptions used to calculate the net periodic cost        
Discount rate (in hundredths) 6.00% 2.75% 2.75%  
Expected long-term return on assets (in hundredths) 5.00% 5.00% 7.00%  
Assumptions used to calculate the benefit obligation        
Discount rate (in hundredths) 6.50% 6.00%    
UNITED STATES | Post-Retirement Benefit Plan        
Assumptions used to calculate the net periodic cost        
Discount rate (in hundredths) 6.00% 2.75% 2.50%  
Expected long-term return on assets (in hundredths) 5.00% 5.00% 7.00%  
Assumptions used to calculate the benefit obligation        
Discount rate (in hundredths) 6.60% 6.00%    
Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year 6.50% 7.00% 6.00% 6.25%
Defined Benefit Plan, Ultimate Health Care Cost Trend Rate 4.75% 4.75% 4.50% 4.50%
Medical cost trend rate decreases to ultimate rate in year 2029 2029 2027 2029
v3.23.4
RESTRUCTURING AND OTHER RELATED COSTS (Details)
$ in Millions
 12 Months Ended
Oct. 31, 2023
USD ($)
numberOfCustomers
Restructuring Cost and Reserve [Line Items]  
Restructuring Reserve, Beginning Balance $ 0
Restructuring Charges 46
Non-cash settlement (8)
Payments for Restructuring (1)
Restructuring Reserve, Ending Balance $ 36
Restructuring and Related Cost, Positions Eliminated [Abstract]  
Restructuring and Related Cost, Number of Positions Eliminated | numberOfCustomers 400
Cost of Product and Services  
Restructuring Cost and Reserve [Line Items]  
Restructuring Charges $ 11
Research and Development  
Restructuring Cost and Reserve [Line Items]  
Restructuring Charges 6
Selling, General and Administrative  
Restructuring Cost and Reserve [Line Items]  
Restructuring Charges 29
Employee Severance  
Restructuring Cost and Reserve [Line Items]  
Restructuring Reserve, Beginning Balance 0
Restructuring Charges 33
Non-cash settlement (1)
Payments for Restructuring (1)
Restructuring Reserve, Ending Balance 31
Facility Closing  
Restructuring Cost and Reserve [Line Items]  
Restructuring Reserve, Beginning Balance 0
Restructuring Charges 13
Non-cash settlement (8)
Payments for Restructuring 0
Restructuring Reserve, Ending Balance $ 5
v3.23.4
GUARANTEES (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Summary of standard warranty accrual activity    
Beginning balance $ 30 $ 30
Accruals for warranties including change in estimates 57 50
Settlements made during the period (58) (50)
Ending balance 29 30
Standard Product Warranty Accrual, Balance Sheet Classification [Abstract]    
Accruals for warranties due within one year 29 30
Bank Guarantees $ 39 $ 37
v3.23.4
COMMITMENTS AND CONTINGENCIES (Details)
$ in Millions
Oct. 31, 2023
USD ($)
Loss Contingencies [Line Items]  
Other Purchase Commitments $ 123
v3.23.4
SHORT-TERM DEBT - Credit Facility and Commercial Paper (Details) - Line of Credit - USD ($)
$ in Millions
 12 Months Ended
Jun. 07, 2023
Jun. 02, 2023
Oct. 31, 2023
Oct. 31, 2022
5 yr unsecured credit facility        
Line of Credit Facility [Abstract]        
Credit facility initiation date Jun. 07, 2023      
Line of credit facility expiration date Jun. 07, 2028      
Maximum borrowing capacity $ 1,500      
Short-term debt terms (years) five      
Outstanding balance     $ 0 $ 0
Proceeds from Line of Credit     360  
Repayments of Line of Credit     360  
Incremental Revolving Credit Facility        
Line of Credit Facility [Abstract]        
Credit facility initiation date Jun. 07, 2023      
Maximum borrowing capacity $ 750      
Outstanding balance     0 0
Commercial Paper        
Line of Credit Facility [Abstract]        
Maximum borrowing capacity   $ 1,500    
Outstanding balance     0 $ 35
Short-term Debt, Weighted Average Interest Rate, at Point in Time       3.54%
Proceeds from commercial paper     1,670  
Repayments of Commercial Paper     1,700  
Uncommitted Money Market Line Credit Agreement        
Line of Credit Facility [Abstract]        
Credit facility initiation date   Jun. 02, 2023    
Maximum borrowing capacity   $ 300    
Outstanding balance     0  
Proceeds from Line of Credit     61  
Repayments of Line of Credit     $ 61  
Minimum amount per advance request   $ 1    
v3.23.4
LONG-TERM DEBT - Carrying Value (Details) - USD ($)
$ in Millions
Oct. 31, 2023
Oct. 31, 2022
Debt Instrument [Line Items]    
Long-Term Debt $ 2,735 $ 2,733
Term Loan Maturing 2025    
Debt Instrument [Line Items]    
Long-Term Debt 600 600
Senior Notes    
Debt Instrument [Line Items]    
Long-Term Debt 2,135 2,133
Senior Notes | Senior Notes 2026    
Debt Instrument [Line Items]    
Long-Term Debt 299 299
Senior Notes | Senior Notes 2029    
Debt Instrument [Line Items]    
Long-Term Debt 496 495
Senior Notes | Senior Notes 2030 [Member]    
Debt Instrument [Line Items]    
Long-Term Debt 496 496
Senior Notes | Senior Notes 2031    
Debt Instrument [Line Items]    
Long-Term Debt $ 844 $ 843
v3.23.4
LONG-TERM DEBT - Senior Notes (Details) - USD ($)
$ in Millions
 12 Months Ended
May 04, 2022
Mar. 12, 2021
Jun. 04, 2020
Sep. 16, 2019
Sep. 06, 2019
Sep. 22, 2016
Sep. 15, 2016
Sep. 15, 2016
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Aug. 01, 2019
Feb. 01, 2016
Jun. 21, 2013
Debt Instrument [Line Items]                            
Loss on extinguishment of debt                 $ 0 $ 9 $ 17      
Senior Notes 2023 [Member]                            
Debt Instrument [Line Items]                            
Fixed interest rate per annum (in hundredths)                           3.875%
Repayments of senior debt $ 609                          
Loss on extinguishment of debt 9                          
Early Repayment of Senior Debt 600                          
Debt Instrument, Increase, Accrued Interest $ 7                          
Senior Notes 2026                            
Debt Instrument [Line Items]                            
Issuance date of debt           Sep. 22, 2016                
Aggregate face amount of debt           $ 300                
Maturity date           Sep. 22, 2026                
Fixed interest rate per annum (in hundredths)           3.05%                
Interest payment frequency           semi-annually                
Date payments commenced           Mar. 22, 2017                
Debt Instrument, Redemption Price, Percentage           99.624%                
Senior Notes 2029                            
Debt Instrument [Line Items]                            
Issuance date of debt       Sep. 16, 2019                    
Aggregate face amount of debt       $ 500                    
Maturity date       Sep. 15, 2029                    
Fixed interest rate per annum (in hundredths)       2.75%                    
Interest payment frequency       semi-annually                    
Date payments commenced       Mar. 15, 2020                    
Debt Instrument, Redemption Price, Percentage       99.316%                    
Senior Notes 2030 [Member]                            
Debt Instrument [Line Items]                            
Issuance date of debt     Jun. 04, 2020                      
Aggregate face amount of debt     $ 500                      
Maturity date     Jun. 04, 2030                      
Fixed interest rate per annum (in hundredths)     2.10%                      
Interest payment frequency     semi-annually                      
Date payments commenced     Dec. 04, 2020                      
Debt Instrument, Redemption Price, Percentage     99.812%                      
Senior Notes 2031                            
Debt Instrument [Line Items]                            
Issuance date of debt   Mar. 12, 2021                        
Aggregate face amount of debt   $ 850                        
Maturity date   Mar. 12, 2031                        
Fixed interest rate per annum (in hundredths)   2.30%                        
Date payments commenced   Sep. 12, 2021                        
Debt Instrument, Redemption Price, Percentage   99.822%                        
Treasury Lock                            
Debt Instrument [Line Items]                            
Derivative, Notional Amount                       $ 250    
Treasury Lock | Senior Notes 2029 | Cash Flow Hedges | Derivatives Designated as Hedging Instrument                            
Debt Instrument [Line Items]                            
Derivative, Notional Amount                       $ 250    
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred         $ (6)       (3)          
Interest Rate Swap [Member] | Senior Notes 2026 | Cash Flow Hedges | Derivatives Designated as Hedging Instrument                            
Debt Instrument [Line Items]                            
Derivative, Notional Amount                         $ 300  
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred             $ (10) $ (10) $ (3)          
v3.23.4
LONG-TERM DEBT - Term Loan (Details) - USD ($)
$ in Millions
Dec. 14, 2023
Oct. 31, 2023
Oct. 31, 2022
Apr. 15, 2022
Line of Credit Facility [Line Items]        
Long-Term Debt   $ 2,735 $ 2,733  
Term Loan Maturing 2025        
Line of Credit Facility [Line Items]        
Maximum borrowing capacity       $ 600
Long-Term Debt   $ 600 $ 600  
Long-Term Debt, Weighted Average Interest Rate, at Point in Time   6.22% 3.98%  
Term Loan Maturing 2025 | Subsequent Event        
Line of Credit Facility [Line Items]        
Repayments of Debt $ 120      
v3.23.4
STOCKHOLDERS' EQUITY Stock Repurchases (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Mar. 01, 2023
Feb. 18, 2021
Nov. 19, 2018
2019 Repurchase Program [Member]            
Share Repurchase Program [Line Items]            
Stock Repurchase Program, Authorized Amount           $ 1,750.0
Stock Repurchased and Retired During Period, Shares     3,100,000      
Stock Repurchased and Retired During Period, Value     $ 365.0      
Remaining authorized repurchase amount         $ 193.0  
2021 Repurchase Program            
Share Repurchase Program [Line Items]            
Stock Repurchase Program, Authorized Amount         $ 2,000.0  
Stock Repurchased and Retired During Period, Shares 661,739 8,400,000 3,000,000      
Stock Repurchased and Retired During Period, Value $ 99.0 $ 1,139.0 $ 423.0      
Remaining authorized repurchase amount $ 339.0          
2023 Repurchase Program            
Share Repurchase Program [Line Items]            
Stock Repurchase Program, Authorized Amount       $ 2,000.0    
Stock Repurchased and Retired During Period, Shares 3,900,000          
Stock Repurchased and Retired During Period, Value $ 476.0          
Remaining authorized repurchase amount 1,524.0          
Taxes Payable 3.2          
Retained Earnings            
Share Repurchase Program [Line Items]            
Stock Repurchased and Retired During Period, Value 517.0 1,028.0 707.0      
Additional Paid-in Capital            
Share Repurchase Program [Line Items]            
Stock Repurchased and Retired During Period, Value $ 62.0 $ 111.0 $ 81.0      
v3.23.4
STOCKHOLDERS' EQUITY STOCKHOLDERS EQUITY DIvidends (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Nov. 15, 2023
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Dividends [Abstract]        
Cash Dividends Declared (per common share)   $ 0.900 $ 0.840 $ 0.776
Cash dividends declared   $ 265 $ 250 $ 236
Aggregate cash dividends paid   $ 265 $ 250 $ 236
Subsequent Event        
Dividends [Abstract]        
Cash Dividends Declared (per common share) $ 0.236      
Cash dividends declared $ 69      
Dividends Payable, Date Declared Nov. 15, 2023      
Dividends payment date Jan. 24, 2024      
Dividends date of record Jan. 02, 2024      
v3.23.4
STOCKHOLDERS' EQUITY - Changes in accumulated other comprehensive income (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Beginning Balance $ (347) $ (282)  
Other comprehensive income (loss) before reclassifications 12 (56)  
Amounts reclassified out of accumulated other comprehensive income (loss) 1 (7)  
Other Comprehensive Income (Loss), Tax (7) 2  
Other Comprehensive Income (Loss) 20 (65) $ 240
Ending Balance (327) (347) (282)
Foreign Currency Translation      
Beginning Balance (335) (185)  
Other comprehensive income (loss) before reclassifications 33 (162)  
Amounts reclassified out of accumulated other comprehensive income (loss) 0 0  
Other Comprehensive Income (Loss), Tax (1) (12)  
Other Comprehensive Income (Loss) 34 (150)  
Ending Balance (301) (335) (185)
Prior Service Credits      
Beginning Balance 123 124  
Other comprehensive income (loss) before reclassifications 0 0  
Amounts reclassified out of accumulated other comprehensive income (loss) (1) (1)  
Other Comprehensive Income (Loss), Tax 0 0  
Other Comprehensive Income (Loss) (1) (1)  
Ending Balance 122 123 124
Actuarial Losses      
Beginning Balance (155) (224)  
Other comprehensive income (loss) before reclassifications (17) 50  
Amounts reclassified out of accumulated other comprehensive income (loss) 2 28  
Other Comprehensive Income (Loss), Tax (5) 9  
Other Comprehensive Income (Loss) (10) 69  
Ending Balance (165) (155) (224)
Unrealized Gains (Losses) on Derivatives      
Beginning Balance 20 3  
Other comprehensive income (loss) before reclassifications (4) 56  
Amounts reclassified out of accumulated other comprehensive income (loss) 0 (34)  
Other Comprehensive Income (Loss), Tax (1) 5  
Other Comprehensive Income (Loss) (3) 17  
Ending Balance $ 17 $ 20 $ 3
v3.23.4
STOCKHOLDERS' EQUITY - Reclassifications out of accumulated other comprehensive income (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Unrealized gains (losses) on derivatives $ 0 $ 34  
Amounts reclassified into earnings related to derivative instruments, tax expense (benefit) 0 (8) $ 4
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 0 26 $ (13)
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax (2) (28)  
Amortization of prior service benefit 1 1  
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax (1) (27)  
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax 0 7  
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax (1) (20)  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax (1) 6  
Cost of Product and Services      
Unrealized gains (losses) on derivatives 2 36  
Interest Expense      
Unrealized gains (losses) on derivatives $ (2) $ (2)  
v3.23.4
SEGMENT INFORMATION Profitability (Details)
$ in Millions
 12 Months Ended
Oct. 31, 2023
USD ($)
segment
Oct. 31, 2022
USD ($)
segment
Oct. 31, 2021
USD ($)
segment
Segment Reporting [Abstract]      
Number of operating segments | segment 3 3 3
Select income statement components      
Net revenue $ 6,833 $ 6,848 $ 6,319
Income from operations 1,350 1,618 1,347
Share-based compensation expense 112 126 111
Depreciation expense $ 128 $ 120 $ 122
Number of operating segments | segment 3 3 3
Operating Segments      
Select income statement components      
Income from operations $ 1,875 $ 1,857 $ 1,613
Corporate, Non-Segment      
Select income statement components      
Share-based compensation expense $ 0 $ 6 $ 5
Revenue Benchmark      
Select income statement components      
Percentage of revenue from a single customer No customer represented 10 percent or more of our total net revenue No customer represented 10 percent or more of our total net revenue No customer represented 10 percent or more of our total net revenue
Life Sciences and Applied Markets      
Select income statement components      
Net revenue $ 3,856 $ 4,007 $ 3,663
Life Sciences and Applied Markets | Operating Segments      
Select income statement components      
Net revenue 3,856 4,007 3,663
Income from operations 1,116 1,186 1,017
Share-based compensation expense 66 69 60
Depreciation expense 63 59 60
Diagnostics and Genomics      
Select income statement components      
Net revenue 1,409 1,389 1,296
Diagnostics and Genomics | Operating Segments      
Select income statement components      
Net revenue 1,409 1,389 1,296
Income from operations 296 301 273
Share-based compensation expense 22 25 22
Depreciation expense 40 39 39
Agilent CrossLab      
Select income statement components      
Net revenue 1,568 1,452 1,360
Agilent CrossLab | Operating Segments      
Select income statement components      
Net revenue 1,568 1,452 1,360
Income from operations 463 370 323
Share-based compensation expense 24 26 24
Depreciation expense $ 25 $ 22 $ 23
v3.23.4
SEGMENT INFORMATION Segment Assets (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Segment Reporting Information [Line Items]    
Total assets $ 10,763 $ 10,532
Long-term investments 164 195
Deferred tax assets 338 259
Right-of-use asset 154 150
Other assets 708 686
Other Noncurrent Assets [Member]    
Segment Reporting Information [Line Items]    
Deferred tax assets 284 246
Operating Segments    
Segment Reporting Information [Line Items]    
Capital Expenditures 298 291
Total assets 8,024 8,313
Operating Segments | Life Sciences and Applied Markets    
Segment Reporting Information [Line Items]    
Capital Expenditures 70 77
Total assets 3,820 3,955
Operating Segments | Diagnostics and Genomics    
Segment Reporting Information [Line Items]    
Capital Expenditures 206 181
Total assets 3,307 3,489
Operating Segments | Agilent CrossLab    
Segment Reporting Information [Line Items]    
Capital Expenditures 22 33
Total assets 897 869
Corporate, Non-Segment    
Segment Reporting Information [Line Items]    
Cash and Cash Equivalents 1,590 1,053
Prepaid Expense, Current 139 119
Long-term investments 164 195
Long term and other receivables 127 134
Deferred tax assets 284 246
Right-of-use asset 154 150
Other assets $ 281 $ 322
v3.23.4
SEGMENT INFORMATION - Reconciliation or Reportable Results (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Operating Income (Loss) $ 1,350 $ 1,618 $ 1,347
Change in fair value of contingent consideration 1 (25)  
Restructuring and other related costs 46    
Interest income 51 9 2
Interest Expense (95) (84) (81)
Other income (expense), net 33 (39) 92
Income before taxes 1,339 1,504 1,360
Operating Segments      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Operating Income (Loss) 1,875 1,857 1,613
Corporate, Non-Segment      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Amortization 139 191 194
Business Combination, Acquisition Related Costs 16 25 41
Transformational Programs 25 30 37
Asset Impairment Charges 277 0 2
Business Exit Costs 0 7 5
Change in fair value of contingent consideration 1 (25) (21)
Restructuring and other related costs 46 0 0
Other expenses 21 11 8
Operating Expenses $ (525) $ (239) $ (266)
v3.23.4
SEGMENT INFORMATION - Entity-Wide Disclosures Revenue (Details) - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Revenue by geography      
Net revenue $ 6,833 $ 6,848 $ 6,319
UNITED STATES      
Revenue by geography      
Net revenue 2,410 2,385 2,159
CHINA Including Hong Kong      
Revenue by geography      
Net revenue 1,383 1,499 1,273
Rest Of World      
Revenue by geography      
Net revenue $ 3,040 $ 2,964 $ 2,887
v3.23.4
SEGMENT INFORMATION - Entity-Wide Disclosure Long-Lived Assets (Details) - USD ($)
$ in Millions
Oct. 31, 2023
Oct. 31, 2022
Segment Reporting Information [Line Items]    
Long-Lived Assets $ 1,851 $ 1,723
UNITED STATES    
Segment Reporting Information [Line Items]    
Long-Lived Assets 1,188 1,080
GERMANY    
Segment Reporting Information [Line Items]    
Long-Lived Assets 192 151
Rest Of World    
Segment Reporting Information [Line Items]    
Long-Lived Assets $ 471 $ 492
v3.23.4
Schedule II Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] - USD ($)
$ in Millions
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2021
Movement in valuation and qualifying accounts [Roll Forward]      
Balance at Beginning of Period $ 115 $ 120 $ 132
Additions Charged to Expenses or Other Accounts 1 7 5
Deductions Credited to Expenses or Other Accounts (4) (12) (17)
Balance at End of Period $ 112 $ 115 $ 120